PDF download Download the whole Issue


GХ technologies for rapid diagnosis of tuberculosis in general healthcare network Borodulina E.A. (Russia, Samara), Shubina A.T. (Russia, Samara), Gerasimov A.N. (Russia, Moscow), Kuznetsova A.N.(Russia, Samara), Kudlay D.A. (Russia, Moscow) P. 7

Evaluation of culturoma of the discharge of the upper respiratory tract and the contents of the colon in patients with atopic dermatitis Zhestkov A.V. (Russia, Samara), Lyamin A.V. (Russia, Samara), Pobezhimova O.O. (Russia, Samara) P. 17

SARS-COV-2 virus and the cardiovascular system interaction: clinical characteristics and pathogenesis Ishmurzin G.P. (Russia, Kazan), Serebryakova O.A. (Russia, Kazan), Syuzev K.N. (Russia, Kazan), Gainullina A.Kh. (Russia, Kazan), Dolganova D.A. (Russia, Kazan) P. 26

Ongoing symptomatic COVID-19 – pharmacotherapy possibilities Zaitsev A.A. (Russia, Moscow), Ternovskaya N.A. (Russia, Moscow), Chelan E.A.(Russia, Moscow), Kulagina I.TS. (Russia, Moscow), Sidorov Y.A. (Russia, Moscow), Likhodiy V.I. (Russia, Moscow) P. 34

Pulmonary hypertension in uence on outcomes of secondary tricuspid insu ciency correction in patients for valvular heart disease Kaipov A.E. (Russia, Kazan), Georgikia R.K. (Russia, Kazan), Abdulyanov I.V. (Russia, Kazan), Mukharyamov M.N. (Russia, Kazan), Vagizov I.I. (Russia, Kazan), BikchurinR.R. (Russia, Kazan), Shornina A.S. (Russia, Ufa) P. 43

The role of immunological factors in the unfavorable outcome of chronic obstructive pulmonary disease Karzakova L.M. (Russia, Cheboksary), Alekseeva E.P. (Russia, Cheboksary), Kudryashov S.I. (Russia, Cheboksary), Zhuravleva N.V. (Russia, Cheboksary), Ukhterova N.D. (Russia, Cheboksary), Andreeva N.P. (Russia, Cheboksary) P. 52

Clinical and functional portrait of a patient with chronic obstructive pulmonary disease phenotype without frequent exacerbations Kulik E.G. (Russia, Blagoveshchensk), Pavlenko V.I. (Russia, Blagoveshchensk), Naryshkina S.V. (Russia, Blagoveshchensk) P. 62

Effect of transplantation of human umbilical cord blood mononuclear cells overexpressing glial neurotrophic factor on the state of microglia and astrocytes in transgenic mice with alzheimer’s disease model Petukhova E.O. (Russia, Kazan), Mukhamedshina Y.O. (Russia, Kazan), Timofeeva A.V. (Russia, Kazan), Rizvanov A.A. (Russia, Kazan), Mukhamedyarov M.A. (Russia, Kazan) P. 68

The main trends of tobacco smoking among russian teenagers for 20 years of the XXI century, Skvortsova E.S. (Russia, Moscow), Lushkina N.P. (Russia, Moscow) P. 76

Iron metabolism in disseminated pulmonary tuberculosis and pneumocystis pneumonia in patients with HIV infection Yakovleva E.V. (Russia, Samara) P. 88


Hyperuricemia: clinical consequences, cardiovascular risk, modern approach to therapy Amirov N.B. (Russia, Kazan), Naumova A.YA. (Russia, Kazan), Fatykhov R.G. (Russia, Kazan), Amirova R.N. (Russia, Kazan)  P. 95

The role of oxidative stress in the pathophysiology of cardiovascular pathology, Demko I.V. (Russia, Krasnoyarsk), Sobko E.A. (Russia, Krasnoyarsk), Solovyeva I.A. (Russia, Krasnoyarsk), Kraposhina A. YU. (Russia, Krasnoyarsk), Gordeeva N.V. (Russia, Krasnoyarsk), Anikin D.A. (Russia, Krasnoyarsk) P. 107

The role of local anesthesia of a laparotomic wound in the prevention of postoperative complications Kontorev K.V. (Russia, Krasnoyarsk), Zdzitovetsky D.E. (Russia, Krasnoyarsk), Borisov R.N. (Russia, Krasnoyarsk) P. 118

Regional analgesia methods for trauma patients, Sharipova V.H. (Uzbekistan, Tashkent), Eshboyev A.T. (Uzbekistan, Tashkent), Eshmurodov D.B. (Uzbekistan, Tashkent) P. 125


The justice and equality in healthcare: a review and critical analysis of the 2016-2017 sociological project - monographs by Zh.V. Savelyeva, l.M. Mukharyamova and I.B. Kuznetsova, Oslopov V.N. (Russia, Kazan), Mishanina Y.S. (Russia, Kazan), Oslopova J.V. (Russia, Kazan) P. 131


The role of polymorphism of the MDR1 gene for the appointment of nonsteroidal anti-in ammatory drugs in pain syndrome Abdashimov Z.B. (Uzbekistan, Tashkent) P. 139



UDC 616-002.5. 5:579.873.21 DOI: 10.20969/VSKM.2022.15(1).7-16


BORODULINA ELENA A., ORCID ID: 0000-0002-3063-1538, Author ID: 651365, SPIN-code: 9770-5890, Dr. Med. Sci., Professor, Head of the Department of Phthisiology and Pulmonology, Samara State Medical University, address: Russia, 443020, Samara, Pionerskaya street, 48, tel.: +7-917-958-34-82; e-mail: borodulinbe@yandex.ru

SHUBINA ANASTASIA T., ORCID ID: 0000-0002-8096-7611, Author ID: 1009823, SPIN-code: 2706-7833, postgraduate student of the Department of Phthisiology and Pulmonology, Samara State Medical University, Russia, 443020, Samara, Pionerskaya street, 48, tel.: +7-927-737-73-08; e-mail: doc.inkova@gmail.com

GERASIMOV ANDREY N., ORCID ID: 0000-0003-4549-7172, Author ID: 141741, SPIN-code: 4742-1459, Dr. Phys.-Math. Sci., Professor, Head of the Department of Medical Informatics and Statistics, Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov, Ministry of Health of Russia, Russian Federation, 119991, Moscow, Trubetskaya st., 8, building 2, tel.: +7-905-550-50-84; e-mail: andr-gerasim@yandex.ru

KUZNETSOVA ALENA N., ORCID ID: 0000-0001-7634-0106, Author ID: 1037619, SPIN-code: 6331-3600, postgraduate student of the Department of Phthisiology and Pulmonology, Samara State Medical University, address: Russia, 443020, Samara, Pionerskaya street, 48, tel.: +7-937-064-94-25, e-mail: alena-suetina@mail.ru

KUDLAY DMITRY A., ORCID ID: 0000-0003-1878-4467, Dr. Med. Sci., Leading Researcher, Laboratory of Personalized Medicine and Molecular Immunology, Federal State Budgetary Institution «SSC Institute of Immunology», Federal Medical and Biological Agency of Russia, 115522, Moscow, Kashirskoe shosse, 24; Professor of the Department of Pharmacology, Institute of Pharmacy, Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov, Ministry of Health of Russia, Moscow, 119991, Trubetskaya st., 8, building 2, e-mail: D624254@gmail.com

Abstract. Introduction. There is still a high percentage of tuberculosis detection by the number of complaints to the general medical network. Di erential diagnosis is often performed in pulmonology departments using a standard diagnostic minimum. Reducing the time of diagnosis of tuberculosis is possible with the introduction of molecular genetic methods in the standards of primary examination. Aim. The aim is to determine the possibility of improving the detection of pulmonary tuberculosis using molecular genetic methods by the example of GeneXpert MTB/RIF cartridge technology in the pulmonology department of the general treatment network of healthcare. Material and methods. GeneXpert MTB/ RIF cartridge technology (MGM) was used in 159 patients with high risks of tuberculosis, characteristic changes on the X-ray image in addition to the standard study for the search for M. tuberculosis in biological material (sputum or bronchoalveolar uid). Аccording to veri ed diagnoses, two groups were formed: 1st - tuberculosis (n = 119), second - pneumonia (n = 40). Statistical processing was carried out using the IBM SPSS Statistics 22.0 statistical software package.Results and discussions. In the di erential diagnosis of tuberculosis in patients of the pulmonology department, there is a commonality of criteria for age (p=0.066), gender (p=0.249), unemployment (p=0.452), HIV infection (p=0.115), drug addiction (p=0.066), hepatitis (p=0.076). Positive results were on smear microscopy with sputum staining by Ziehel-Neelsen 18.9%, bronchoalveolar uid 31%. The method of GeneXpert MTB/RIF cartridge technology showed a high sensitivity of 100% and speci city of 99% in all cases of a veri ed diagnosis of «tuberculosis» using culture methods.Conclusion. In patients with pneumonia who have risk factors for tuberculosis, when the GeneXpert MTB/RIF cartridge technology for M. tuberculosis search is included in the standard diagnostic minimum in the general medical network, the e ectiveness of tuberculosis detection increases while reducing the time of diagnosis.

Key words: tuberculosis, HIV infection, laboratory diagnostics, GeneXpert MTB/RIF.

For reference: Borodulina EA, Shubina AT, Gerasimov AN, Kuznetsova AN, Kudlay DA. GX technologies for rapid diagnosis of tuberculosis in general healthcare network. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1):7–16. DOI: 10.20969/VSKM.2022.15(1).7-16


1. Tiberi S, Migliori GB, Centis R. Commemorating Tiberi S, Migliori GB, Centis R. Commemorating WORLD TB DAY 2020: “ITS TIME” – Its time to End the Global TB Epidemic. International Journal of Infectious Diseases. 2020; 92: S1-S4. DOI: 10.1016/j.ijid.2020.03.001

2. Васильева И.А., Белиловский Е.М., Борисов С.Е., Стерликов С.А. Заболеваемость, смертность и распространенность как показатели бремени туберкулеза в регионах ВОЗ, странах мира и в Российской Федерации. Часть 1: Заболеваемость и распространенность туберкулеза // Туберкулез и болезни легких. – 2017. – Т. 95, No 6. – С.9-21. [Vаsilyevа IА, Belilovsky EM, Borisov SE, Sterlikov SА. Zabolevayemost’, smertnost’ i rasprostranennost’ kak pokazateli bremeni tuberkuleza v regionakh VOZ, stranakh mira i v Rossiyskoy Federatsii. Chast’ 1: Zabolevayemost’ i rasprostranennost’ tuberkuleza [Incidence, mortality and prevalence as indicators of tuberculosis burdenin who regions, countries of the world and the russian federation; Part 1: Tuberculosis incidence and prevalence]. Tuberkulez i bolezni legkikh [Tuberculosis and lung disease]. 2017; 95 (6): 9-21. (In Russ.)]. DOI: 10.21292/2075-1230-2017-95-6-9-21

3. Гусейналиева Н.В. Совершенствование выявления туберкулеза в учреждениях первичного медицинского звена и его влияние на показатель заболеваемости // Туберкулез и болезни легких. – 2020. – Т. 98, No 10. – С.41-46. [Guseynalieva NV. Sovershenstvovaniye vyyavleniya tuberkuleza v uchrezhdeniyakh pervichnogo meditsinskogo zvena i yego vliyaniye na pokazatel’ zabolevayemosti [Improved detection of tuberculosis in primary health care and its impact on the incidence]. Tuberkulez i bolezni legkikh [Tuberculosis and Lung Diseases]. 2020; 98 (10): 41-46. (In Russ.)]. DOI: 10.21292/2075-1230-2020-98-10-41-46

4. Догадаева Е.Г., Лопатина Т.Н., Соколов В.Д. Особенности диагностики туберкулеза // Врач. – 2020. – Т. 31, No 10. – С. 74-84. [Dogadaeva EG, Lopatina TN, Sokolov VD. Osobennosti diagnostiki tuberkuleza [Tuberculosis Diagnostic Features]. Vrach [The Doctor]. 2020; 31 (10): 74-84. (In Russ.)]. DOI: 10.29296/25877305-2020-10-14

5. Павлунин А.В., Шарафутдинова М.А., Борисова С.Б., и др. Причины несвоевременного выявления и ошибки диагностики туберкулеза органов дыхания в общей лечебной сети // Туберкулез и социально-значимые заболевания. – 2015. – No 2. – С.63-66. [Pavlunin AV, Sharafutdinova MA, Borisova SB, Mishanov RF, Medovarov EV. Prichiny nesvoevremennogo vyjavlenija i oshibki diagnostiki tuberkuleza organov dyhanija v obshhej lechebnoj seti [Causes of late detection and diagnostic errors of respiratory tuberculosis in the general medical network]. Tuberkulez i sotsial’no-znachimyye zabolevaniya [Tuberculosis and socially signi cant diseases]. 2015; 2: 63-66. (In Russ.)].

6. Данцев В.В., Иванов В.В., Карпущенко В.Г., и др. Проблемы дифференциальной диагностики туберкулеза легких и внебольничной пневмонии у военнослужащих // Вестник Российской Военно-медицинской академии. – 2015. – No 2 (4). – С.32-37. [Dantsev VV, Ivanov VV, Karpuschenko VG, Muchaidze RD, Kharitonov MA, Kitsishin VP, Shitov YuN. Problemy di erentsial’noy diagnostiki tuberkuleza legkikh i vnebol’nichnoy pnevmonii u voyennosluzhashchikh [Problems of di erential diagnosis of pulmonary tuberculosis and community acquired pneumonia at military servicemen]. Vestnik Rossiyskoy Voyennomeditsinskoy akademii [Bulletin of the Russian military medical academy]. 2015; 4 (52): 32-37. (In Russ.)].

7. Карпина Н.Л. Особенности дифференциальной диагностики заболеваний легких с синдромом инфильтрации // Вестник ЦНИИТ. – 2018. – No 1. – С.26-32. [Karpina NL. Osobennosti di erentsial’noy diagnostiki zabolevaniy legkikh s sindromom in l’tratsii [The peculiarities of di erential diagnosis of pulmonary diseases characterized by in ltration]. Vestnik CNIIT [Bulletin of TsNIIT]. 2018; 1: 26-32. (In Russ.)]. DOI: 10.7868/S2587667818010041

8. Дубровская И.И., Багишева Н.В., Мордык А.В., и др. Выявление и дифференциальная диагностика туберкулеза у пациентов пульмонологического отделения с внебольничной пневмонией и хронической обструктивной болезнью легких // Пульмонология.– 2020. – Т. 3, No 3. – С.305-311. [Dubrovskaya II, Bagisheva NV, Mordyk AV, Nebesnaya EYu, Bakhshieva LI. Vyyavleniye i di erentsial’naya diagnostika tuberkuleza u patsiyentov pul’monologicheskogo otdeleniya s vnebol’nichnoy pnevmoniyey i khronicheskoy obstruktivnoy bolezn’yu legkikh [Detection and di erential diagnosis of tuberculosis in patients of the pulmonary department with community-acquired pneumonia and chronic obstructive pulmonary disease]. Pulmonologiya [Pulmonology]. 2020; 3 (3): 305-311. (In Russ.)]. DOI: 10.18093/0869-0189-2020-30-3-305-311

9. Veselova E, Panova A, Kaminskiy G, Testov V, Samoilova A, Vasilyeva I. Mycobacterium tuberculosis detection rates by molecular genetic methods among patients with tuberculosis in the Russian Federation. European Respiratory Journal, Supplement. 2019; 54 (S63): PA2991. DOI: 10.1183/13993003.congress-2019.PA2991

10.Shi J, Dong W, Ma Y, et al. Genexpert MTB/RIF outperforms mycobacterial culture in detecting mycobacterium tuberculosis from salivary sputum. BioMed Research International. 2018; 4: 1-5. DOI: 10.1155/2018/1514381

11. Stevens WS, Scott LE, Noble L, Gous N, Dheda K. Impact of the Genexpert MTB/RIF technology on tuberculosis control. Microbiology Spectrum. 2017; 5 (1): TBTB2-0040-2016. DOI: 10.1128/ microbiolspec.TBTB2-0040-2016

12. Экспертное заключение членов основной̆ группы Европейской̆ лабораторной̆ инициативы, подготовленное для Европейского региона. Aлгоритм лабораторной диагностики и мониторинга лечения туберкулеза легких и туберкулеза с лекарственной устойчивостью на основе применения современных быстрых молекулярных методов. – ВОЗ, 2017. – 40 с. [Vsemirnaya organizatsiya zdravookhraneniya [World health organization]. Algoritm laboratornoj diagnostiki i monitoringa lechenija tuberkuleza legkih i tuberkuleza s lekarstvennoj ustojchivost’ju na osnove primenenija sovremennyh bystryh molekuljarnyh metodov [Algorithm for laboratory diagnosis and monitoring of the treatment of pulmonary tuberculosis and drug-resistant tuberculosis based on the use of modern fast molecular methods]. Jekspertnoe zakljuchenie chlenov osnovnoj̆ gruppy Evropejskoj̆ laboratornoj̆ iniciativy, podgotovlennoe dlja Evropejskogo regiona [Expert opinion of the members of the core group of the European Laboratory Initiative, prepared for the European Region]. 2017; 40 p. (In Russ.)].

13. Автоматизированная технология амплификации нуклеиновых кислот в режиме реального времени для быстрого, одновременного выявления туберкулеза и устойчивости к рифампицину: анализ Xpert MTB/RIFдля диагностики легочного и внелегочного туберкулёза у взрослых и детей. – ВОЗ, 2013. – 40 с. [Vsemirnaya organizatsiya zdravookhraneniya [World health organization]. Avtomatizirovannaja tehnologija ampli kacii nukleinovyh kislot v rezhime real’nogovremeni dlja bystrogo, odnovremennogo vyjavlenija tuberkuleza i ustojchivosti k rifampicinu: analiz Xpert MTB/ RIFdlja diagnostiki legochnogo i vnelegochnogo TB u vzroslyh i detej [Automated real-time nucleic acid ampli cation technology for rapid, simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary tuberculosis in adults and children]. 2013; 40 p. (In Russ.)]

14.Черноусова Л.Н., Севастьянова Э.В., Ларионова Е.Е., и др. Федеральные клинические рекомендации по организации и проведению микробиологической и молекулярно-генетической диагностики туберкулеза. – Москва: Российское общество фтизиатров, 2015. – 36 с. [Chernousova LN, Sevast’janova JeV, Larionova EE, Smirnova TG, Andreevskaja SN, Popov SA, Zhuravlev VJu, Puzanov VA, Mar’jandyshev AO, Vahrusheva DV, Kravchenko MA, Safonova SG, Vasil’eva IA, Jergeshov AJe. Federal’nye klinicheskie rekomendacii po organizacii i provedeniju mikrobiologicheskoj i molekuljarno-geneticheskoj diagnostiki tuberkuleza [Federal clinical guidelines for the organization and conduct of microbiological and molecular genetic diagnosis of tuberculosis]. Moskva: Rossiyskoye obshchestvo ftiziatrov [Moscow: Russian Society of Phthisiologists]. 2015; 36 p. (In Russ.)].

15. Эргешов А.Э., Черноусова Л.Н., Андреевская С.Н. Новые технологии диагностики лекарственно-устойчивого туберкулеза // Вестник Российской академии медицинских наук. 2019. – Т. 74, No 6. – С.413-422. [Ergeshov AE, Chernousova LN, Andreevskaya SN. Novyye tekhnologii diagnostiki lekarstvenno-ustoychivogo tuberkuleza [New technologies for the diagnosis of drug-resistant tuberculosis]. Vestnik Rossiyskoy akademii meditsinskikh nauk [Annals of the Russian academy of medical sciences]. 2019; 74 (6): 413-422. (In Russ.)]. DOI: 10.15690/vramn1163

16. Викторова И.Б., Дегтярева С.Ю., Кулабухова Е.И., и др. Обнаружение mycobacterium tuberculosis в мокроте у больных коинфекцией ВИЧ/туберкулез различными методами (обзор литературы) // Журнал инфектологии. – 2018. – Т. 10, No 2. – С.30-38. [Viktorova IB, Degtyareva SYu, Kulabukhova EI, Beloborodova EN, Zimina VN. Obnaruzheniye mycobacterium tuberculosis v mokrote u bol’nykh koinfektsiyey VICH/tuberkulez razlichnymi metodami (obzor literatury) [Detection of mycobacterium tuberculosis in sputumin patients coinfected with HIV/tuberculosis by various methods (literature review)]. Zhurnal infektologii [Jurnal Infektologii]. 2018; 10 (2): 30-38. (In Russ.)]. DOI: 10.22625/2072-6732-2018-10-2-30-38

17. Андреевская С.Н., Смирнова Т.Г., Ларионова Е.Е., и др. Сравнение картриджной технологии Xpert MTB/RIF с микробиологическими методами выявления микобактерий туберкулеза и определения лекарственной чувствительности // Туберкулез и социально-значимые заболевания. – 2013. – No 2. – С.25-29. [Andreevskaya SN, Smirnova TG, Larionova EE, Burakova MV, Vasiljeva IA, Chernousova LN. Sravneniye kartridzhnoy tekhnologii Xpert MTB/RIF s mikrobiologicheskimi metodami vyyavleniya mikobakteriy tuberkuleza i opredeleniya lekarstvennoy chuvstvitel’nosti [Comparison of XPERT MBT/RIF cartridge technology with microbiological methods for mbt detection and drug susceptibility testing]. Tuberkulez i sotsial’no-znachimyye zabolevaniya [Tuberculosis and socially signi cant diseases]. 2013; 2: 25-29. (In Russ.)]

18.Елисеев П.И., Детьен А., Дэйкомб Р., и др. Влияние внедрения молекулярно-генетических методов на сроки начала химиотерапии больных туберкулезом с МЛУ МБТ в Архангельской области // Туберкулез и болезни легких. – 2017. – Т. 95, No 12. – С.10-17. [Eliseev PI, Detjen A, Dacombe R, Pillips P, Squire SB, Maryandyshev AO. Vliyaniye vnedreniya molekulyarno-geneticheskikh metodov na sroki nachala khimioterapii bol’nykh tuberkulezom s MLU MBT v Arkhangel’skoy oblasti [Impact of molecular genetic methods on the initiation of chemotherapy in multiple drug resistanttuberculosis patients in Arkhangelsk region]. Tuberkulez i bolezni legkikh [Tuberculosis and Lung Diseases]. 2017; 95 (12): 10-17. (In Russ.)]. DOI: 10.21292/2075-1230-2017-95-12-10-17

19.Цыбикова Э.Б., Пунга В.В., Русакова Л.И. Туберкулез, сочетанный С ВИЧ-инфекцией, в России: статистика и взаимосвязи // Туберкулёз и болезни лёгких. – 2018. – Т. 96, No 12. – С.9-17. [Tsybikova EB, Punga VV, Rusakova LI. Tuberkulez, sochetannyy S VICH-infektsiyey, v Rossii: statistika i vzaimosvyazi [Tuberculosis with concurrent HIV infection in Russia: statistics and correlations. Tuberkulez i bolezni legkikh [Tuberculosis and Lung Diseases]. 2018; 96 (12): 9-17. (In Russ.)]. DOI: 10.21292/2075-1230-2018-96-12-9-17

20.Загдын З.М. Организация выявления туберкулеза среди пациентов с ВИЧ-инфекцией в субъектах Российской Федерации с высоким уровнем её распространенности // Социальные аспекты здоровья населения. – 2019. – Т. 65, No 2. – С.8. [Zagdyn ZM. Organizatsiya vyyavleniya tuberkuleza sredi patsiyentov s VICH-infektsiyey v sub»yektakh Rossiyskoy Federatsii s vysokim urovnem yeyo rasprostranennosti [Organization of tuberculosis screening among HIV-Infected patients in the Russian regions with high HIV prevalence]. Sotsial’nyye aspekty zdorov’ya naseleniya [Social aspects of population health]. 2019; 65 (2): 8. (In Russ.)]. DOI: 10.21045/2071-5021-2019-65-2-8

21. Шугаева С.Н., Савилов Е.Д., Кошкина О.Г., и др. Влияние ВИЧ-инфекции на напряженность эпидемического процесса туберкулеза на территории высокого риска обеих инфекций // Туберкулез и болезни легких. – 2018. – Т. 96, No 2. - С.5-10. [Shugаevа SN, Sаvilov ED, Koshkinа OG, Zаrbuev AN, Untаnovа LS. Vliyaniye VICH-infektsii na napryazhennost’ epidemicheskogo protsessa tuberkuleza na territorii vysokogo riska obeikh infektsiy [Impact of HIV infection on the intensity of tuberculosis epidemics on the territories of high risks for both infections]. Tuberkulez i bolezni legkikh [Tuberculosis and Lung Diseases]. 2018; 96 (2): 5-10. (In Russ.)]. DOI: 10.21292/2075-1230-2018-96-2-5-10

22.Чжао И., Загдын З.М., Павлова М.В., и др. Туберкулез и ВИЧ-инфекция в Российской Федерации: факторы риска МЛУ-ТБ среди пациентов с ВИЧ-инфекцией (обзор) // Медицинский альянс. – 2020. – Т. 8, No 1. – С.6-13. [Zhao Y, Zagdyn Z, Pavlova M, Archakova L, Sokolovich E, Yablonskiy P. Tuberkulez i VICH-infektsiya v Rossiyskoy Federatsii: faktory riska MLU-TB sredi patsiyentov s VICH-infektsiyey (obzor) [Tuberculosis and HIV in the Russian Federation: Risk Factors of MDR-TB in HIV-infected Patients (review)]. Meditsinskiy al’yans [Medical Alliance]. 2020; 8 (1): 6-13. (In Russ.)]. DOI: 10.36422/23076348-2020-8-1-6-13

23. Reechaipichitkul W, Phetsuriyawong A, Chaimanee P, Ananta P. Diagnostic test of sputum Genexpert MTB/RIF for smear negative pulmonary tuberculosis. Southeast Asian Journal of Tropical Medicine and Public Health. 2016; 47 (3): 457-466.

24.Adil A, Shareef H. Molecular detection of the mutation in rpoB gene responsible to rifampicin resistance in mycobacterium tuberculosis. Biochemical and Cellular Archives. 2019; 19 (2): 4431-4434. DOI: 10.35124/bca.2019.19.2.4431

25. Елисеев П.И., Тарасова И.В., Марьяндышев А.О. Роль молекулярно-генетических методов в повышении эффективности диагностики туберкулеза с лекарственной устойчивостью микобактерий // Туберкулез и болезни легких. – 2014. – Т. 91, No 9. – С.19. [Eliseev PI, Tarasova IV, Maryandyshev AO. Rol’ molekulyarno-geneticheskikh metodov v povyshenii e ektivnosti diagnostiki tuberkuleza s lekarstvennoy ustoychivost’yu mikobakteriy [The role of molecular genetic methods in improving the e ectiveness of diagnosis of tuberculosis with drug-resistant mycobacteria]. Tuberkulez i bolezni legkikh [Tuberculosis and Lung Diseases]. 2014; 91 (9): 19. (In Russ.)]. DOI: 10.21292/2075-1230-2014-0-9-19-19

26. Севастьянова Э.В., Черноусова Л.Н. Современные алгоритмы микробиологической диагностики туберкулеза // Туберкулез и болезни легких. – 2018. – Т. 96, No 7. – С.1-17. [Sevastyanova EV, Chernousova LN. Sovremennyye algoritmy mikrobiologicheskoy diagnostiki tuberkuleza [Modern algorithms of microbiological diagnostics of tuberculosis]. Tuberkulez i bolezni legkikh [Tuberculosis and Lung Diseases]. 2018; 96 (7): 11-17. (In Russ.)]. DOI: 10.21292/2075-1230-2018-96-7-11-17

27.Мотанова Л.Н., Грабовская М.С., Фольц И.В. Возможности специфических иммунологических тестов у пациентов с туберкулезом в сочетании с ВИЧ-инфекцией // Туберкулез и болезни легких. – 2021. – Т. 99, No 10. – С.46-51. [Motanova LN, Grabovskaya MS, Folts IV. Vozmozhnosti spetsi cheskikh immunologicheskikh testov u patsiyentov s tuberkulezom v sochetanii s VICH-infektsiyey [Possibilities of speci c immunological tests in patients with TB/HIV coinfection]. Tuberkulez i bolezni legkikh [Tuberculosis and Lung Diseases]. 2021; 99 (10): 46-51. (In Russ.)]. DOI: 10.21292/2075-1230-2021-99-10-46-51


UDC: 616.155.35:616.516.5:612.017.1 DOI: 10.20969/VSKM.2022.15(1).17-25


ZHESTKOV ALEXANDER V., ORCID ID: 0000-0002-3960-830X, MD, D. Med. Sci., Professor, Chief of the Department of Clinical Microbiology, Allergology and Immunology, Samara State Medical University. 443079, Russia, Samara, Gagarina Str., 18, e-mail: avzhestkov2015@yandex.ru

LYAMIN ARTEM V., ORCID ID: 0000-0002-5905-1895, MD, D. Med. Sci., Associate Professor, Department of Clinical Microbiology, Allergology and Immunology, Samara State Medical University. 443079, Russia, Samara, Gagarina Str., 18, e-mail: avlyamin@rambler.ru

POBEZHIMOVA OLGA O., ORCID ID: 0000-0001-9593-4807, Postgraduate student, Department of Clinical Microbiology, Allergology and Immunology, Samara State Medical University. 443079, Russian Federation, Samara, Gagarina Str., 18, e-mail: ImmunologSamara888@yandex.ru

Abstract. Aim. The aim of the study is to study the species diversity of the micro ora of the discharge of the nose, oropharynx and the contents of the colon in atopic dermatitis. Material and methods. The study included 80 patients with atopic dermatitis. Patients are divided into 3 groups depending on the severity of AD (Focusing on the SCORAD scale). The patients underwent collection of biomaterials from the oral and nasal cavities and intestines. Sowing of the material was carried out on an extended list of nutrient media. As a result of the MALDI-ToF mass spectrometry on the Micro ex LT (Bruker, Germany), the resulting microorganisms were recognized by direct and extended deposition using formic acid. Results and discussion. When seeding feces patients from all groups, statistically signi cant di erences were revealed for the following microorganisms, depending on the severity: Enterococcus faecium (61%), Streptococcus anginosus (16.7%), Parabacteroides distasonis (22.2%) were found in remission; at the stage of exacerbation with exacerbation of atopic dermatitis in the form of a limited form - Enterococcus faecalis (39.3%), Lactobacillus fermentum (16.1%), Streptococcus parasanguinis (9%);with a common form of exacerbation, Klebsiella pneumonia (50%), Klebsiella oxytoca (50%), Enterococcus mundtii (16.7%), Echerichia vulneris (16.7%), Lactobacillus salivarius (83.3%), Raoultella ornithinolytica(16.7%), Enterococcus avium (50%), Enterobacter asburie (16.7%), Citr obacter braaki (33.3%), Bacteroides vulgates (33.3%), Bi dobacterium adolescentis(16.7%), Enterococcus durans (16.7%), Lactobacillus crispatus (16.7%), Corynebacterium amycolatum (33.3%), Streptococcus sanguinis (16.7%). Inoculation of oropharyngeal discharge from patients with atopic dermatitis revealed statistically signi cant di erences for the following microorganisms, depending on the severity: Streptococcus australis (11.1%) was detected in remission; in the stage of exacerbation with a limited form of atopic dermatitis, Rothia mucalaginosa (19.6%), Streptococcus saliverius (39.3%) were identi ed; in the stage of exacerbation with a widespread form of atopic dermatitis, Streptococcus anginosus (16.7%;), Candida albicans (33.3%), Streptococcus gordonii (16.7%), Staphylococcus haemolyticus (16.7%), Neisseria oralis (33.3%), Corynebacterium amycolatum (16.7%), Kocuria rhizophila (33.3%), Lactobacillus rhamnosus (16.7%). Inoculation of nasal discharge from patients with atopic dermatitis revealed statistically signi cant di erences for the following microorganisms, depending on the severity: Staphylococcus haemolyticus (16.7%), Staphylococcus lugdunensis (11.1%), Staphylococcus copitis (11.1%) were found in remission. At the stage of exacerbation with a widespread form of atopic dermatitis, Proteus mirabilis (16.7%), Streptococcus vestibularis (16.7%), Streptococcus sobrinus (16.7%), Staphylococcus warneri (16.7%), Corynebacterium coyleae (16.7%), Lactobacillus plantarum (16.7%). Conclusion. Our results indicate enzymatic de ciency and signi cant changes in the qualitative composition of the microbiota in people with atopic dermatitis, which violates the body's immunomodulating function.

Key words: atopic dermatitis, microbiota, oral cavity, nose, intestines, immunopathogenesis.

For reference: Zhestkov AV, Lyamin AV, Pobezhimova OO. Evaluation of the culturoma of the discharge of the upper respiratory tract and the contents of the colon in patients with atopic dermatitis. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1):17–25. DOI: 10.20969/VSKM.2022.15(1).17-25


1. Мирзоян В.Л., РазнатовскийК.И., хов К.Н. Атопический дерматит. Алгоритмы диагностики и лечения: учебное пособие // СПб.: СЗГМУ им. И.И. Мечникова, 2018. – 64 с. [Mirozyn VL, Raznatovskii KI, Monaxov KN. Atopicheskiidermatit; Algoritmidiagnostiki I lechenia [Atopic dermatitis; Diagnostic and treatment algorithms: textbook]. Sankt – Peterburg: Severo-Zapadnyy gosudarstvennyy meditsinskiy universitet imeni I I Mechnikova [Saint Petersburg: Northwestern State Medical University named after I I Mechnikov]. 2018; 64 р. (In Russ.)].

2. Козин В.М., Козина Ю.В. Клиническая дерматология: учебно-методическое пособие // Витебск: ВГМУ, 2020. – 182 с. [Kozin VM, Kozina UV. Klinicheskay dermatologia: uchebno-metodicheskoe posobie [Clinical dermatology: teaching aid]. Vitebsk: VGMU [Vitebsk: VSMU]. 2020; 182 p. (In Russ.)].

3. Хаитов Р.М. Иммунология: учебник, 2-е изд., перераб. и доп. // М.: Гэотар-Медиа, 2015. – 528 с. [Khaitov RM. Immunologia: Uchebnik [Immunology: Textbook]. Moskva: Geotar-Media [Moscow: Geotar-Media]. 2015; 2: 528 p. (In Russ.)].

4. Ковальчук Л.В., Игнатьева Г.А., Ганковская Л.В. Иммунология: практикум // М.: Гэотар-Медиа, 2015. – 176 с. [Kovalchuk LB., Ignateva GA., Gankovskay LV. Immunologia: praktikum [Immunology: workshop]. Moskva: Geotar-Media [Moscow: Geotar-Media]. 2015; 176 p. (In Russ.)].

5. Костинов М.П., Чучалин А.Г. Руководство по клинической иммунологии в респираторной медицине // М.: ООО «АТМО», 2016. – 203 с. [Kostinov MP, Chuchalin AG. Rukovodstvo po klinicheskoy immunologii v respiratornoy medicine [Clinical Immunology Guide to Respiratory Medicine]. Moskva: OOO «ATMO» [Moscow: OOO «ATMO»]. 2016; 203 р. (In Russ.)].

6. Мигачева Н.Б. Распространенность атопического дерматита у детей школьного возраста г. Самары // Аллергология и иммунология в педиатрии. – 2019. – Т.3, вып. 58. – С. 38-44. [Migacheva NB. Rasprostranennost atopicheskogo dermatita u detey shkolnogo vozrasta goroda Samara [Prevalence of atopic dermatitis in schoolchildren in Samara]. Allergologia i immunologia v pediatrii [Allergology and immunology in pediatrics]. 2019; 3 (58): 38-44. (In Russ.)].

7. Колтуков В.К, Казюкова Т.В., Айрапетян А.С, Антипова Н.В. Атопический дерматит в детском возрасте // Медицинский совет. – 2015. – Т.1, вып. 2. – С. 60-65. [Koltukov VK, Kazukova TV, Ayrapetyn AS, Antipova NV. Atopicheskii dermatit v detskom vozraste [Atopic dermatitis in childhood]. Medizinskii sovet [Medical Council]. 2015; 1 (2): 60-65. (In Russ.)].

8. Dagmar Simon, Andreas Wollenberg, Harald Renz, Hans-Uwe Simon. Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019. International Archives of Allergology and Immunology. 2019; 178 (3): 207-218. DOI: 10.1159/000497383.

9. Svetlana Saini, Milind Pansare. New ideas and treatments for atopic dermatitis. North American Pediatric Clinical Cases. 2019; 66 (5): 1021-1033. DOI: 10.1016/j.pcl.2019.06.008.

10.Jennifer B Mancuso, Stephanie S Lee, Amy S Paller, Yukihiro Ohya, Lawrence F Eichen eld. Management of severe atopic dermatitis in children. Allergy and Clinical Immunology. On practice. 2021; 9 (4): 1462-1472. DOI: 10.1016/j. jaip.2021.02.017.

11. Hiwell K Williams, Joanne Chalmers. Prevention of atopic dermatitis. Actadermatovenerologica. 2020; 10 (12): 213. DOI: 10.2340/00015555-3516.

12.Lina J Suarez, Hernan Garson, SilieArboleda, Adriana Rodriguez. Dysbacteriosis of the oral cavity and autoimmunity: from local periodontal reactions to unbalanced systemic immunity. The boundaries of immunology. 2020; 1 (3): 591. DOI: 10.3389/ mmu.2020.591255.

13.Bo Yan, Yingqi Chen, Catherine Stanton, R Paul Ross, Yuan-Kun Li, Jianxin Zhao, Hao Zhang, Wei Chen. Species-level composition of bi dobacteria and lactobacilli and diversity of intestinal microbiota in infants up to 6 weeks of age. International Journal of Molecular Sciences. 2019; 20 (13): 3036. DOI: 10.3390 / ijms20133306.

14.Ian M Sims, Gerald W Tannock. Galacto- and fructooligosaccharides used for the growth in cocultures of bi dobacteria species characteristic of the intestines of infants. Applied and Environmental Microbiolog. 2020; 86 (11): 214. DOI: 10.1128/AEM.00214-20.

15. William E Ru , Teri M. Grayling, Martin A. Kriegel. Host-Microbiota Interaction in Immune-Mediated Diseases. Surveys of nature. Microbiota. 2020; 18 (9): 521. DOI: 10.1038/s41579-020-0367-2.

16. Salvucci E. Superorganism of the human microbiome and its modulation to restore health. International Journal of Food Science and Nutrition. 2019; 70 (7): 781. DOI: 10.1080/09637486.2019.1580682.

17.Christa M Felix, ShehaTahsin, Xin-Jung Joyce Wu. Host-Microbiota Interaction in Mediating Immune Disorders. Annals of the New York Academy of Sciences. 2018; 1417 (1): 57. DOI: 10.1111/nyas.13508.

18.Maran L Sprouse, Nicholas Bates, Christa M Felix, Xin-Jung Joyce Wu. In uence of gut microbiota on gut autoimmunity: a focus on T-lymphocytes. Immunology. 2019; 156 (4): 305. DOI: 10.1111/imm.13037.

19.Li-Na Dong, Mu Wang, Jian Guo, Jun-Ping Wang. Role of gut microbiota and metabolites in in ammatory bowel disease. Chinese Medical Journal. 2019; 132 (13): 1610. DOI: 10.1097/ CM9.0000000000000290.

20.Taichi Suzuki, Ruth I Lei. The role of microbiota in human genetic adaptation. Science (New York). 2020; 370 (6521): 82. DOI: 10.1126/ science.aaz6827.

21. Arika Mustafa, Muhammad Ibrahim, Muhammad Asif Rashid, SumairaKanwal, Annam Hussein, Asma Sami, Raza Ahmed, Zhu Bo. Genome-wide analysis of four strains of the Enterobacter cloacae complex type: understanding the virulence and adaptation of the niche. Scienti c representative. 2020; 10 (1): 8150. DOI: 10.1038/ s41598-020-65001-4.

22. Paula Karasi, Sylvia Maria Rasedo, Claudine Jacot, Anne Marie Ely, Maria de Los Angeles Serradell, Maria C Urdachi. Enterococcus durans EP1 is a promising anti-in ammatory probiotic capable of stimulating sIgA and increasing Faecalibacterium prausnitzii abundance. The boundaries of immunology. 2017; 8 (1): 88. DOI: 10.3389/ mmu.2017.00088.

23.Holowacz S, Blondeau C, Guinobert I, Guilbot A, Hidalgo S, Bisson JF. Lactobacillus salivarius LA307 and Lactobacillus rhamnosus LA305 attenuate skin in ammation in mice. Benef Microbes. 2018; 9 (2): 299-309. DOI: 10.3920/ BM2017.0084.

24.Ok-Jin Park, Yongkag Kwon, Chaeyeon Park, Yoon JooSeo, Park Tae Hwan, Songho Jung, JintekIm, Chul Hui Yun, Seung Hyun Han. Streptococcus gordonii: pathogenesis and host response to components of its cell wall. Microorganisms. 2020; 8 (12): 1852. DOI: 10.3390/microorganisms8121852.

25. Anshu Babbar, Venkatesan Naveen Kumar, Rene Bergmann, Israel Barrantes, Dietmar H. Pieper, Andreas Itzek, D Patrick Nietzsche-Schmitz. Members of a new subgroup of Streptococcus anginosus possess virulence-related genes previously seen in Streptococcus pyogenes. International Journal of Medical Microbiology. 2017; 307 (3): 174. DOI: 10.1016/j. ijmm.2017.02.002.

26.LM Loomes, M.A. Kerr, BW Senior. In vitro and in vivo cleavage of immunoglobulin G by proteinase secreted by the urinary tract pathogen Proteus mirabilis. Journal of Medical Microbiology. 1993; 39 (3): 225. DOI: 10.1099/00222615-39-3-225.

27.Isabel Veiga-Malta, Margarida Duarte, Marcia Dinis, Del na Tavares, ArnaldoVideira, Paula Ferreira. Streptococcus sobrinus enolase is an immunosuppressive protein. Cell microbiology. 2004; 6 (1): 79. DOI: 10.1046/j.1462-5822.2003.00344.x


UDC 616.981.21/958.7 DOI: 10.20969/VSKM.2022.15(1).26-33


ZAITSEV ANDREY A., ORCID ID: 0000-0002-0934-7313, Doctor Medical Sciences, Professor, Honored Doctor of the Russian Federation, Chief Pulmonologist of the Main Military Clinical Hospital named after Academician N.N. Burdenko, Russia, 105094, Moscow, Hospital pl., 3, tel. 8-916-588-32-12, e-mail: a-zaicev@yandex.ru

TERNOVSKAYA NINA A., Pulmonologist, Main Military Clinical Hospital named after Academician N.N. Burdenko, Russia, 105094, Moscow, Hospital pl., 3, tel. 8-903-175-89-29, e-mail: nina.vishna@yandex.ru

CHELAN EKATERINA A., Pulmonologist, Main Military Clinical Hospital named after Academician N.N. Burdenko, Russia, 105094, Moscow, Hospital pl., 3, tel. 8-963-641-69-80

KULAGINA IRINA TS., ORCID ID: 0000-0002-5387-5244, Candidate of Medical Sciences, Head of the 20th Pulmonology Department of the Main Military Clinical Hospital. Academician N.N. Burdenko, Russia, 105094, Moscow, Hospital pl., 3, e-mail: irina-kulagina@mail.ru

SIDOROV YURI A., Pulmonologist, Main Military Clinical Hospital named after academician N.N. Burdenko, Russia, 105094, Moscow, Hospital pl., 3

LIKHODIY VYACHESLAV I., Candidate of Medical Sciences, Head of the 30th Pulmonology Department, Main Military Clinical Hospital named after Academician N.N. Burdenko, Russia, 105094, Moscow, Hospital pl., 3, tel. 8-916-520-21-77

Abstract. Introduction. The medical community continues to search for modern methods of treating the ongoing symptomatic COVID-19 and post-COVID syndrome. Among all symptoms of ongoing symptomatic COVID-19, respiratory disorders are the most challenging and leading not only to impaired quality of life, but also to patient's disability. Thus, it seems relevant to study various options for the treatment of ongoing symptomatic COVID-19, including drugs with adaptogenic e ects. Aim. The aim of the study was to seek the e ects of the drug Trecresan on the recovery of patients who had COVID-19 (reduction of the severity of asthenia, restoration of lung function and other indicators) in comparison with standard (real practice) therapy of patients who incurred a new coronavirus infection COVID-19. To evaluate and conduct a comparative analysis of the safety of the treatment regimens used for "ongoing symptomatic COVID-19" with patients who have moderate and severe case of a new coronavirus infection. Material and methods. The study included 103 patients with ongoing symptomatic COVID-19 who were hospitalized in a pulmonology department. The rst group included 53 patients who were treated with the drug Trecresan, the 2nd group included 50 patients. During the examination of patients, the following was performed: A comprehensive study of lung function, including the designation of the di usion capacity of the lungs - DLCO, the level of SpO2 (saturation), a 6-minute walking test, an assessment asthenia severity on the MFI-20 (Multidimensional Fatigue Inventory) scale. The clinical e ciency of complex therapy was analyzed after 8-10 days of treatment. The endpoints necessary for subsequent analysis were the timing of COVID-19 symptoms resolution (severity of asthenia, performance, etc.) and adverse events developed during treatment. Results and discussion. The inclusion of the drug Trekrezan in the treatment of patients with ongoing symptomatic COVID-19 led to an improvement in overall well-being. There was a signi cant decrease in the severity of asthenia on the MFI-20 scale, a statistically signi cant decrease in the degree of shortness of breath and improvement in the patient’s quality of life were revealed, a decrease in the inpatient period was noted. Conclusion. It has been established that medium-term therapy using the adaptogen Trekrezan with patients with ongoing symptomatic COVID-19 and post-COVID syndrome reduces the severity of symptoms of the disease, increases exercise tolerance, reduces the severity of asthenia on the MFI-20 scale, reduces the inpatient period.

Keywords: adaptogen therapy, ongoing symptomatic COVID-19 and post-COVID syndrome, asthenia, oxygen saturation.

For reference: Zaitsev AA, Ternovskaya NA, Chelan EA, Kulagina Its, Sidorov YA, Likhodiy VI. Ongoing symptomatic COVID-19 – pharmacotherapy possibilities. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1): 26–33.DOI: 10.20969/VSKM.2022.15(1).26-33


1. Зайцев А.А. Письмо в редакцию // Клиническая микробиология и антимикробная химиотерапия. – 2020. – No 22(2). – С.84-86. [Zaitsev 8. AA. Pis’mo v redakciyu [Letter to the editor]. Klinicheskaya mikrobiologiya i antimikrobnaya himioterapiya [Clinical microbiology and antimicrobial chemotherapy]. 2020; 22 (2): 84-86. (In Russ.)]. DOI: 10.36488/cmac.2020.2.84-86.

2. Callard F, Perego E. How and why patients made Long Covid. Social Science & Medicine. 2021; 268: 113426, https://doi.org/10.1016/ j.socscimed.2020.113426

3. Ngai JC, Ko FW, Ng SS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010; 15 (3): 543-550. DOI: 10.1111/j.1440-1843.2010.01720.x.

4. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021; 27 (4): 601-615 DOI: 10.1038/s41591-021-01283-z

5. Funke-Chambour M, Bridevaux PO, Clarenbach CF, Soccal PM, Nicod LP, von Garnier C; Swiss COVID Lung Study Group and the Swiss Society of Pulmonology. Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID. Respiration. 2021; 100 (8): 826-841. DOI: 10.1159/000517255.

6. Зайцев А.А., Савушкина О.И., Черняк А.В., Кулагина И.Ц., Крюков Е.В. Клинико-функциональная характеристика пациентов, перенесших новую коронавирусную инфекцию COVID-19 // Практическая пульмонология. - 2020. – No 1. – С.78-81. [Zaitsev AA, Savushkina OI, Chernyak AV, Kulagina ITs, Kryukov EV. Kliniko-funkcional’naya harakteristika pacientov, perenesshih novuyu koronavirusnuyu infekciyu COVID-19 [Clinical and functional characteristics of patients who have undergone a new coronavirus infection COVID-19]. Prakticheskaya pul’monologiya [Practical pulmonology]. 2020; 1: 78-81. (In Russ.)].

7. Савушкина О.И., Зайцев А.А., Малашенко М.М., Черняк А.В., Кулагина И.Ц., Чернов С.А., Крюков Е.В. Роль функционального исследования системы дыхания в оценке эффективности медицинской реабилитации пациентов, перенесших COVID-19 // Медицинский альянс. – 2021. – Т. 9, No 3. – С.82-88. [Savushkina OI, Zaitsev AA, Malashenko MM, Chernyak AV, Kulagina ITs, Chernov SA, Kryukov EV. Rol’ funkcional’nogo issledovaniya sistemy dyhaniya v ocenke e ektivnosti medicinskoj reabilitacii pacientov, perenesshih COVID-19 [The role of functional research of the respiratory system in assessing the e ectiveness of medical rehabilitation of patients who have undergone COVID-19]. Medicinskij al’yans [Medical alliance]. 2021; 9 (3): 82-88. (In Russ.)].

Лещенко И.В., Глушкова Т.В. О функциональных нарушениях и развитии фиброза легких у больных, перенесших новую коронавирусную инфекцию // Пульмонология. - 2021. – No 31 (5). – С.653-662. [Leshchenko IV, Glushkova TV. O funkcional’nyh narusheniyah i razvitii broza legkih u bol’nyh, perenesshih novuyu koronavirusnuyu infekciyu [On functional disorders and the development of pulmonary brosis in patients who have undergone a new coronavirus infection]. Pul’monologiya [Pulmonology]. 2021; 31 (5): 653-662. (In Russ.)]. DOI: 10.18093/0869-0189-2021-31-5-653-662

9. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2021; 27 (4): 328-337. DOI: 10.1016/j.pulmoe.2020.10.013

10.Zhao YM, Shang YM, Song WB, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinical Medicine. 2020; 25: 100463. DOI: 10.1016/ j.eclinm.2020.100463

11. Зайцев А.А., Синопальников А.И. Рациональная фармакотерапия острых респираторных вирусных инфекций // Consilium Medicum. – 2008. – Т.10, No 10. – С.80-86. [Zaitsev AA, Sinopalnikov AI. Ratsional’naya farmakoterapiya ostrykh respiratornykh virusnykh infektsiy [Rational pharmacotherapy of acute respiratory viral infections]. Consilium Medicum [Consilium Medicum]. 2008; 10 (10): 80-86. (In Russ.)].

12.Зайцев А.А. Кашель: проблемы и решения // Практическая пульмонология. - 2020. - No 2. - С.78-86. [Zaitsev AA. Kashel’: problemy i resheniya [Cough: problems and solutions]. Prakticheskaya pul’monologiya [Practical pulmonology]. 2020; 2: 78-86. (In Russ.)].


UDC: 616.12+616.98 DOI: 10.20969/VSKM.2022.15(1).34-42


ISHMURZIN GENNADY P., ORCID ID: 0000-0002-0962-5790; C. Med. Sci., associate professor, Department of internal medicine, Kazan State Medical University; 420012, Russia, Tatarstan, Kazan, Butlerov Str., 49,
e-mail: ishm08@mail.ru

SEREBRYAKOVA OLGA A., ORCID ID: 0000-0002-2608-7904; student, Kazan State Medical University; 420012, Russia, Tatarstan, Kazan, Butlerov Str., 49

SYUZEV KIRILL N., ORCID ID: 0000-0003-3061-3150; junior researcher, Department of general pathology, Kazan State Medical University; 420012, Russia, Tatarstan, Kazan, Butlerov Str., 49

GAINULLINA AIGUL KH., ORCID ID: 0000-0001-5196-2566; student, Kazan State Medical University Ministry; 420012, Russia, Tatarstan, Kazan, Butlerov Str., 49

DOLGANOVA DARIA A., ORCID ID: 0000-0001-5444-6145; student, Kazan State Medical University; 420012, Russia, Tatarstan, Kazan, Butlerov Str., 49

Abstract. Introduction. The coronavirus disease 2019 (COеVID-19) caused by the SARS-CoV-2 virus led to the global pandemic, and by the beginning of August 2021, more than six million people fell ill in Russia. The study of the interaction between the SARS-CoV-2 virus and the cardiovascular system has great importance for the e ective treatment of patients with this disease. Aim. The aim of the study was to identify the frequency of cardiovascular complications, based on the analysis of the patient’s medical histories with viral pneumonia caused by SARS-CoV-2 virus. And to compare the results obtained with the data of literary sources and justify their pathogenetic occurrence. Material and methods.70 medical histories of patients with viral pneumonia caused by the SARS-CoV-2 virus who were admitted to the temporary infectious diseases hospital in Kazan were analyzed. The comorbidity, routine methods of laboratory (Complete blood count, qualitative and quantitative troponin test), and instrumental (ECG, Echo) diagnostics were studied. Descriptive statistics were calculated: median and interquartile range, categorical variables were presented in quantity and percentage. An unpaired t-test was used for the analysis of statistical signi cance. The critical value was assumed to be p≤0.05. Literature in eLIBRARY.ru, PubMed, GoogleScholar, Web of Science in recent years, mainly in 2020-2021, were analyzed. Results and discussion. Among the comorbidity: hypertension – in 31 (44%) patients, chronic heart failure – in 14 (20%) patients, coronary heart disease – in 10 (14.2%), diabetes mellitus – in 8 (11.4%), and 16 (22%) patients su ered from obesity. The most frequent complications were regurgitation on the valves (57,14%), cardiac arrhythmias (35,7%), of which supraventricular arrhythmias were the most common. There was no dependence of the increased level of Tr I on the degree of respiratory failure. Among patients with elevated Tr I levels, a chronological association with a previous infection with speci c symptoms was revealed in all patients with high reliability of the presence of myocarditis in 12 (17,14%) patients. Conclusion. COVID-19 a ects not only the respiratory system but also has a signi cant impact on the cardiovascular system because of the patient's immune response and the probable cytopathic e ect of the virus.Key words: coronavirus, COVID-19, SARS-CoV-2, myocarditis, arrhythmia, angiotensin.

For reference: Ishmurzin GP, Serebryakova OA, Syuzev KN, Gainullina AKh, Dolganova DA. SARS-CoV-2 virus and the cardiovascular system interaction: clinical characteristics and pathogenesis. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1): 34–42. DOI: 10.20969/VSKM.2022.15(1).34-42


1. Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, in ammation and intervention. Nature Reviews Immunology. 2020; 20: 363–374. DOI: 10.1038/s41577-020-0311-8.

2. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology. 2020; 109 (5): 531-538. DOI: 10.1007/s00392-020-01626-9.

3. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area JAMA. 2020; 323 (20): 2052-2059. DOI: 10.1001/ jama.2020.6775.

4. Муромцева Г.А., Концевая А.В., Константинов В.В. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ // Кардиоваскулярная терапия и профилактика. – 2014. – Вып. 13 (6). – С.4-11. [Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. Rasprostranennost’ faktorov riska neinfektsionnykh zabolevaniy v rossiyskoy populyatsii v 2012-2013 gg; Rezul’taty issledovaniya ESSE-RF [The prevalence of non-infectious diseases risk factors in russian population in 2012-2013 years; The results of ECVD-RF]. Kardiovaskulyarnaya terapiya i pro laktika [Cardiovascular Therapy and Prevention]. 2014; 13 (6): 4-11. (In Russ.)]. DOI: 10.15829/1728-8800-2014-6-4-11.

5. Drucker DJ. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. Cell Metabolism. 2021; 33 (3): 479-498. DOI: 10.1016/j.cmet.2021.01.016.

6. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using Open SAFELY. Nature. 2020; 584 (7821): 430-436. DOI: 10.1038/s41586-020-2521-4.

7. WangD,HuB,HuC,etal.ClinicalCharacteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061-1069. DOI: 10.1001/jama.2020.1585.

8. Coromilas EJ, Kochav S, Goldenthal I, et al. Worldwide Survey of COVID-19-Associated Arrhythmias. Circulation: Arrhythmia and Electrophysiology. 2021; 14 (3): e009458. DOI: 10.1161/CIRCEP.120.009458.

9. Cooper LT Jr. Myocarditis. N Engl J Med. 2009; 360 (15): 1526-1538. DOI: 10.1056/ NEJMra0800028.

10.Purohit A, Rokita AG, Guan X, et al. Oxidized Ca(2+) / calmodulin-dependent protein kinase II triggers atrial brillation. Circulation. 2013; 128 (16): 1748-1757. DOI: 10.1161/ CIRCULATIONAHA.113.003313.

11. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020; 5 (9): 1036-1041. DOI: 10.1001/jamacardio.2020.1834.

12.Lazzerini PE, Acampa M, Laghi-Pasini F, et al. Cardiac Arrest Risk During Acute Infections: Systemic In ammation Directly Prolongs QTc Interval via Cytokine-Mediated E ects on Potassium Channel Expression. Circulation: Arrhythmia and Electrophysiology. 2020; 13 (8): e008627. DOI: 10.1161/CIRCEP.120.008627.

13.Peltonen T, Näpänkangas J, Ohtonen P, et al. (Pro)renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis. Atherosclerosis. 2011; 216 (1): 35-43. DOI: 10.1016/j. atherosclerosis.2011.01.018.

14.Dweck MR, Bularga A, Hahn RT, et al. Global evaluation of echocardiography in patients with COVID-19. European Heart Journal - Cardiovascular Imaging. 2020; 21 (9): 949-958. DOI: 10.1093/ehjci/jeaa178.

15.Tudoran C, Tudoran M, Lazureanu VE, et al. Evidence of Pulmonary Hypertension after SARS-CoV-2 Infection in Subjects without Previous Signi cant Cardiovascular Pathology. Journal of Clinical Medicine. 2021; 10 (2): 199. DOI: 10.3390/jcm10020199. 16.Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and Cardiovascular Disease. Circulation. 2020; 14 (20): 1648-1655. DOI: 10.1161/CIRCULATIONAHA.120.046941.

17.Leone O, Veinot JP, Angelini A, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012; 21 (4): 245-274. DOI: 10.1016/j.carpath.2011.10.001.

18.Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. HeartRhythm. 2020;17 (9): 1463-1471. DOI: 10.1016/j.hrthm.2020.05.001


UDC 616.12-008.331.1-089 DOI: 10.20969/VSKM.2022.15(1).43-51


KAIPOV ARTUR E., ORCID ID: 0000-0001-8531-1315, Cardiovascular Surgeon, Interregional Clinical Diagnostic Center, 420101, Kazan, st. Karbysheva, 12a, e-mail: turik4martn@mail.ru, cell. tel.: 89377703642.

GEORGIKIA ROIN K., ORCID ID: 0000-0003-0309-7605, Professor, Doctor of Medical Sciences, Head of the Department of Cardiovascular and Endovascular Surgery, Kazan State Medical University, 420101, Kazan, st. Butlerov 49 , e-mail: roink@mail.ru

ABDULYANOV ILDAR V., ORCID ID: 0000-0003-2892-2827, Associate Professor, Candidate of Medical Sciences, Cardiovascular Surgeon, Interregional Clinical Diagnostic Center, 420101, Kazan, st. Karbysheva, 12a., the Head of the Department of cardiology, roentgen-endovascular and cardiovascular surgery of Kazan State Medical Academy – the branch of Russian Medical Academy of Postgraduate Education, Russia, 420012, Kazan, Butlerov str., 36, e-mail: ildaruna@mail.ru,

MUKHARYAMOV MURAT N., ORCID ID: 0000-0001-5814-7177, Associate Professor, Candidate of Medical Sciences, Interregional Clinical Diagnostic Center, 420101, Kazan, st. Karbysheva, 12a, e-mail: murat. mukharyamov@med.uni-jena.de,

VAGIZOV ILDAR I., ORCID ID: 0000-0002-3511-3211, Head of the Department of Cardiothoracic Surgery, Interregional Clinical Diagnostic Center, 420101, Kazan, st. Karbysheva, 12a, e-mail: i_vagizov@mail.ru

BIKCHURIN RUSLAN R., ORCID ID: 0000-0002-2174-1831, Interregional Clinical Diagnostic Center, 420101, Kazan, st. Karbysheva, 12a, e-mail: ruslan_radikovich89@mail.ru

SHORNINA ANNA S., ORCID ID: 0000-0001-9902-881X, Bashkir State Medical University, 450008, Ufa, st. Lenin, 3, e-mail: a.shornina@mail.ru

Abstract. Aim. The aim of the study is to compare the e ect of pulmonary hypertension on the outcome of tricuspid valve plasty in the groups with moderate and signi cant pulmonary hypertension. Material and methods. The results of surgical treatment of 620 patients with cardiac valve diseases were analyzed. Pulmonary artery systolic pressure (PASP) measured by echocardiography. Two groups were distinguished: Group 1 – pulmonary artery systolic pressure ˂ 50 mmHg. – 250 patients, Group 2-systolic pulmonary artery pressure ≥50 mm Hg. – 370 patients. Depending on the method of tricuspid insu ciency correction, subgroups were identi ed in each group: subgroup A – suture plasty was used, subgroup B – annuloplasty ring. Mann-Whitney U test was used to compare two independent samples. Chi-square test was used to compare the percentages in the groups. Results and discussion. In group I (PASP up to 50 mmHg) pressure in the PA decreased in the postoperative period, however in the long-term period in the suture plasty subgroup (subgroup A) PASP increased (p=0.01), in the annuloplasty ring subgroup (subgroup B) PASP after surgery and in the long-term period has not changed signi cantly. The mean value of tricuspid regurgitation (TR) was 1.27±0.4 in subgroup B and 2.1±0.6 in subgroup A (p=0.0227). In group II (signi cant pulmonary hypertension), postoperative PASP decreased to 50.5±13.2 (subgroup A) and 53.4±8.0 (subgroup B) mm Hg, however in the long-term follow-up there was an increase of pressure in PA to 58.3±10.7 and 56.4±11.8 mm Hg, respectively. In subgroup B, the long-term results were better in terms of TR degree, 1.6±0.5, in contrast to subgroup A, where the average degree was 2.6±0.7 (p=0.001). Tricuspid valve (TV) plasty with a annuloplasty ring preserved coaptation of the TV cusps and prevented residual tricuspid insu ciency despite the intensity of pulmonary hypertension. Conclusion. Surgical treatment of mitral and aortic heart diseases leads to decrease or normalization of pulmonary artery pressure. Pulmonary hypertension in the postoperative period is a factor that in uences the intensity of TR. All patients with signi cant functional TR as an outcome of left heart valve pathology should undergo TV annuloplasty. Correction with annuloplasty ring only is recommended for patients with signi cant pulmonary hypertension and signi cant TR.

Keywords: acquired heart diseases, pulmonary hypertension, tricuspid insu ciency, tricuspid valve plasty.

For reference: Kaipov AE, Dzhordzhikiya RK, Abdulyanov IV, Mukharyamov MN, Vagizov II, Bikchurin RR, Shornina AS. Pulmonary hypertension in uence on outcomes of secondary tricuspid insu ciency correction in patients for valvular heart disease. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1): 43–51. DOI: 10.20969/VSKM.2022.15(1).43-51


1. Micha T Maeder, Otto D Schoch, Rebekka Kleiner, Lucas Joerg, Daniel Weilenmann. Pulmonary hypertension associated with left-sided heart disease. Swiss Medical Weekly. 2017; 147: w14395. DOI: 10.4414/smw.2017.14395

2. Micha T Maeder, Lukas Weber, Marc Buser, Marc Gerhard, Philipp K Haager, Francesco Maisano, Hans Rickli. Pulmonary Hypertension in Aortic and Mitral Valve Disease. Frontiers in Cardiovascular Medicine. 2018; 5: 40. DOI: 10.3389/fcvm.2018.00040.

3. Lauren D C Casa, Joseph R Dolensky, Erin M Spinner, Emir Veledar, Stamatios Lerakis, Ajit P Yoganathan. Impact of pulmonary hypertension on tricuspid valve function. Annals of Biomedical Engineering. 2013;41(4):709-24. DOI: 10.1007/ s10439-012-0713-2.

4. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scienti c Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017 Sep 21;38(36):2739-2791. DOI: 10.1093/eurheartj/ehx391.

5. Абдульянов И.В., Вагизов И.И., Каипов А.Э., Хайруллин Р.Н. Хирургическое лечение вторичной трикуспидальной регургитации с помощью, модифицированной шовной аннулопластики // Вестник современной клинической медицины. – 2018. – Т. 11, вып. 2. – С.7-13. [Abdulyanov IV, Vagizov II, Kaipov AE, Khayrullin RN. Khirurgicheskoye lecheniye vtorichnoy trikuspidal'noy regurgitatsii s pomoshch'yu, modi tsirovannoy shovnoy annuloplastiki [Surgical treatment of secondary tricuspid regurgitation by the modi ed suture annuloplastic]. Vestnik sovremennoy klinicheskoy meditsiny [The Bulletin of Contemporary Clinical Medicine]. 2018; 1 (2): 7-13. (In Russ.)]. DOI: 10.20969/VSKM.2018.11(2).7-13.

6. Dreyfus GD, Corbi PJ, Chan KMJ, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? The Annals of thoracic surgery. 2005; 79 (1): 127-132. DOI: 10.1016/j.athoracsur.2004.06.057

7. Богачев-Прокофьев А.В., Овчаров М.А., Ленько Е.В., Пивкин А.Н., Афанасьев А.В., Шарифулин Р.М., Сапегин А.В., Караськов А.М. Сравнение эффективности и безопасности нехирургического ведения и пластики трикуспидального клапана у пациентов с сопутствующей умеренной недостаточностью трикуспидального клапана при хирургическом лечении пороков клапанов левых отделов сердца: метаанализ // Кардиология и сердечно-сосудистая хирургия. – 2018. – No 2. – С.4-14. [Bogachev-Prokof'yev AV, Ovcharov MA, Len'ko EV, Pivkin AN, Afanas'yev AV, Sharifulin RM, Sapegin AV, Karas'kov AM. Sravneniye e ektivnosti i bezopasnosti nekhirurgicheskogo vedeniya i plastiki trikuspidal'nogo klapana u patsiyentov s soputstvuyushchey umerennoy nedostatochnost'yu trikuspidal'nogo klapana pri khirurgicheskom lechenii porokov klapanov levykh otdelov serdtsa: metaanaliz [Comparison of the e cacy and safety of non-surgical management and tricuspid valve repair in patients with concomitant moderate tricuspid valve insu ciency in the surgical treatment of left heart valvular disease: a meta-analysis]. Kardiologiya i serdechno-sosudistaya khirurgiya [Cardiology and Cardiovascular Surgery]. 2018; 2: 4-14. (In Russ.)]. DOI: 10.17116/kardio20181124-14.

8. Zhu TY, Wang JG, Meng X. Does concomitant tricuspid annuloplasty increase perioperative mortality and morbidity when correcting left-sided valve disease? Interactive CardioVascular and Thoracic Surgery. 2015; 20 (1): 114–118. DOI: 10.1093/icvts/ivu326

9. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD; ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129 (23): 2440-2492. DOI: 10.1161/ CIR.0000000000000029.

10.Khorsandi M, Banerjee A, Singh H, Srivastava AR. Is a tricuspid annuloplasty ring signi cantly better than a De Vega's annuloplasty stitch when repairing severe tricuspid regurgitation? Interact Cardiovasc Thorac Surg. 2012; 15 (1): 129-135. DOI: 10.1093/icvts/ivs070.

11. Murashita T, Okada Y, Kanemitsu H, Fukunaga N, Konishi Y, Nakamura K, Koyama T. Long-term outcomes of tricuspid annuloplasty for functional tricuspid regurgitation associated with degenerative mitral regurgitation: suture annuloplasty versus ring annuloplasty using a exible band. Ann Thorac Cardiovasc Surg. 2014; 20 (6): 1026-1033. DOI: 10.5761/atcs. oa.13-00292.

12.Fukuda S, Gillinov AM, McCarthy PM, Stewart WJ, Song JM, Kihara T, Daimon M, Shin MS, Thomas JD, Shiota T. Determinants of recurrent or residual functional tricuspid regurgitation after tricuspid annuloplasty. Circulation. 2006; 114 (1 Suppl): I582-I587. DOI: 10.1161/ CIRCULATIONAHA.105.001305.

13.Azarnoush K, Nadeemy AS, Pereira B, Leesar MA, Lambert C, Azhari A, Eljezi V, Dauphin N, Geo roy E, Camilleri L. Clinical outcomes of tricuspid valve repair accompanying left-sided heart disease. World J Cardiol. 2017; 9 (10): 787-793. DOI: 10.4330/wjc.v9.i10.787.

14.Maeder MT, Schoch OD, Kleiner R, Joerg L, Weilenmann D, Swiss Society For Pulmonary Hypertension. Pulmonary hypertension associated with left-sided heart disease. Swiss Med Wkly. 2017; 147: w14395. DOI: 10.4414/ smw.2017.14395.


 UDC 616.24-007.63; 616-097 DOI: 10.20969/VSKM.2022.15(1).52-61


KARZAKOVA LOUISE M., ORCID ID: 0000-0002-5899-6352; SCOPUS Author ID: 56916027300, D. Med. Sci, Professor, Head of the Department of Internal Medicine, Chuvashskii State University, 428015 Russia, Cheboksary, Moskovskii' pr., 15, +7 (903) 358-82-89, e-mail: luizak58@mail.ru.

ALEKSEEVA EVGENIYA P., ORCID ID: 0000-0002-3799-4278; Assistant Professor, Department of Internal Medicine, Chuvashskii State University, 428015 Russia, Cheboksary, Moskovskii' pr., 15, +7 (961) 340-05-80, e-mail: evgenia010307@mail.ru

KUDRYASHOV SERGEY I., ORCID ID: 0000-0003-2277-9425; C. Med. Sci., Associate Professor, Department of Internal Medicine, Chuvashskii State University, 428015 Russia, Cheboksary, Moskovskii' pr., 15,
+7 (917) 652-34-99, e-mail: medicpro21@mail.ru

ZHURAVLEVA NADEZHDA V., ORCID ID: 0000-0001-6470-7724; C. Med. Sci., Associate Professor, Department of Internal Medicine, Chuvashskii State University, 428015 Russia, Cheboksary, Moskovskii' pr., 15,
+7 (903) 358-71-78, e-mail: zhuravlevanv@mail.ru

UKHTEROVA NADEZHDA D., ORCID ID: 0000-0003-1808-6845; C. Med. Sci., Associate Professor, Department of Internal Medicine, Chuvashskii State University, 428015 Russia, Cheboksary, Moskovskii' pr., 15,
+7 (906) 136-73-41; e-mail: 55dd@mail.ru

ANDREEVA NATALIA P., ORCID ID: 0000-0002-1989-3334; SCOPUS Author ID: 21733375100, C. Med. Sci., Allergist/Immunologist, City Children's Clinical Hospital, Russia, 428015, Cheboksary, Traktorostroiteley str., 12, +7 (903) 358-27-02; e-mail: Nataliutt@ya.ru

Abstract. Aim. The aim of the research was to study the role of immunological mechanisms in the unfavorable outcome of chronic obstructive pulmonary disease (COPD). Material and methods. The research included 116 patients hospitalized in 2005-2006 in the pulmonology department of patients with the exacerbation of mild and moderate COPD. Research protocol: general clinical and special (immunological) methods of examination were performed in patients with COPD. Instrumental research methods included: spirography, ECG, EchoCG, brobronchoscopy, chest X-ray. After diagnostic bronchoscopy, bronchoalveolar uid (BAF) was taken for cytological and immunological examination. On the rst and second days of inpatient treatment, patients underwent immunological studies: immunophenotyping of mononuclear cells (MNC), assessment of phagocytic activity of leukocytes (latex test, nitroblue tetrazolium (NBT) test) in blood and BAF, determination of the content of immunoglobulins in blood serum and BAF, study of cytokine levels in blood serum, BAF and MNC culture supernatant under conditions of their spontaneous production and activation in the mitogen-stimulated (phytohemagglutinin "Difco" 5 mg/ml) proliferation. Statistical data processing was carried out using the Statistica 10.0 program. In 2020, the long-term survival of COPD patients was assessed. The cohort of patients was divided into two groups. Survivors were included in the rst group (n=44), and patients who died by 2020 were included in the other group (n=72). The retrospective comparison of the studied indicators was determined at the time of COPD exacerbation in 2005-2006 in these patient groups. Results and discussion. In the surviving patients, the BAF cytogram was distinguished by the higher macrophage content and the increased number of NBT-positive cells in this population with the reduced neutrophil content in both blood and BAF. The deceased had elevated levels of IgM and IgA in the blood serum and BAF. The results of the study of cytokine production in MNC cultures in vitro indicate that the ratio of IFN-γ/IL-4 in the conditions of spontaneous cytokine production was higher in the deceased compared with the indicators of the surviving patients. This fact indicates the polarization of the immune response of the deceased in the direction of the cell type mediated by Th1 cells, which is con rmed by the peculiarities of the BAF cytokine pro le in the deceased – the signi cant increase in the value of IFN-γ/IL-4 relative to the indicators in the survivors. Conclusion. The unfavorable outcome of COPD is associated with the increase in the number of neutrophil cells in BAF, in the blood, with the predominance of Th1-type activation of adaptive immunity at the local level and activation of both cellular and humoral mechanisms of adaptive immunity at the systemic level. The increased activity of innate immunity in COPD exacerbation, manifested by the increase in the number and metabolic activity of macrophages, is associated with the long-term survival of patients.

Key words: chronic obstructive pulmonary disease, mortality, disease outcome, cytokines, Th1 cells.

For reference: Karzakova LM, Alekseeva EP, Kudryashov SI, Zhuravleva NV, Ukhterova ND, Andreeva NP. The role of immunological factors in the unfavorable outcome of chronic obstructive pulmonary disease. The Bulletin of Contemporary Clinical Medicine. 2022;15(1):52– 61. DOI: 10.20969/VSKM.2022.15(1).51-62.


1. Lortet-Tieulent J, Soerjomataram I, López-Campos JL, Ancochea J, Coebergh JW, Soriano JB. International trends in COPD mortality, 1995-2017. Eur Respir J. 2019; 54 (6): 1901791. DOI: 10.1183/13993003.01791-2019.

2. RabeKF,WatzH.Chronicobstructivepulmonary disease. Lancet. 2017; 389 (10082): 1931-1940. DOI: 10.1016/S0140-6736(17)31222-9.

3. Tam A, Tanabe N, Churg A, Wright JL, Hogg JC, Sin DD. Sex di erences in lymphoid follicles in COPD airways. Respir Res. 2020; 21 (1): 46. DOI: 10.1186/s12931-020-1311-8.

4. Bai JW, Chen XX, Liu S, Yu L, Xu JF. Smoking cessation a ects the natural history of COPD. Int J Chron Obstruct Pulmon Dis. 2017; 12: 3323-3328. DOI:10.2147/COPD.S150243.

5. Gamble E, Grootendorst DC, Hattotuwa K, O’Shaughnessy T, Ram FS, Qiu Y, Zhu J, Vignola AM, Kroegel C, Morell F, Pavord ID, Rabe KF, Je ery PK, Barnes NC. Airway mucosal in ammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J. 2007; 30 (3): 467-471. DOI: 10.1183/09031936.00013006.

6. MacLeod M, Papi A, Contoli M, Beghé B, Celli BR, Wedzicha JA, Fabbri LM. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology. 2021; 26 (6): 532-551. DOI: 10.1111/resp.14041.

7. Waeijen-Smit K, Houben-Wilke S, DiGian-domenico A, Gehrmann U, Franssen FME. Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease. Intern Emerg Med. 2021; 16 (3): 559-569. DOI: 10.1007/s11739-020-02612-9.

8. Whittaker Brown SA, Braman S. Recent Advances in the Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Med Clin North Am. 2020; 104 (4): 615-630. DOI: 10.1016/j.mcna.2020.02.003.

9. Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí A, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL. An O cial American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015; 191 (7): e4-e27. DOI: 10.1164/ rccm.201501-0044ST.

10. Tockman MS, Anthonisen NR, Wright EC, Donithan MG. Airways obstruction and the risk for lung cancer. Ann Intern Med. 1987; 106 (4): 512-518. DOI: 10.7326/0003-4819-106-4-512.

11. Клиническая лабораторная диагностика (методы и трактовка лабораторных исследований) / под ред. проф. В.С.Камышникова. – 2-е изд. – М.: МЕДпресс-информ, 2017. – 720 с. [Kamyshnikov VS, ed. Klinicheskaya laboratornaya diagnostika (metody i traktovka laboratornyh issledovanij) [Clinical laboratory diagnostics (methods and interpretation of laboratory research)]. Moskva: MEDpress-inform [Moscow: MEDpress-inform]. 2017; 2: 720 p. (In Russ.)].

12.Карзакова Л.М., Кудряшов С.И., Луткова Т.С. [и др.]. Основы общей иммунологии: учеб. Пособие / Чебоксары: Издательство Чувашского университета, 2020. – 200 с. [Karzakova LM, Kudryashov SI, Lutkova T.S, Sokolova EV, Sidorov IA. Osnovy obshchej immunologii: uchebnoe posobie [Fundamentals of general immunology: textbook]. Cheboksary: Izdatel’stvo Chuvashskogo universiteta [Cheboksary: Chuvash University Press]. 2020; 200 p. (In Russ.)].

13. Раков А.Л., Панфилов Д.Н., Гельцер Б.И. Местный клеточный и гуморальный иммунитет у больных острым бронхитом / Военно-медицинский журнал. – 2001. – No 2. – С.44-49. [Rakov AL, Pan lov DN, Gel’cer BI. Mestnyj kletochnyj i gumoral’nyj immunitet u bol’nyh ostrym bronhitom [Local cellular and humoral immunity in patients with acute bronchitis]. Voenno-medicinskij zhurnal [Military Medical Journal.]. 2001; 2: 44-49. (In Russ.)].

14.Schildge J, Klar B, Hardung-Backes M. Die Mastzelle in der bronchoalveolären Lavage bei interstitiellen Lungenerkrankungen [Mast cells in bronchoalveolar lavage uid of patients with interstitial lung diseases]. Pneumologie. 2003; 57 (4): 202-207. DOI: 10.1055/s-2003-38569.

15.Bastian A, Tunkel C, Lins M, Böttcher H, Hirt SW, Cremer J, Bewig B. Immunoglobulin A and secretory immunoglobulin A in the bronchoalveolar lavage from patients after lung transplantation. Clin Transplant. 2000;14(6):580-5. DOI: 10.1034/j.1399-0012.2000.140611.x.

16.Мурашов Э.Г., Столов С.В., Тотолян А.А. Цитокиновый профиль бронхоальвеолярной жидкости у больных бронхиальной астмой / Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. – 2012. – Т. 4, No1. – С. 67-72. [Murashov EG, Stolov SV, Totolyan AA. Citokinovyj pro l’ bronhoal’veolyarnoj zhidkosti u bol’nyh bronhial’noj astmoj [Cytokine pro le of bronchoalveolar uid in patients with bronchial asthma]. Vestnik Severo-Zapadnogo gosudarstvennogo medicinskogo universiteta imeni II Mechnikova [Bulletin of the II Mechnikov Northwestern State Medical University]. 2012; 4 (1): 67-72. (In Russ.)].

17.Forsslund H, Yang M, Mikko M, Karimi R, Nyrén S, Engvall B, Grunewald J, Merikallio H, Kaarteenaho R, Wahlström J, Wheelock ÅM, Sköld CM. Gender di erences in the T-cell pro les of the airways in COPD patients associated with clinical phenotypes. Int J Chron Obstruct Pulmon Dis. 2016; 12: 35-48. DOI: 10.2147/COPD. S113625.

18. Byun MK, Cho EN, Chang J, Ahn CM, Kim HJ. Sarcopenia correlates with systemic in ammation in COPD. Int J Chron Obstruct Pulmon Dis. 2017; 12: 669-675. DOI: 10.2147/COPD.S130790.

19.Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest. 2012; 122 (8): 2749-2755. DOI: 10.1172/ JCI60324.

20.Cheng G, Zhang N, Wang Y, Rui J, Yin X, Cui T. Antibodies of IgG, IgA and IgM against Human Bronchial Epithelial Cell in Patients with Chronic Obstructive Pulmonary Disease. Clin Lab. 2016; 62 (6): 1101-1108. DOI: 10.7754/clin. lab.2015.151020.

21.Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, Green L, Hacken-Bitar J, Huh J, Bakaeen F, Coxson HO, Cogswell S, Storness-Bliss C, Corry DB, Kheradmand F. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med. 2007; 13 (5): 567-569. DOI: 10.1038/nm1583.

22.Ravindran M, Khan MA, Palaniyar N. Neutrophil Extracellular Trap Formation: Physiology, Pathology, and Pharmacology. Biomolecules. 2019; 9 (8): 365. DOI: 10.3390/biom9080365.

23. Castanheira FVS, Kubes P. Neutrophils and NETs in modulating acute and chronic in ammation. Blood. 2019; 133 (20): 2178-2185. DOI: 10.1182/ blood-2018-11-844530.

24.Dicker AJ, Crichton ML, Pumphrey EG, Cassidy AJ, Suarez-Cuartin G, Sibila O, Furrie E, Fong CJ, Ibrahim W, Brady G, Einarsson GG, Elborn JS, Schembri S, Marshall SE, Palmer CNA, Chalmers JD. Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018; 141 (1): 117-127. DOI: 10.1016/j. jaci.2017.04.022.

25.Ma A, Wen L, Yin J, Hu Y, Yue X, Li J, Dong X, Gupta Y, Ludwig RJ, Krauss-Etschmann S, Riemekasten G, Petersen F, Yu X. Serum Levels of Autoantibodies Against Extracellular Antigens and Neutrophil Granule Proteins Increase in Patients with COPD Compared to Non-COPD Smokers. Int J Chron Obstruct Pulmon Dis. 2020; 15: 189-200. DOI: 10.2147/COPD.S235903.



 UDC: 616.235:616-052 DOI: 10.20969/VSKM.2022.15(1).62-67


KULIK EKATERINA G., SPIN-код: 7661-1946; ORCID ID: 0000-0002-6059-1813; C. Med. Sci., associate professor, Department of Internal Medicine, Amur State Medical Academy, 675006, Russia, Amur Region, Blagoveshchensk, st. Gorky, house 95, e-mail: rybas_katya@mail.ru

PAVLENKO VALENTINA I., SPIN-код: 1172-1390; ORCID ID: 0000-0001-8794-9929; Dr. med. Sci., associate professor, professor, Department of Internal Medicine, Amur State Medical Academy, 675006, Russia, Amur Region, Blagoveshchensk, st. Gorky, building 95.

NARYSHKINA SVETLANA V., SPIN-код: 3909-2850; ORCID ID: 0000-0003-0587-456X; Dr. med. Sci., Professor, Head of the Department of Internal Medicine, Amur State Medical Academy, 675006, Russia, Amur Region, Blagoveshchensk, st. Gorky, building 95.

Abstract. Introduction. According to current data, the COPD phenotype without frequent exacerbations is frequently encountered and requires close attention. However, in the course of a literary search, it was possible to nd only isolated scienti c works with a generalized description of the features of this phenotype. Aim. The aim of the study is to compile a typical clinical portrait of a patient with the COPD phenotype without frequent exacerbations based on the analysis of clinical, laboratory and functional parameters. Material and methods. The study included 45 patients aged 57.2±1.1 years with a diagnosis of COPD without frequent exacerbations in age. In all patients, the concentration of proin ammatory cytokines, C-reactive protein in blood serum was determined by immunoferment analysis. Results and discussion.Males (93.3%) with a smoker index of 33.7± 2.5 packs/years and a disease duration of more than 10 years dominated the studied cohort. The average score on the CAT test was 10.32±0.05 points, on the mMRC scale more than two points. The post - bronchodilation value of FEV1 corresponded to the average severity of obstructive disorders in 91.1% of individuals. Among the examined patients, persons with bronchitic type of COPD predominated (53.3%). The concentration of in ammatory biomarkers determined in the blood serum signi cantly exceeded the levels of the reference values. Also, patients with COPD with the studied phenotype was found to have low adherence to treatment and dispensary observation and late visit to the doctor. Conclusions. The obtained results of the study made it possible to draw up a clinical portrait of the patient with the COPD phenotype without frequent exacerbations.

Key words: phenotype, chronic obstructive pulmonary disease without frequent exacerbations, rare exacerbations.

For reference: Kulik EG, Pavlenko VI, Naryshkina SV. Clinical and functional portrait of a patient with chronic obstructive pulmonary disease phenotype without frequent exacerbations. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1):62–67. DOI: 10.20969/VSKM.2022.15(1).62-67.


1. Под ред. Белевского А.С. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2014 г.) // Москва: Российское респираторное общество, 2015 – 92 с. [Belevskogo AS, ed. Global’naya strategiya diagnostiki, lecheniya i pro laktiki hronicheskoj obstruktivnoj bolezni legkih (peresmotr 2014 goda) [Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2014)]. Moskva: Rossijskoe respiratornoe obshchestvo [Moscow: Russian Respiratory Society]. 2015; 92 p. (In Russ.)].

2. Оперативные демографические показатели за январь - июнь 2020 года // Федеральная служба государственной статистики: [сайт]. - 2020. – URL: https://rosstat.gov.ru/regional_statistics [Operativnye demogra cheskie pokazateli za yanvar’ - iyun’ 2020 goda [Operational demographic indicators for January - June 2020]. Federal’naya sluzhba gosudarstvennoj statistiki [Federal State Statistics Service]. 2020; https:// rosstat.gov.ru/regional_statistics (In Russ.)].

3. Mannino DM, Clerisme-Beaty EM, Franceschina J, Ting N, Leidy NK. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data. Int J Chron Obstruct Pulmon Dis. 2018; 13: 1515-1525. DOI: 10.2147/COPD.S149669.

4. Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP. E ect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017; 128: 85-91. DOI: 10.1016/j.rmed.2017.04.013. Epub 2017 Apr 24.

5. Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax. 2012; 67 (3): 238-243. DOI: 10.1136/ thoraxjnl-2011-200768.

6. Концевая А.В., Муканеева Д.К., Баланова Ю.А., и др. Экономический ущерб от болезней органов дыхания и хронической обструктивной болезни легких в Российской Федерации в 2016 году // Пульмонология. – 2019. -No 29 (2). – С.159–166. [Koncevaya AV, Mukaneeva DK, Balanova YuA, Hudyakov MB, Drapkina OM. Ekonomicheski ushcherb ot bolezne organov dyhaniya i hronichesko obstruktivno bolezni legkih v Rossi sko Federacii v 2016 godu [Economic burden of respiratory diseases and chronic obstructive pulmonary disease in Russian Federation, 2016]. Pul’monologiya [Pulmonologiya]. 2019; 29 (2): 159-166. (In Russ.)]. DOI: 10.18093/0869-0189-2019-29-2-159-166.

7. Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, Varela MVL, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report; GOLD Executive Summary. Arch Bronconeumol. 2017; 53 (7): 411-412. DOI: 10.1016/ j.arbres.2017.06.001.

8. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010; 182 (5): 598-604. DOI: 10.1164/ rccm.200912-1843CC.

9. НевзороваВ.А.,АвдеевС.Н.,КондрашоваН.М., и др. Дискуссионные вопросы терапии хронической обструктивной болезни легких (Материалы совета экспертов ДФО ОТ 13.06.2018 Г., Владивосток) // Тихоокеанский медицинский журнал. - 2019. - T. 75. - No 1. - С.5-12. [Nevzorova VA, Avdeev SN, Kondrashova NM, Shumatov VB, Kudelya LM, Sukhanova GI, Kinyaykin MF, Naumova IV, Kudryavtseva VA, Khizhnyak YuYu, Musatov IB. Diskussionnye voprosy terapii hronicheskoj obstruktivnoj bolezni legkih (Materialy soveta ekspertov DFO 13/06/2018, Vladivostok) [Argumentative issues of chronic obstructive pulmonary disease (materials of panel of experts, Far Eastern Federal District from 13/06/2018, Vladivostok)]. Tihookeanskij medicinskij zhurnal [Paci c Medical Journal]. 2019; 1: 5-12. (In Russ.)].

10.Tudoric N, Koblizek V, Miravitlles M, Valipour A, Milenkovic B, Barczyk A, Somfay A, Zykov K, Kostov K, Zbozinkova Z, Svoboda M, Sorli J, Krams A, Tkacova R. GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort Eur Respir J. 2017; 49 (4): 1602518. DOI: 10.1183/13993003.02518-2016.

11. Колосов В.П., Павленко В.И. Прогнозирование частоты обострения хронической обструктивной болезни легких, сочетанной с ишемической болезнью сердца // Бюллетень физиологии и патологии дыхания. - 2012. - No 45. - С.35- 37. [Kolosov VP, Pavlenko VI. Prognozirovanie chastoty obostreniya hronicheskoj obstruktivnoj bolezni legkih, sochetannoj s ishemicheskoj bolezn’yu serdca [Prognostication of the frequency of chronic obstructive pulmonary disease exacerbation combined with the ishemic heart disease]. Byulleten’ ziologii i patologii dyhaniya [Bulletin Physiology and Pathology of Respiration]. 2012; 45: 35-37. (In Russ.)].

12.Calle Rubio M, Casamor R, Miravitlles M. Identi cation and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study. Int J Chron Obstruct Pulmon Dis. 2017; 12: 2373-2383. DOI: 10.2147/COPD.S137872.

13.Зыков К.А., Овчаренко С.И., Авдеев С.Н., и др. Фенотипические характеристики пациентов с хронической обструктивной болезнью легких, имеющих стаж курения, в российской федерации: Данные исследования POPE-STUDY // Пульмонология. - 2020. - Т. 30., No 1. - С.42-52. [Zykov KA, Ovcharenko SI, Avdeev SN, Zhestkov AV, Il’kovich MM, Nevzorova VA, Farkhutdinov UR, Khamitov RF, Rvacheva AV, Chuchalin AG. Fenotipicheskie harakteristiki pacientov s hronicheskoj obstruktivnoj bolezn’yu legkih, imeyushchih stazh kureniya, v rossijskoj federacii: Dannye issledovaniya POPE-STUDY [Phenotypic characteristics of COPD patients with a smoking history in POPE-study in the Russian Federation]. Pul’monologiya [Pulmonologiya]. 2020; 30 (1): 42-52. (In Russ.)].

14.Овчаренко C.B. Хроническая обструктивная болезнь легких: реальная ситуация в России и пути ее преодоления // Пульмонология. - 2011. - No 6 – С.69-72. [Ovcharenko SI. Hronicheskaya obstruktivnaya bolezn’ legkih: real’naya situaciya v Rossii i puti ee preodoleniya [Chronic obstructive pulmonary disease: actual situation in Russia and ways to solve the problem]. Pul’monologiya [Pulmonologiya]. 2011; 6: 69-72. (In Russ.)]. DOI: 10.18093/0869-0189-2011-0-6-69-72.

15.Чучалин А.Г., Авдеев С.Н., Айсанов З. Р., и др. Хроническая обструктивная болезнь легких. Федеральные клинические рекомендации // Москва: Российское Респираторное общество, 2018. - 76 с. [Chuchalin AG, Avdeev SN, Ajsanov ZR, et al. Hronicheskaya obstruktivnaya bolezn’ legkih. Federal’nye klinicheskie rekomendacii [Chronic obstructive pulmonary disease. Federal clinical guidelines]. Moskva: Rossijskoe Respiratornoe obshchestvo [Moscow: Russian Respiratory Society]. 2018; 76 p. (In Russ.)]. 16. Jones PW, Harding G, Berry P, et al. Development and rst validation of the COPD Assessment. Eur Respir J. 2009; 34 (3): 648-654.

17.Donaldson GC, Wedzicha JA. The causes and consequences of seasonal variation in COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2014; 9: 1101–1110.

18. Методические рекомендации по использованию метода спирометрии // Москва: Российское Респираторное общество, 2019. - 36 с. Режим доступа: URL: https://spulmo.ru/ obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii/ [Rossijskoe Respiratornoe obshchestvo [Russian Respiratory Society]. Metodicheskie rekomendacii po ispol’zovaniyu metoda spirometrii [Metodical guidelines for the use of the spirometry method]. Moskva [Moscow]. 2019; 36 p. (In Russ.)].

19.Трушина Е.Ю., Костина Е.М., Молотилов Б.А., и др. Роль цитокинов IL-4, IL-6, IL-8, IL-10 в иммунопатогенезе хронической обструктивной болезни легких // Медицинская иммунология. – 2019. - Т. 21, No 1. – С.89-98. [Trushina EYu, Kostina EM, Molotilov BA, Tipikin VA, Baranova NI. Rol’ citokinov IL-4, IL-6, IL-8, IL-10 v immunopatogeneze hronicheskoj obstruktivnoj bolezni legkih [Role of IL-4, IL-6, IL-8, IL-10 cytokines in the immunopathogenesis of chronic obstructive pulmonary disease]. Meditsinskaya Immunologiya [Medical Immunology]. 2019; 21 (1): 89-98. (In Russ.)]. DOI: 10.15789/1563-0625-2019-1-89-98

20.Eapen MS, Myers S, Walters EH, Sohal SS. Airway in ammation in chronic obstructive pulmonary disease (COPD): a true paradox. Expert Rev Respir Med. 2017; 11 (10): 827-839. DOI: 10.1080/17476348.2017.1360769.


UDC 611.813.1 DOI: 10.20969/VSKM.2022.15(1).68-75


PETUKHOVA ELENA O., ORCID ID: 0000-0002-9100-815X; Researcher, Institute of Neuroscience, Kazan State Medical University, 49 Butlerova str., Kazan, 420012, Russia, tel: +7-843-292-72-99, e-mail: petukhovaeo@mail.ru

MUKHAMEDSHINA YANA O., ORCID ID: 0000-0002-9435-340X; C. Med. Sci., Associate Professor, Department of Histology, Cytology and Embryology, Kazan State Medical University, 420012, Russia, Kazan, 49 Butlerova Str., Leading Researcher of Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 18 Kremlevskaya Str., Kazan, 420008, Russia, tel: +7-843-292-76-19, e-mail: yana.k-z-n@mail.ru

TIMOFEEVA ANNA V., ORCID ID: 0000-0002-3393-6775; laboratory assistant-researcher of Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan, Kremlevskaya str. 18, 420008, Russia, tel: +7-843-292-76-19, anua_tima@mail.ru

RIZVANOV ALBERT A., ORCID ID: 0000-0002-9427-5739; Doctor of Biological Sciences, Chief Researcher of Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan,
Kremlevskaya str. 18, 420008, Russia, tel: +7-843-293-43-07, e-mail: rizvanov@gmail.com

MUKHAMEDYAROV MARAT A., ORCID ID: 0000-0002-0397-9002; Doctor of Medical Sciences, Professor of the Department of Normal Physiology, Kazan State Medical University, 49 Butlerova str., Kazan, 420012, Russia, tel: +7-843-292-72-99, e-mail: marat.muhamedyarov@kazangmu.ru

Abstract. Introduction. Alzheimer's disease is a neurodegenerative disease characterized by a progressive decline in cognitive functions. Alzheimer’s disease is the most common form of dementia and one of the main causes of disability in older people. Neuroin ammation is an important factor in the pathogenesis of Alzheimer's disease. The neuroin ammatory reaction observed in Alzheimer's disease is primarily caused by resident immune cells of the central nervous system, including microglia and astrocytes. Aim. The aim of this work was to study the e ect of transplantation of human umbilical cord blood mononuclear cells (UCBMC) overexpressing glial neurotrophic factor (GDNF) on the state of microglia and astrocytes in APP/PS1 transgenic mice with Alzheimer's disease model. Material and methods. Xenotransplantation of gene-cell structures to experimental animals was carried out retroorbitally, once in the amount of 2 million cells. Immuno uorescence examination of cryostatic sections of the brain was carried out by applying antibodies to ionized calcium-binding adaptive molecule 1 (Iba1, marker of microglia and macrophages) and antibodies to glial brillar acid protein (GFAP, marker of astrocytes) and subsequent imaging on a confocal scanning microscope LSM 510-Meta (Carl Zeiss). Results and discussion. It was found that transplantation of UCBMC overexpressing GDNF reduced the severity of microgliosis in the parietal cortex and dentate gyrus of the hippocampus, and also reduced the severity of astrogliosis in the CA3 zone of the hippocampus of the brain of APP/PS1 mice. Transplantation of UCBMC overexpressing enhanced green uorescent protein (EGFP) only reduced the severity of microgliosis in the parietal cortex of APP/PS1 mice.Conclusion. The data obtained indicate a high therapeutic potential of transplantation of UCBMC overexpressing GDNF in Alzheimer's neuropathology.

Keywords: Alzheimer's disease, neuroin ammation, microglia, astrocytes, gene-cell therapy.

For reference: Petukhova EO, Mukhamedshina YO, Timofeeva AV, Rizvanov AA, Mukhamedyarov MA. The e ect of transplantation of human umbilical cord blood mononuclear cells overexpressing glial neurotrophic factor on the state of microglia and astrocytes in transgenic mice with Alzheimer's disease model. // Вестник современной клинической медицины. – 2022. – Т. 15, вып. 1. – С.68–75. DOI: 10.20969/VSKM.2022.15(1).68-75.


1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003; 60 (8): 1119-1122. DOI: 10.1001/archneur.60.8.1119.

2. Heppner FL, Ransoho RM, Becher B. Immune attack: the role of in ammation in Alzheimer disease. Nat Rev Neurosci. 2015; 16 (6): 358-372. DOI: 10.1038/nrn3880.

3. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C, Manalastas A, Hil ker M, P ster S, Schwerdel C, Riether C, Meyer U, Knuesel I. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroin ammation. 2012; 9: 151. DOI: 10.1186/1742-2094-9-151.

4. Gisondi P, Sala F, Alessandrini F, Avesani V, Zoccatelli G, Beltamello A, Moretto G, Gambina G, Girolomoni G. Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatology. 2014; 228 (1): 78-85. DOI: 10.1159/000357220.

5. Thaler JP, Yi CX, Schur EA, Guyenet SJ, Hwang BH et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 2012; 122 (1): 153-162. DOI: 10.1172/JCI59660.

6. Mayeux R, Ottman R, Tang MX, Noboa-Bauza L, Marder K, Gurland B, Stern Y. Genetic susceptibility and head injury as risk factors for Alzheimer’s disease among community-dwelling elderly persons and their rst-degree relatives. Ann Neurol. 1993; 33 (5): 494-501. DOI: 10.1002/ ana.410330513.

7. Darlington D, Deng J, Giunta B, Hou H, Sanberg CD, Kuzmin-Nichols N, Zhou HD, Mori T, Erhart J, Sanberg PR, Tan J. Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-beta-associated neuropathology in Alzheimer mice. Stem Cells Dev. 2013; 22 (3): 412-421. DOI: 10.1089/scd.2012.0345.

8. Nikolic WV, Hou H, Town T, Zhu Y, Giunta B, Sanberg CD, Zeng J, Luo D, Erhart J, Mori T, Sanberg PR, Tan J. Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice. Stem Cells Dev. 2008; 17 (3): 423-439. DOI: 10.1089/scd.2008.0018.

9. Петухова Е.О., Мухамедшина Я.О., Ризванов А.А., и др. Трансплантация мононуклеарных клеток пуповинной крови человека улучшает пространственную память у APP/PS1 трансгенных мышей с моделью болезни Альцгеймера // Гены и клетки. – 2014. – Вып. 9, No 3. – С.40-45. [Petuhova EO, Mukhamedshina YO, Rizvanov AA, Mukhitov AR, Ze rov AL, Islamov RR, Mukhamedyarov MA. Transplantaciya mononuklearnyh kletok pupovinnoj krovi cheloveka uluchshaet prostranstvennuyu pamyat’ u APP/ PS1 transgennyh myshej s model’yu bolezni Al’cgejmera [Transplantation of mononuclear cells of human umbilical cord blood improves spatial memory in APP/PS1 transgenic mice with Alzheimer’s disease model]. Geny i kletki [Genes and Cells]. 2014; 9 (3): 40-45. (In Russ.)].

10.Rocha SM, Cristovao AC, Campos FL, Fonseca CP, Baltazar G. Astrocyte-derived GDNF is a potent inhibitor of microglial activation. Neurobiol Dis. 2012; 47 (3): 407-415. DOI: 10.1016/ j.nbd.2012.04.014. 



 UDC 613.84.373 DOI: 10.20969/VSKM.2022.15(1).76-87


SKVORTSOVA ELENA S., ORCID ID: 0000-0003-2723-4029; SCOPUS Autor ID: 57213394865, D. Med. Sci, professor, Chief Researcher of the Department of Public Health and Demography, Federal Research Institute for Health Organization and Informatics, Russia, 127254, Moscow, Dobrolyubov str., 11, e-mail: scvortsova@mednet.ru

LUSHKINA NINA P., ORCID ID: 0000-0002-4861-2773; SCOPUS Autor ID: 57225233709; Candidate of Economic Sciences, Leading Researcher of the Department of Public Health and Demography, Federal Research Institute for Health Organization and Informatics, Russia, 127254, Moscow, Dobrolyubov Str., 11.

Abstract. Introduction. To this day, the problem of tobacco smoking among the population remains relevant throughout the world. Since the majority of smokers (about 90%) acquire this habit before the age of 18, WHO believes that special attention should be paid to protecting the younger generation from smoking and the harmful e ects of tobacco. For this, it is necessary to conduct research to study the behavior of school-age children. Aim. The aim is to identify the main trends of tobacco smoking among urban teenagers-schoolchildren in the Russian Federation for the period from 1999-2000, 2010-2011 and 2019-2020. Material and methods. A sample of adolescents in each subject of the Russian Federation was formed by multi-stage selection with alternating typological, random and continuous examination. In 1999-2000, 12912 urban teenagers were interviewed, of which 5939 boys and 6973 girls, in 2010-2011 - 15323, of which 6961 boys and 8362 girls, in 2019-2020 - 14084 teenagers, of which 6535 boys and 7549 girls. Statistical development of materials was carried out using the computer program "Risk factors". The Pearson criterion 2 was used to calculate the statistical signi cance of the di erences in indicators. Results and discussion. During the period under review, the prevalence of smoking and daily smoking tended to decrease, both among boys (4.5 times) and among girls (3.2 times). At the same time, if the prevalence of boys who smoked over girls also decreased and by 2019-2020 the proportion of boys and girls who smoked was equal, then among teenagers who smoked daily, the proportion of boys remained, as before, higher than the proportion of girls (1,2 times). The proportion of teenagers who smoked for reasons of emerging addiction ("like", "out of habit", "I can't quit") tended to increase, both among boys and girls. During the period under review, the motive of the rst smoking test "curiosity", both boys and girls, retained its primacy. The age interval for introducing urban teenagers-schoolchildren to tobacco smoking has not changed either (from 10 years to 17 years inclusive). However, the "peak" of initiation to smoking in boys moved from the age range up to 10 years inclusive in 1999-2000 and, starting from 2010-2011. and in 2019-2020, for the age range of 13-14 years, for girls, the age range of 13-14 years retained its position as the "peak" of initiation to smoking. Conclusion. A comparative analysis showed a signi cant decrease in the prevalence of smoking among urban teenage schoolchildren in the Russian Federation.

Key words: Russia, urban adolescents, tobacco smoking, prevalence, motives, dynamics.

For reference: Skvortsova ES, Lushkina NP. The main trends in tobacco smoking among Russian adolescents over the 20 years of the XXI century. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1):76–87. DOI: 10.20969/ VSKM.2022.15(1).76-87.


1. ВОЗ. Рамочная Конвенция ВОЗ по борьбе против табака (РКБТ) // Женева, 2003. – 59 с. [ VOZ. Ramochnaya Konventsiya VOZ po bor’be protiv tabaka (RKBT) [WHO Framework Convention on Tobacco Control]. Zheneva, Shveytsariya [Geneva, Switzerland]. 2003; 59 p. http://apps.who.int/iris/bitstream/ handle/10665/42811/9241591013.pdf;jsessionid =5FC1544EFFA3AC852A9C0F046AF5AB15?se quence=1]

2. National Center for Chronic Disease Prevention and Health Promotion (US) O ce on Smoking and Health. Preventing Tobacco Use Among Youth and Young Adults: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2012. https:// pubmed.ncbi.nlm.nih.gov/22876391/

3. 3. GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021; 397 (10292): 2337-2360. DOI: 10.1016/S0140-6736(21)01169-7

4. Preventing Tobacco Use Among Youths, Surgeon General fact sheet. Preventing Tobacco Use Among Youths, Surgeon General fact sheet. 2017. https://www.hhs.gov/surgeongeneral/reports-and-publications/tobacco/preventingyouth-tobacco-use-factsheet/index.html

5. WHO. European Tobacco Control Situation Report, 2014. Copenhagen: WHO Regional Office for Europe. 2014. https://www.euro.who.int/_data/assets/pdf_file/0009/248418/European-Tobacco-Control-Status-Report-2014-Eng.pdf

6. Inchley, Joanna & Currie, Dorothy & Young, Taryn & Samdal, Oddrun & Torsheim, Torbjørn & Auguston, Lise & Mathisen, Frida & Aleman-Diaz, Aixa & Molcho, Michal & Weber, Martin & Barnekow, Vivian. Growing up unequal: gender and socioeconomic di erences in young people’s health and well-being. Health Behaviour in School-aged Children (HBSC) Study: International Report from the 2013/14 Survey. Copenhagen: WHO Regional O ce for Europe; Denmark. 2016; 294 p. https:// www.researchgate.net/publication/301542608_ Growing_up_unequal_gender_and_ socioeconomic_di erences_in_young_people’s_ health_and_well-being_Health_Behaviour_ in_School-aged_Children_HBSC_Study_ International_Report_from_the_201314_Survey

7. Jo Inchley, Dorothy Currie, Sanja Budisavljevic, Torbjørn Torsheim, Atle Jåstad, Alina Cosma, Colette Kelly & Ársæll Már Arnarsson, ed. International Report: Spotlight on adolescent health and well-being: Findings from the 2017/2018 Health Behaviour in School-aged Children (HBSC) survey in Europe and Canada. Copenhagen: WHO Regional O ce for Europe; Copenhagen, Denmark. 2020; 72 p. https://apps.who.int/iris/bitstream/hand le/10665/332100/9789289055024-rus.pdf

8. Антонов Н.С., Сахарова Г.М., Передельская М.Ю., Русакова Л.И. Динамика распространенности потребления табака под воздействием государственной антитабачной политики в Российской Федерации // Вестник центрального научно-исследовательского института туберкулеза. – 2019. – No2. – С.35-44. [Antonov NS, Saharova GM, Peredel`skaya MYu, Rusakova LI. Dinamika rasprostranennosti potrebleniya tabaka pod vozdejstviem gosudarstvennoj antitabachnoj politiki v Rossijskoj Federacii [The Dynamics of the Prevalence of Tobacco consumption under the In uence of the State anti-tobacco Policy in the Russian Federation]. Vestnik central`nogo nauchno-issledovatel`skogo instituta tuberkuleza [Bulletin of the Central Research Institute of Tuberculosis (CTRI Bulletin)]. 2019; 2: 35-44. (in Russ.)]. DOI: 10.7868/S2587667819020043

9. Федеральный закон от 23.02.2013 N 15-ФЗ (ред. от 30.07.2020) «Об охране здоровья граждан от воздействия окружающего табачного дыма, последствий потребления табака или потребления никотинсодержащей продукции» (ст.10.) [Federal`ny`j zakon ot 23/02/2013 No 15-FZ (30/07/2020 red) «Ob oxrane zdorov`ya grazhdan ot vozdejstviya okruzhayushhego tabachnogo dy`ma, posledstvij potrebleniya tabaka ili potrebleniya nikotinsoderzhashhej produkcii» (statya 10) [Federal Law No 15-FZ of 23/02/2013 (as amended on 30/07/2020) «On the protection of citizens’ health from exposure to Ambient tobacco smoke, the consequences of Tobacco Use or Consumption of Nicotine-containing products» (Article 10)]. 2013. (in Russ.)].

10. Салагай О.О., Сахарова Г.М., Антонов Н.С. Результаты государственной политики по борьбе против табака в Российской Федерации // Панорама общественного здравоохранения. – 2018. – Т.44. – No3. – С.271-490. [Salagaj OO, Saxarova GM, Antonov NS. Rezul`taty` gosudarstvennoj politiki po bor`be protiv tabaka v Rossijskoj Federacii [Results of the state policy on tobacco control in the Russian Federation]. Panorama obshhestvennogo zdravooxraneniya [Panorama of Public health.]. 2018; 4 (3): 271-490. (In Russ.)].

11. Салагай О.О., Сахарова Г.М., Антонов Н.С. Динамика потребления табачной и никотинсодержащей продукции в Российской Федерации в 2019-2021 гг. // Медицина. – 2021. – Т. 9. – No 2. – С.34-47. [Salagaj OO, Saxarova GM, Antonov NS. Dinamika potrebleniya tabachnoj i nikotinsoderzhashchej produkcii v Rossijskoj Federacii v 2019-2021 godah [Dynamics of consumption of tobacco and nicotine-containing products in the Russia in 2019-2021]. Medicina [Medicine]. 2021; 9 (2): 34-47. (In Russ.)]. DOI: 10.29234/2308-9113-2021-9-2-34-47

12.Салагай О.О., Сахарова Г.М., Антонов Н.С. Структура потребления табачных и никотинсодержащих изделий среди населения Российской Федерации // Пульмонология. – 2020. – Т. 30. – No 4. – С.453-462. [Salagaj OO, Saharova GM, Antonov NS. Struktura potrebleniya tabachnyh i nikotinsoderzhashchih izdelij sredi naseleniya Rossijskoj Federacii [The structure of consumption of tobacco and nicotine- containing products among the population of the Russian Federation]. Pul’monologiya [Pulmonology]. 2020; 30 (4): 453-462. (In Russ.)] DOI: 10.18093/0869-0189-2020-30-4-453-462 https://www.elibrary.ru/item.asp?id=44085430

13.Салагай О.О., Сахарова Г.М., Антонов Н.С. Динамика информированности населения о мерах по борьбе против табачной и никотин-содержащей продукции в Российской Федерации в 2019-2021 гг. // Медицина. – 2021. – Т. 9. – No 3. – С.1-15. [Salagaj OO, Saharova GM, Antonov NS. Dinamika informirovannosti
naseleniya o merah po bor’be protiv tabachnoj i nikotinsoderzhashchej produkcii v Rossijskoj Federacii v 2019-2021 godah [Dynamics of public awareness about measures to combat tobacco and nicotine-containing products in the Russian Federation in 2019-2021]. Medicina [Medicine]. 2021; 9 (3): 1-15. (In Russ.)]. DOI: 10.29234/2308-9113-2021-9-3-1-15

14.Салагай О.О., Антонов Н.С., Сахарова Г.М., Смирнов К.А. Анализ осведомленности населения о мерах по снижению распространенности потребления табачной продукции в Российской Федерации // Наркология. – 2020. – Т. 19. – No 9. – С.18-38. [Salagaj OO, Antonov NS, Saxarova GM, Smirnov KA. Analiz osvedomlennosti naseleniya o merax po snizheniyu rasprostranennosti potrebleniya tabachnoj produkcii v Rossijskoj Federacii. [Analysis of public awareness of measures to reduce the prevalence of tobacco consumption in the Russian Federation]. Narkologiya [Narcology]. 2020; 19 (9): 18-38. (In Russ.)]. DOI: 10.25557/1682-8313.2020.09.18-38

15.Скворцова Е.С., Зубкова Н.З. Характеристика распространенности курения среди старшеклассников Московской области // Профилактика заболеваний и укрепление здоровья. – 2005. – Т.8. – No 1. – С.26-30. [Skvorczova ES, Zubkova NZ. Xarakteristika rasprostranennosti kureniya sredi starsheklassnikov Moskovskoj oblasti [Features of the prevalence of smoking among high school students of the Moscow region]. Pro laktika zabolevanij i ukreplenie zdorov`ya [Disease prevention and health promotion]. 2005; 8 (1): 26-30. (In Russ.)].

16. Скворцова Е.С. Распространенность и основные мотивы курения среди городских старшеклассников в Российской Федерации в 2010-2011 годах // Профилактическая медицина. – 2016. – Т.19. – No1. – С.44-50. [Skvorczova ES. Rasprostranennost` i osnovny`e motivy` kureniya sredi gorodskix starsheklassnikov v Rossijskoj Federacii v 2010-2011 godah [Prevalence and main motives of smoking among urban high school students in the Russian Federation in 2010-2011]. Pro lakticheskaya medicina [Preventive medicine]. 2016; 19 (1): 44-50. (In Russ.)]. DOI: 10.17116/profmed201619144-50

17.Лисицын Ю.П. Общественное здоровье и здравоохранение. Учебник. 2-е издание // М.: ГЭОТАР-Медиа, 2010. – 512 с. [Lisicyn YuP. Obshchestvennoe zdorov’e i zdravoohranenie: uchebnik, 2 izdanie [Public health and healthcare: textbook, 2nd edition]. Moskva: GEOTAR-Media [Moscow: GEOTAR-Media]. 2010; 210 p. (In Russ.)].

18. Скворцова Е.С., Коновалов Д.Н. Свидетельство о государственной регистрации программы для ЭВМ No 2013619820 AnkProс «Факторы риска». Дата гос. регистрации в Реестре программ для ЭВМ 17 октября 2013 г. [Skvorczova ES, Konovalov DN. Svidetel’stvo o gosudarstvennoj registracii programmy dlja JeVM No 2013619820 AnkProc «Faktory` riska»; Data gosudarstvennoi registracii v Reestre programm dlja JeVM 17 oktjabrja 2013 goda [Certi cate of state registration of the computer program No 2013619820 AnkProc «Risk factors»; Date of state registration in the Register of computer programs October 17, 2013). 2013. (In Russ.)].

19. GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017; 389 (10082): 1885-1906. DOI: 10.1016/S0140-6736(17)30819-X

20.Chuanwei Ma, Bo Xi, Zilin Li, Han Wu, Min Zhao, Yajun Liang, Pascal Bovet. Prevalence and trends in tobacco use among adolescents aged 13–15 years in 143 countries, 1999– 2018: ndings from the Global Youth Tobacco Surveys. The Lancet Child & Adolescent Health. 2021; 5 (4): 245-255. DOI: 10.1016/S2352-4642(20)30390-4


UDC 616.24-002.52 DOI: 10.20969/VSKM.2022.15(1).88-94


YAKOVLEVA ELENA V., ORCID ID: 0000-0003-1858-5206, SPIN ID: 5682-6180, Postgraduate student, Department of Phthisiology and Pulmonology, Samara State Medical University, st. Chapaevskaya 89, Samara, 443099, Russia; e-mail: elena130894@mail.ru

Abstract. Introduction. The main disease that complicates HIV is Pneumocystis pneumonia. It often requires di erential diagnosis with tuberculosis. Aim. The aim of the study was to conduct a comparative analysis of the clinical features and main indicators of iron metabolism in HIV infection with disseminated pulmonary tuberculosis and Pneumocystis pneumonia and to identify potential di erential diagnostic markers of tuberculosis. Material and methods. The study included two groups of patients with HIV infection: 42 patients with disseminated pulmonary tuberculosis and 44 patients with Pneumocystis pneumonia. The clinical and laboratory data was carried out, the main indicators of iron metabolism were determined: iron concentration, hepcidin, ferritin. Statistical data processing was performed using the MedCalc 19.2.6 statistical software. Results and discussions. In the group of patients with Pneumocystis pneumonia, the proportion of patients with a severe condition is greater, the level of CD4-lymphocytes is signi cantly lower - 5 times less than in tuberculosis (p <0.001). Statistically signi cant di erences between the groups were found for hepcidin and serum. The median for hepcidin is 1.4 times higher in group 1 than in group 2 (p <0.001), for serum - 1.5 times less in group 1 than in group 2 (р<0,001). In patients with HIV and pulmonary dissemination, a higher probability of tuberculosis was revealed with hepcidin more than 13810 pg/ml (sensitivity 80.95%, speci city 75%, ROC AUC 0.854) and with an iron concentration less than 10 μmol / L (sensitivity 85.7%, speci city 59.1%, ROC AUC 0.733). Conclusion. When examining patients with HIV infection and pulmonary dissemination syndrome who have a common anamnesis, clinical and radiological, laboratory data and a high degree of suspicion of tuberculosis, it was established by the analysis of ROC curves that the peptide hormone hepcidin has the greatest practical value for its further comprehensive study as a potential and a promising marker for the diagnosis of tuberculosis.

Key words: HIV infection; disseminated tuberculosis; pneumocystis pneumonia; pulmonary dissemination; hepcidin.

For reference: Yakovleva E.V. Iron metabolism in disseminated pulmonary tuberculosis and pneumocystis pneumonia in patients with HIV infection. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1): 88–94. DOI: 10.20969/ VSKM.2022.15(1).88-94.


1. Илькович М.М., Новикова Л.Н., Илькович Ю.М. Противоречия в представлениях об интерстициальных заболеваниях легких // Доктор.Ру. – 2013. – No 8 (86). – С.41-45. [Ilkovich MM, Novikova LN, Ilkovich YM. Protivorechiya v predstavleniyah ob intersticial’nyh zabolevaniyah legkih [Contradictions in the concept of interstitial lung disease]. Doktor Ru [Doktor Ru]. 2013; 8 (86): 41-45. (In Russ.)].

2. Wallis A, Spinks K. The diagnosis and management of interstitial lung diseases. BMJ. 2015; 7: 70-72. DOI: 10.1136/bmj.h2072.

3. Бородулина Е.А., Вдоушкина Е.С., Инькова А.Т. Туберкулез легких у больных ВИЧ-инфекцией // Врач. – 2020. – No 31 (1). – С.37-43. [Borodulina EA, Vdoushkina ES, In’kova AT. Tuberkulez legkih u bol’nyh VICH-infekciej [Pulmonary tuberculosis in patients with HIV infection]. Vrach [Doctor]. 2020; 31 (1): 37-43. (In Russ.)]. DOI: https://doi.org/10.29296/25877305-2020-01-07/

4. Мишин В.Ю., Эргешов А.Э., Мишина А.В. Диагностика и дифференциальная диагностика диссеминированных поражений легких у больных с ВИЧ-инфекцией (обзор) // Consilium Medicum. – 2018. – Vol. 20 (3). – С.8-13. [Mishin VY, Ergeshov AE, Mishina AV. Diagnostika i di erencial’naya diagnostika disseminirovannyh porazhenij legkih u bol’nyh s VICH-infekciej (obzor) [Diagnostics and di erential diagnosis of disseminated lung lesions in patients with HIV infection (review)]. Consilium Medicum [Consilium Medicum]. 2018; 20 (3): 8-13. (In Russ.)]. DOI: 10.26442/2075-1753_20.3.8-13.

5. Винокуров А.С., Соколина И.А., Винокурова О.О. Клинико-рентгенологические особенности лимфогенной диссеминации при туберкулезе легких // Вестник рентгенологии и радиологии. – 2020. – No 101(4). – С. 253-262 [Vinokurov AS, Sokolina IA, Vinokurova OO. Kliniko-rentgenologicheskie osobennosti limfogennoj disseminacii pri tuberkuleze legkih [Clinical and radiological features of lymphogenous dissemination in pulmonary tuberculosis]. Vestnik rentgenologii i radiologii [Bulletin of radiology and radiology]. 2020; 101 (4): 253-262. (In Russ.)].

6. Ермак Т.Н. Пневмоцистоз // в книге: ВИЧ-инфекция и СПИД : национальное руководство, под ред. В. В. Покровского. - 2-е изд., перераб. и доп. - Москва: ГЭОТАР-Медиа, 2020. – С.189-197. [Yermak TN. Pnevmotsistoz; v knige: VICH-infektsiya i SPID: natsional’noye rukovodstvo pod redakciey VV Pokrovskogo [Pneumocystosis; in the book: HIV infection and AIDS: national guidelines, VV Pokrovsky ed]. Moskva: GEOTAR-Media [Moscow: GEOTAR-Media]. 2020; 2: 189-197. (In Russ.)].

7. Михайлова Н.Р., Ермак Т.Н., Михайловский А.М. Пневмоцистная пневмония и генерализованный туберкулез у больных ВИЧ-инфекцией // Терапевтический архив. – 2013. – No 85 (11). – С.67-68. [Mikhailova NR, Ermak TN, Mikhailovsky AM. Pnevmocistnaya pnevmoniya i generalizovannyj tuberkulez u bol’nyh VICH-infekciej [Pneumocystis pneumonia and generalized tuberculosis in patients with HIV infection]. Terapevticheskij arhiv [Therapeutic archive]. 2013; 85 (11): 67-68. (In Russ.)].

8. Боровицкий В.С. Пневмоцистная пневмония. Этиология, патогенез, клиника, дифференциальная диагностика, лечение // Проблемы медицинской микологии. – 2012. – No 14 (1). – С.13–20 [Borovitsky VS. Pnevmocistnaya pnevmoniya; Etiologiya, patogenez, klinika, di erencial’naya diagnostika, lechenie [Pneumocystis pneumonia; Etiology, pathogenesis, clinical picture, di erential diagnosis, treatment]. Problemy medicinskoj mikologii [Problems of medical mycology]. 2012; 14 (1): 13–20. (In Russ.)].

9. Лямин А.В., Халиулин А.В., Исматуллин Д.Д., и др. Железо как эссенциальный фактор роста микобактерий // Известия Самарского научного центра Российской академии наук. – 2016. – No 18 (5). – С.320-327. [Lyamin AV, Khaliulin AV, Ismatullin DD et al. Zhelezo kak essencial’nyj faktor rosta mikobakterij [Iron as an essential growth factor for mycobacteria]. Izvestiya Samarskogo nauchnogo centra Rossijskoj akademii nauk [Bulletin of the Samara Scienti c Center of the Russian Academy of Sciences]. 2016; 18 (5): 320-327. (In Russ.)].

10.Sritharan M. Iron Homeostasis in Mycobacterium tuberculosis: Mechanistic Insights into Siderophore-Mediated Iron Uptake. J Bacteriol. 2016; 2: 18-22. DOI: 10.1128/JB.00359-16.

11. Абдуллаев Р.Ю., Комиссарова О.Г., Терентьева О.Р. Особенности обмена железа при туберкулезе // Туберкулез и болезни легких. – 2021. – No 99 (3). – С.58-66. [Abdullaev RY, Komissarova OG, Terentyeva OR. Osobennosti obmena zheleza pri tuberkuleze [Features of iron metabolism in tuberculosis]. Tuberkulez i bolezni legkih [Tuberculosis and lung disease]. 2021; 99 (3): 58-66. (In Russ.)]. DOI: 10.21292/2075-1230-2021-99-3-58-66.

12.Hella J, Cercamondi CI, Mhimbira F, et al. Anemia in tuberculosis cases and household controls from Tanzania: Contribution of disease, coinfections, and the role of hepcidin. PLoS One 2018; 13 (4): e0195985. DOI: 10.1371/journal. pone.0195985. eCollection2018.

13.Abreu R, Essler L, Loy A et al. Heparin inhibits intracellular Mycobacterium tuberculosis bacterial replication by reducing iron levels in human macrophages. Sci Rep. 2018; 8 (1): 72-96. DOI: 10.1038/s41598-018-25480-y.

14.Tashiro K, Yamamoto M, Ushio R, et al. Hepcidin exerts a negative immunological e ect in pulmonary tuberculosis without HIV co-infection, prolonging the time to culture-negative. Int J Infect Dis. 2019; 86: 47-54. DOI: 10.1016/ j.ijid.2019.06.023.

15.Minchella PA, Donkor S, et al. Iron homeostasis and progression to pulmonary tuberculosis disease among household contacts. Tuberculosis. 2015; 95 (3): 288-293. DOI: 10.1016/j.tube.2015.02.042. Epub 2015 feb 24.

16.Kerkho AD, Meintjes G, Opie J, et al. Anaemia in patients with HIV-associated TB: relative contributions of anaemia of chronic disease and iron de ciency. Int J Tuberc Lung Dis. 2016: 20 (2): 193-201. DOI: 10.5588/ijtld.15.0558. 17.Wisaksana R, de Mast Q, Alisjahbana B, et al. Inverse relationship of serum hepcidin levels with CD4 cell counts in HIV-infected patients selected from an Indonesian prospective cohort study. PLoS One. 2013; 8 (11): e79904. DOI: 10.1371/ journal.pone.0079904.

18. Майорова М.О., Пьянзова Т.В. Особенности гемограммы у лиц с туберкулезом на фоне ВИЧ-инфекции // Туберкулез и болезни легких. – 2015. – No 4 (4). – С.49-53. [Mayorova MO, Pyanzova TV. Osobennosti gemogrammy u lic s tuberkulezom na fone VICH-infekcii [Features of hemogram in persons with tuberculosis on the background of HIV infection]. Tuberkulez i bolezni legkih [Tuberculosis and lung disease]. 2015; 4 (4): 49-53. (In Russ.)]. DOI: 10.21292/2075-1230-2015-0-4-49-53

19. Никитин Ю.Е., Никитин Е.Н., Шкляев А.Е. Клиническое значение гепцидина при внебольничной пневмонии, осложненной анемией // Практическая медицина. – 2014. – No 3 (79). – С.162-167. [Nikitin YE, Nikitin EN, Shklyaev AE. Klinicheskoe znachenie gepcidina pri vnebol’nichnoj pnevmonii, oslozhnennoj anemiej [Clinical signi cance of hepcidin in community-acquired pneumonia complicated by anemia]. Prakticheskaya medicina [Practical medicine]. 2014; 3 (79): 162-167. (In Russ.)].

20.Kerkho AD, Meintjes G, Burton R, et al. Relationship Between Blood Concentrations of Hepcidin and Anemia Severity, Mycobacterial Burden, and Mortality Among Patients With HIV-Associated Tuberculosis. J Infect Dis. 2016; 213 (1): 61-70. DOI: 10.1093/infdis/jiv364. Epub 2015 Jul 1.

21.Minchella PA, Armitage AE, Darboe B et al. Elevated hepcidin at HIV diagnosis is associated with incident tuberculosis in a retrospective cohort study. Int J Tuberc Lung Dis. 2014; 18 (11): 1337-1349. DOI: 10.5588/ijtld.14.0143.

22.Tandara L, Salamunic I. Iron metabolism: current facts and future directions. Biochem Med. 2012; 22: 311–328. DOI: 10.11613/bm.2012.034. 23.Ganz T, Nemeth E. Iron homeostasis in host defence and in ammation. Nat Rev Immunol. 2015; 15 (8): 500–510. DOI: 10.1038/nri3863. 24. Harrington-Kandt R, Stylianou E, Eddowes LA, et al. Hepcidin de ciency and iron de ciency do not alter tuberculosis susceptibility in a murine Mtb infection model. PLoS One. 2018; 13 (1): e0191038. DOI: 10.1371/journal.pone.0191038



UDC 616-08.:-036.-039.81 DOI: 10.20969/VSKM.2022.15(1).95-106


AMIROV NAIL B., ORCID ID: 0000-0003-0009-9103; D. Med. Sci., professor of the Department of outpatient therapy and general medical practice of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49; tel. +7-843-291-26-76, e-mail: namirov@mail.ru

NAUMOVA ASEL YA., ORCID ID: 0000-0002-9963-9466; 6th year student of the medical Faculty, Department of outpatient therapy and general medical practice of Kazan State Medical University, Russia, 420012, Kazan, st. Butlerova, 49, tel. +7-996-952-51-22, e-mail: vahitovaasel@gmail.com

FATYKHOV RENAT G., ORCID ID: 0000-0001-5651-8341; the Head of the Clinical Hospital of the Medical Care unit of the Ministry of Internal Affairs of Russia in the Republic of Tatarstan, Russia, 420000, Kazan, Orenburgskiy tract str., 132, tel. +7(843)291-26-84, e-mail: fatyhov.renat2011@yandex.ru

AMIROVA RENATA N., ORCID ID: 0000-0001-6867-3648; head of the personal insurance programs support department, doctor-expert of the Kazan branch of SOGAZ JSC, Russia, Kazan, тел. +7-903-307-99-47; e-mail: renata1980@mail.ru

Abstract. Introduction. In recent decades, increased attention has been paid to hyperuricemia due to the widespread prevalence of this pathology in the population (16.8%), the presence of a connection with the risk of developing cardiovascular diseases, as well as the variety of its clinical consequences. Aim. A review of current data on the causes of hyperuricemia, clinical aspects, the e ect of hyperuricemia on cardiovascular risk, and the current view of therapy, including asymptomatic hyperuricemia. Material and methods. The review carried out topical medical publications in foreign and domestic literature on this issue, accumulated at the present time. Results and discussion. An increase in uric acid level can occur as a result of inaccuracies in the diet, taking certain medications, impaired excretion of uric acid due to impaired renal function and other reasons. Hyperuricemia is the main cause of gout, which can manifest itself as acute gouty arthritis, chronic topical arthritis, urate nephropathy, and other diseases. Modern research shows that an increase in serum uric acid concentration is associated with an increased cardiovascular risk. Acting as an independent predictor of arterial hypertension, coronary heart disease, chronic heart failure, chronic kidney disease. Treatment with xanthine oxidase inhibitors (allopurinol, febuxostat) can a ect hyperuricemia, gout, and various forms of ischemic and vascular damage. As evidence of the e cacy of urate-lowering therapy remains controversial, these drugs are not currently indicated for routine prophylactic treatment in patients without gout symptoms. In 2018, specialists in the eld of hyperuricemia proposed an algorithm for the management of patients with asymptomatic hyperuricemia. However, the algorithm is not recommended for everyday practice due to further research's need to verify it. Conclusion. Classic manifestations of hyperuricemia such as gout and kidney damage remain the main indications for urate-lowering therapy. At the same time, the increased cardiovascular risk in hyperuricemia, proven by numerous studies, requires special attention in treating patients with comorbid pathology. Diet and lifestyle changes remain an integral part of therapy. The nal decision on the need for pharmacological treatment of patients with asymptomatic hyperuricemia with xanthine oxidase inhibitors is made individually. The development of algorithms and indications for the appointment of urate-lowering therapy continues. Recommendations for drug therapy for hyperuricemia are only possible after large, double-blind, placebo-controlled, randomized trials.

Key words: hyperuricemia; the risk of cardiovascular disease; gout, urate-lowering therapy; xanthine oxidase inhibitors.

For reference: Amirov NB, Naumova AYa, Fatykhov RG, Amirova RN. Hyperuricemia: clinical consequences, cardiovascular risk, modern approach to therapy. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1): 95–106.DOI: 10.20969/VSKM.2022.15(1).95-106.


1. Mallat SG, Al Kattar S, Tanios BY, Jurjus A. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. Curr Hypertens Rep. 2016; 18 p.

2. Шальнова С. А., Деев А. Д., Артамонова Г. В., и др. Гиперурикемия и ее корреляты в Российской Популяции (результаты эпидемиологического исследования ЭССЕ-РФ) // Рациональная Фармакотерапия в кардиологии. – 2014. – Т. 10., No 2. – C.153-159. [Shal’nova SA, Deev AD, Artamonova GV, Duplyakov DV, Efanov AYu, Zhernakova YuV. Giperurikemiya i ee korrelyaty v Rossijskoj Populyacii (rezul’taty epidemiologicheskogo issledovaniya ESSE-RF) [Hyperuricemia and its correlates in the Russian Population (results of an epidemiological study ESSE-RF)]. Racional’naya farmakoterapiya v kardiologii [Rational Pharmacotherapy In Cardiology]. 2014; 10 (2): 153-159. (In Russ.)].

3. Молчанова О.В., Бритов А.Н., Платонова Е.В. Значение повышенного уровня мочевой кислоты в развитии и профилактике хронических неинфекционных заболеваний // Профилактическая медицина. – 2020. – Т. 23., No 2. – С.102-108. [Molchanova OV, Britov AN, Platonova EV. Znachenie povyshennogo urovnya mochevoj kisloty v razvitiii pro laktike hronicheskih neinfekcionnyh zabolevanij [The importance of an increased level of uric acid in the development and prevention of chronic non-infectious diseases].Pro lakticheskaya Medicina [Preventive Medicine]. 2020; 23: 102–108. (In Russ.)].

4. Sah OSP, Qing YX. Associations between hyperuricemia and chronic kidney disease: A review. Nephrourol Mon. 2015; 7: 1–5.

5. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016; 388: 2039–2052. 6. ShahinL,PatelKM,HeydariMK,KesselmanMM. Hyperuricemia and Cardiovascular Risk. Cureus. 2021; 13: 1–8. DOI: 10.7759/cureus.14855

7. Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В. Артериальная гипертензия у взрослых. Клинические рекомендации 2020 // Российский кардиологический журнал. – 2020. – Т.25., No 3. – С.149-218. [Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyahto EV. Arterial’naya gipertenziya u vzroslyh: Klinicheskie rekomendacii 2020 [Arterial hypertension in adults: Clinical guidelines 2020 Russian]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiolog]. 2020; 25: 3 –149. (In Russ.)].

8. Hyndman D, Liu S, Miner JN. Urate Handling in the Human Body. Curr Rheumatol Rep. 2016; 18 (6): 34. DOI: 10.1007/s11926-016-0587-7

9. Li L, Zeng C, Zhang Y. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020; 12: 3167–3181.

10.Мочевая кислота (в крови) (Uric acid), показания к назначению, правила подготовки к сдаче анализа, расшифровка результатов и показатели нормы. [Mochevaya kislota (v krovi) (Uric acid), pokazaniya k naznacheniyu, pravila podgotovki k sdache analiza, rasshifrovka rezul’tatov i pokazateli normy [Uric acid (in the blood) (Uric acid), indications for the appointment, the rules for preparing for the test, deciphering the results and indicators of the norm. (In Russ.)]. https://www.invitro.ru/library/ labdiagnostika/27184.

11.Плаксина Т.В. Диагностика и лечение подагры // Консилиум. Ревматология. – 2018. – Т. 3., No 2s. – С.26-27. [Plaksina TV. Diagnostika i lechenie podagry [Diagnosis and treatment of gout].Konsilium Revmatologiya [Consilium Rheumatology]. 2018; 3: 26–27. (In Russ.)].

12. Елисеев М.С. Подагра: Клинические российские рекомендации // М.: Геотар, 2017– 2017. – С.253-264. [Eliseev MS. Podagra: Klinicheskie rossijskie rekomendacii [Gout: Clinical Russian guidelines]. Moskva: Geotar [Moscow: Geotar]. 2017: 253–264. (In Russ.)].

13. Амиров Н.Б., Маянская С.Д., Цибулькин Н.А., и др. Нарушение пуринового обмена - гиперурикемия, подагра и их осложнения в общеклинической практике (клиника, диагностика, лечение и профилактика): учебно-методическое пособие // Казань : Медицина, 2010. – 44 с. [Amirov NB, Mayanskaya SD, Cibul’kin NA, Galeeva ZM, Potapova MV, Sabirov LF. Narushenie purinovogo obmena - giperurikemiya, podagra i ih oslozhneniya v obshcheklinicheskoj praktike (klinika, diagnostika, lechenieipro laktika) [Violation of purine metabolism - hyperuricemia, gout and their complications in general clinical practice (clinic, diagnosis, treatment and prevention)]. Kazan’: Medicina [Kazan: Medicine]. 2010; 44 p. (In Russ.)].

14.Cicero AFG, Fogacci F, Kuwabara M, Borghi C. Therapeutic strategies for the treatment of chronic hyperuricemia: An evidence-based update. Med. 2021; 57: 1–18.

15. Winder M, Owczarek AJ, Mossakowska M, Holecki M, Broczek K, Grodzicki T. Serum uric acid is a weak independent predictor of overall survival in older adults. J Clin Med 2021;10.

16.Kuwabara M, Niwa K, Hisatome I, Nakagawa T, Roncal-Jimenez CA, Andres-Hernando A. Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases Five-Year Japanese Cohort Study. Hypertension. 2017; 69: 1036–1044.

17. Kielstein JT, Pontremoli R, Burnier M. Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection. Curr Hypertens Rep. 2020; 22 (12): 102. DOI: 10.1007/s11906-020-01116-3.

18.Brucato A, Cianci F, Carnovale C. Management of hyperuricemia in asymptomatic patients: A critical appraisal. European Journal of Internal Medicine. 2020; 74: 8-17.

19. Kamei K, Konta T, Hirayama A, Ichikawa K, Kubota I, Fujimoto S. Associations between serum uric acid levels and the incidence of nonfatal stroke: a nationwide community-based cohort study. Clin Exp Nephrol. 2017; 21: 497–503.

20.Kuwabara M. Hyperuricemia, Cardiovascular Disease, and Hypertension. Pulse. 2016; 3: 242–252.

21.Ruocco G, Palazzuoli A. Hyperuricemia in US Population with Heart Failure: Causal or Incidental Bystander? CardioRenal Med. 2019; 9: 341–343.

22. Maloberti A, Giannattasio C, Bombelli M, Desideri G, Cicero AFG, Muiesan ML. Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project. High Blood Press Cardiovasc Prev. 2020; 27: 121–128.

23.Padda J, Khalid K, Padda S, Boddeti NL, Malhi BS, Nepal R. Hyperuricemia and Its Association With Ischemic Stroke. Cureus. 2021; 13 (9): e18172. DOI: 10.7759/cureus.18172.

24.Chaudhary NS, Bridges SL, Saag KG, Rahn EJ, Curtis JR, Ga o A. Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. Hypertens (Dallas, Tex 1979). 2020; 75: 246–256.

25. Kimura Y, Tsukui D, Kono H. Uric acid in in ammation and the pathogenesis of atherosclerosis. Int J Mol Sci. 2021; 22 (22): 12394. DOI: 10.3390/ijms222212394.

26.Zuo T, Liu X, Jiang L, Mao S, Yin X, Guo L. Hyperuricemia and coronary heart disease mortality: A meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016; 16: 1–10.

27.LiM,HuX,FanY,LiK,ZhangX,HouW. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep. 2016; 6: 1–11.

28.Gill D, Cameron AC, Burgess S, Li X, Doherty DJ, Karhunen V. Urate, Blood Pressure, and Cardiovascular Disease: Evidence from Mendelian Randomization and Meta-Analysis of Clinical Trials. Hypertension. 2021: 383–392.

  1. Vargas-Santos AB, Neogi T. Management of Gout and Hyperuricemia in CKD. Am J Kidney Dis. 2017; 70: 422–439.

  2. Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, Nakagawa T, Madero M, Feig DI. Uric acid and hypertension: An update with recommendations. Am J Hypertens. 2020; 33: 583–594.

31.Sato Y, Feig DI, Stack AG, Kang DH, Lanaspa MA, Ejaz AA. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol. 2019; 15: 767–775.

32.So AK, Martinon F. In ammation in gout: Mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017; 13: 639–647.

33.Uedono H, Tsuda A, Ishimura E, Yasumoto M, Ichii M, Ochi A. Relationship between serum uric acid levels and intrarenal hemodynamic parameters. Kidney Blood Press Res. 2015; 40: 315–322.

34.Isaka Y, Takabatake Y, Takahashi A, Saitoh T, Yoshimori T. Hyperuricemia-induced in ammasome and kidney diseases. Nephrol Dial Transplant. 2016; 31: 890–896.

  1. Ramirez MEG, Bargman JM. Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy – A review. J Adv Res. 2017; 8: 551–554.

  2. García-Arroyo FE, Gonzaga G, Muñoz-Jiménez I, Blas-Marron MG, Silverio O, Tapia E, и др. Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. PLoS One. 2018; 13: 1–20.

37.Petreski T, Ekart R, Hojs R, Bevc S. Hyperuricemia, the heart, and the kidneys–to treat or not to treat? Ren Fail. 2020; 42: 978–986.

38.Russo E, Verzola D, Leoncini G, Cappadona F, Esposito P, Pontremoli R. Treating hyperuricemia: The last word hasn’t been said yet. J Clin Med. 2021; 10: 1–8.

39. Benn CL, Dua P, Gurrell R, Loudon P, Pike A, Ian Storer R. Physiology of hyperuricemia and urate-lowering treatments. Front Med. 2018; 5: 1–28.

40.Головач И.Ю., Егудина Е.Д., Тер-Вартаньян С.Х. Бессимптомная гиперурикемия: тайные взаимосвязи, невидимые эффекты и потенциальные осложнения // Научно-практическая ревматология. – 2021. – Vol. 58., No 6. – P.725-733. [Golovach IY, Yehudina YD, Ter-Vartanіan SK. Bessimptomnaya giperurikemiya: tajnye vzaimosvyazi, nevidimye e ektyi potencial’nye oslozhneniya [Asymptomatic hyperuricemia: Secret relationships, invisible e ects and potential complications]. Nauchno-Prakticheskaya Revmatologiya [Rheumatology Science and Practice]. 2021; 58: 725–733. (In Russ.)].

41.Britnell SR, Chillari KA, Brown JN. The Role of Xanthine Oxidase Inhibitors in Patients with History of Stroke: A Systematic Review. Curr Vasc Pharmacol. 2018; 16: 583–588.

42.Bove M, Cicero AFG, Borghi C. The E ect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function. Curr Hypertens Rep. 2017; 19 (12): 95. DOI: 10.1007/s11906-017-0793-3.

43.Luna G, Dolzhenko A V., Mancera RL. Inhibitors of Xanthine Oxidase: Sca old Diversity and Structure-Based Drug Design. ChemMedChem. 2019; 14: 714–743.

44. Цурко В.В., Громова М.А., Червякова Ю.Б., Копелев А.А. Гиперурикемия и сердечно-сосудистые заболевания: современные аспекты терапии // Лечебное дело. – 2019. – Т. 1. – С.14-19. [Curko VV, Gromova MA, Chervyakova YuB, Kopelev AA. Giperurikemiya i serdechno-sosudistye zabolevaniya: sovremennye aspekty terapii [Hyperuricemia and cardiovascular diseases: modern aspects of therapy]. Lechebnoe delo [Medicine]. 2019; 1: 14–19. (In Russ.)].

45. Орлова Е.В. Гиперурикемия в терапевтической практике – лечить или наблюдать // Трудный Пациент. – 2018. – Т. 10., No 16. – С.16-21. [Orlova EV. Giperurikemiya v terapevticheskojpraktike – lechit’ ili nablyudat’ [Hyperuricemia in therapeutic practice - treat or observe]. Trudnyj Pacient [Di cult Patient]. 2018; 10: 16–21. (In Russ.)].

46.Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T. 2012 American college of rheumatology guidelines for management of gout. part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012; 64: 1431–1446.

47.FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020; 72: 879–895.

48. Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol. 2017; 36: 2637–2644.

49. Hakoda M, Kasagi F. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan. Mod Rheumatol. 2019; 29: 880–884. DOI: 10.1080/14397595.2018.1519149.

50. Bredemeier M, Lopes LM, Eisenreich MA, Hickmann S, Bongiorno GK, d’Avila R. Xanthine oxidase inhibitors for prevention of cardiovascular events: A systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2018; 18: 1–11.

51. Zhang T, Pope JE. Cardiovascular e ects of urate-lowering therapies in patients with chronic gout: A systematic review and meta-analysis. Rheumatol (United Kingdom). 2017; 56: 1144–1153.

52.Borghi C, Tykarski A, Widecka K, Filipiak KJ, Domienik-Karłowicz J, Kostka-Jeziorny K. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018; 25: 545– 564. DOI: 10.5603/CJ.2018.0116.

53. Чазова И.Е., Жернакова Ю.В., Кисляк О.А., и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском // Системные гипертезии. – 2019. – Т. 16., No 4. – С.8-21. [Chazova IE, Zhernakova YuV, Kislyak OA, Nedogoda SV, Podzolkov VI. Konsensus po vedeniyu pacientov s giperurikemiej i vysokim serdechno-sosudistym riskom [Consensus on the management of patients with hyperuricemia and high cardiovascular risk].Sistemnye Gipertezii [Systemic Hypertension]. 2019; 16: 8–21. (In Russ.)].

54.Кобалава Ж.Д., Троицкая Е.А. Бессимптомная гиперурикемия: подходы к лечению в аспекте риска развития сердечно-сосудистых и почечных заболеваний // Кардиология. – 2020. – Т. 60., No 12. – С.104-109. [Kobalava ZhD, Troickaya EA. Bessimptomnaya giperurikemiya: podhody k lecheniyu v aspekte riska razvitiya serdechno-sosudistyh i pochechnyh zabolevanij [Asymptomatic hyperuricemia: approaches to treatment in terms of the risk of developing cardiovascular and renal diseases]. Kardiologiya [Cardiology]. 2020; 60 (12): 104–10 9. (In Russ.)].

55.Крючкова О.Н., Ицкова Е.А., Лутай Ю.А., и др. Гиперурикемия как фактор сердечно-сосудистого риска, актуальность коррекции бессимптомной гиперурикемии // Крымский терапевтический журнал. – 2020. – No 4. - С.34-37. [Kryuchkova ON, Ickova EA, Lutaj YuA, Turna EYu, Kostyukova EA, Zhukova NV. Giperurikemiya kak faktor serdechno-sosudistogo riska, aktual’nost’ korrekcii bessimptomnoj giperurikemii [Hyperuricemia as a factor of cardiovascular risk, the relevance of the correction of asymptomatic hyperuricemia]. Krymskij terapevticheskij zhurnal [Crimean Therapeutic Journal]. 2020; 4: 34–37. (In Russ.)].

56.Li S, Yang H, Guo Y, Wei F, Yang X, Li D. Comparative e cacy and safety of urate-lowering therapy for the treatment of hyperuricemia: A systematic review and network meta-analysis. Sci Rep. 2016; 6: 1–12.

57.Bove M, Cicero AFG, Veronesi M, Borghi C. An evidence-based review on urate-lowering treatments: Implications for optimal treatment of chronic hyperuricemia. Vasc Health Risk Manag. 2017; 13: 23–28.



 UDC 616.1-092:577.121.7 DOI: 10.20969/VSKM.2022.15(1).107-117


DEMKO IRINA V., ORCID ID: 0000-0001-8982-5292, Researcher ID: O-9740-2015, SPIN-код: 6520-3233, Author ID: 608300; D. Med. Sci., Professor, Head of Department of Advanced Internal Medicine and Immunology with Postgraduate Physician Training Course, Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, st. Partizana Zheleznyaka 1, Krasnoyarsk, 660022, Russia; Head of Pulmonology and Allergology Center, Krasnoyarsk State Territorial Clinical Hospital: st. Partizana Zheleznyaka 3A, Krasnoyarsk, 660022, Russia; tel: +7 (913) 507 84 08; e-mail: demko64@mail.ru

SOBKO ELENA A., ORCID ID: 0000-0002-9377-5213, Researcher ID: AAG-7668-2019, SPIN-код: 9132-6756, Author ID: 720783; D. Med. Sci., Professor, Department of Advanced Internal Medicine and Immunology with Postgraduate Physician Training Course, Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, st. Partizana Zheleznyaka 1, Krasnoyarsk, 660022, Russia; Head of the Department of Allergology, Krasnoyarsk State Territorial Clinical Hospital: st. Partizana Zheleznyaka 3A, Krasnoyarsk, 660022, Russia; tel: +7 (923) 327 11 92; e-mail: sobko29@mail.ru

SOLOVYEVA IRINA A., ORCID ID: 0000-0002-1999-9534, Researcher ID: M-3771-2014, SPIN-код: 8713-5470, Author ID: 716541; D. Med. Sci., Associate Professor, Department of Advanced Internal Medicine and Immunology with Postgraduate Physician Training Course, Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, st. Partizana Zheleznyaka 1, Krasnoyarsk, 660022, Russia; Pulmonologist, Krasnoyarsk State Territorial Clinical Hospital: st. Partizana Zheleznyaka 3A, Krasnoyarsk, 660022, Russia; tel: +7 (391) 220 04 95; e-mail: acad-prorector@krasgmu.ru

KRAPOSHINA ANGELINA YU., ORCID ID: 0000-0001-6896-877X, Researcher ID: L-5636-2016, SPIN-код: 8829-9240, Author ID: 608302; C. Med. Sci., Associate Professor, Department of Advanced Internal Medicine and Immunology with Postgraduate Physician Training Course, Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, st. Partizana Zheleznyaka 1, Krasnoyarsk, 660022, Russia; Pulmonologist, Krasnoyarsk State Territorial Clinical Hospital: st. Partizana Zheleznyaka 3A, Krasnoyarsk, 660022, Russia; tel: +7 (391) 228 34 69; e-mail: angelina-maria@inbox.ru

GORDEEVA NATALYA V., ORCID ID: 0000-0002-0586-8349, Researcher ID: AAN-1580-2020, SPIN-код: 7914-7630, Author ID: 815871; C. Med. Sci., Associate Professor, Department of Advanced Internal Medicine and Immunology with Postgraduate Physician Training Course, Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, st. Partizana Zheleznyaka 1, Krasnoyarsk, 660022, Russia; Pulmonologist, Krasnoyarsk State Territorial Clinical Hospital: st. Partizana Zheleznyaka 3A, Krasnoyarsk, 660022, Russia; tel: +7 (913) 199 06 53; e-mail: natagorday@yandex.ru

ANIKIN DMITRY A., ORCID ID: 0000-0002-7418-897X, Researcher ID: AAH-8919-2021, SPIN-код: 3045-8493, Author ID: 1019131; Assistant Professor, Department of Advanced Internal Medicine and Immunology with Postgraduate Physician Training Course, Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, st. Partizana Zheleznyaka 1, Krasnoyarsk, 660022, Russia; General Practitioner, Krasnoyarsk State Territorial Clinical Hospital: st. Partizana Zheleznyaka 3A, Krasnoyarsk, 660022, Russia; tel: +7 (983) 140 27 37; e-mail: anikin27111994@mail.ru

Abstract. Introduction. In the pathogenesis of a number of diseases, a signi cant role is played by redox imbalance, which is referred to as oxidative (oxidative stress) stress. Aim. The aim of the study is to review current information on the pathophysiological mechanisms of the in uence of oxidative stress on the development of cardiovascular pathology.Material and methods. A review of current published studies on the e ect of oxidative stress on the development and course of cardiovascular pathology was carried out. Results and discussion. Oxidative stress, disorders of the antioxidant system, and in ammation are considered the leading links in the pathogenesis and progression factors of atherosclerotic cardiovascular diseases, heart failure, arterial hypertension, and others. Conclusion. By maintaining the physicochemical parameters of biological membranes regulating intracellular homeostasis and protein kinase activity, free radicals take part in key biological reactions, such as di erentiation, proliferation, and apoptosis. Strengthening reactions of free radical oxidation of lipids leads to damage to membranes and enzymatic systems, acting as a trigger factor for hidden genetically determined changes. In ammation is a pathological process inextricably linked with oxidative stress, which develops in tissues in response to their damage due to the action of agents of an infectious and non-infectious nature. Maladaptive in ammation leads to systolic and diastolic dysfunction through cardiovascular remodeling. Oxidative stress due to damage to the endothelial lining leads to the formation of endothelial dysfunction. The combination of the described pathological processes leads to cardiovascular diseases.

Key words: oxidative stress, in ammation, heart failure, atherosclerosis.

For reference: Demko IV, Sobko EA, Solovyeva IA, Kraposhina AY, Gordeeva NV, Anikin DA. The role of oxidative stress in the pathophysiology of cardiovascular pathology. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1): 107–117. DOI: 10.20969/VSKM.2022.15(1).107-117.


1. JonesD.RedoxPioneer:ProfessorHelmutSies. Antioxidants & Redox signaling. 2014; 18 (21): 2459–2468. DOI: 10.1089/ars.2014.6037.

2. Sies H. Oxidative stress: a concept in redox biology and medicine. H Redox Biol. 2015; (4): 180–183. DOI: 10.1016/j.redox.2015.01.002.

3. Podgorska А, Burian M, Szal BA. Extra-cellular but extra-ordinarily important for cells: apoplastic reactive oxygen species metabolism. Front Plant Sci. 2017; (8): 1353. DOI: 10.3389/ fpls.2017.01353.

4. Schrieber M, Chandel N. ROS function in redox signaling and oxidative stress. Curr Biol. 2014; 24 (10): 453–462. DOI: 10.1016/j.cub.2014.03.034.

5. Lenoir O, Flosseau K, Ma FX, et al. Speci c control of pancreatic endocrine β- and δ-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9. Diabetes. 2011; 60: 2861– 2871. DOI: 10.2337/db11-0440.

6. Cassuto J, Dou H, Czikora I, et al. Peroxynitrite disrupts endothelial caveolae leading to eNOS uncoupling and diminished ow-mediated dilation in coronary arterioles of diabetic patients. Diabetes. 2014; 63 (4): 1381–1393. DOI: 10.2337/db13-0577.

7. Cadenas S. Mitochondrial uncoupling, ROS generation and cardioprotection. Biochim Biophys Acta Bioenerg. 2018; 1859 (9): 940– 950. DOI: 10.1016/j.bbabio.2018.05.019.

8. Bibli S, Zhou Z, Zukunft S, et al. Tyrosine phosphorylation of eNOS regulates myocardial survival after an ischaemic insult: role of PYK2. Cardiovascular Research. 2017; 113: 926–937. DOI: 10.1093/cvr/cvx058.

9. Ильина И.Ю., Доброхотова Ю.Э. Роль окислительного стресса в развитии гинекологических заболеваний // Акушерство и гинекология. – 2021. – No2. – С.150–156. [Il’ina IYu, Dobrohotova YuE. Rol’ okislitel’nogo stressa v razvitii ginekologicheskih zabolevanij [Role of oxidative stress in the development of gynecological diseases]. Akusherstvo i ginekologiya [Obstetrics and gynecology]. 2021; 2: 150–156. (In Russ.)]. DOI: 10.18565/ aig.2021.2.150-156.

10.Черданцев Д.В., Николаева Л.П., Степаненко А.В., и др. Роль окислительного стресса в патогенезе сосудистых осложнений сахарного диабета // Международный журнал прикладных и фундаментальных исследований. – 2010. – No5. – С.127–130. [Cherdancev DV, Nikolaeva LP, Stepanenko AV, Dyatlov VYu. Rol’ okislitel’nogo stressa v patogeneze sosudistyh oslozhnenij saharnogo diabeta [The role of oxidative stress in the pathogenesis of vascular complications of diabetes mellitus]. Mezhdunarodnyj zhurnal prikladnyh i fundamental’nyh issledovanij [Journal of Basic and Applied Research International]. 2010; 5: 127–130. (In Russ.)].

11. Ni HM, Williams JA, Ding WX. Mitochondrial dynamics and mitochondrial quality control. Redox Biol. 2015; (4): 6–13. DOI: 10.1016/j. redox.2014.11.006.

12. Brand M. Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling. Free Radic Biol Med. 2016; 100: 14–31. DOI: 10.1016/ j.freeradbiomed.2016.04.001.

13.Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart. 2007; 93: 903–907. DOI: 10.1136/hrt.2005.068270.

14.Залетова Т.С. Патофизиология ожирения и ассоциированной с ним сердечно-сосудистой патологии // Вопросы диетологии. – 2014. – Т. 4, No1. – С.29–33. [Zaletova TS. Pato ziologiya ozhireniya i associirovannoj s nim serdechno-sosudistoj patologii [Pathophysiology of obesity and associated cardiovascular pathology]. Voprosy dietologii [Dietetics Journal]. 2014; 4 (1): 29–33. (In Russ.)].

15. Тюзиков И.А., Калинченко С.Ю., Ворслов С.О., и др. Роль окислительного стресса в патогенезе андрологических заболеваний. Тиоктовая (альфа-липоевая) кислота – новые грани фармакотерапевтических опций в современной андрологической практике // Эффективная фармакотерапия. – 2018. – No 9. – С.20– 37. [Tyuzikov IA, Kalinchenko SYu, Vorslov SO, Tishova YuA. Rol’ okislitel’nogo stressa v patogeneze andrologicheskih zabolevanij. Tioktovaya (al’fa-lipoevaya) kislota – novye grani farmakoterapevticheskih opcij v sovremennoj andrologicheskoj praktike [Role of Oxidative Stress in the Pathogenesis of Andrological Diseases. Thioctic (Alpha-Lipoic) Acid (Espa-Lipon) – New Edges of Pharmacotherapeutic Options in Modern Andrological Practice]. E ektivnaya farmakoterapiya [E ective pharmacotherapy]. 2018; 9: 20–37. (In Russ.)].

16.Dutta EH, Behnia F, Boldogh I, et al. Oxidative stress damage-associated molecular signaling pathways di erentiate spontaneous preterm birth and preterm premature rupture of the membranes. Mol Hum Reprod. 2016; 22 (2): 143–157. DOI: 10.1093/molehr/gav074.

17. Forstermann U, Sessa WS. Nitric oxide syntheses: regulation and function. European Heart Journal. 2012; 33 (7): 829–837. DOI: 10.1093/eurheartj/ehr304.

18. Ахминеева А.Х. Белковый оксидативный стресс при сочетанной респираторно-кардиальной коморбидности // Курский научно-практический вестник «Человек и его здоровье». – 2015. – No 4. – С.8–12. [Ahmineeva AH. Belkovyj oksidativnyj stress pri sochetannoj respiratorno-kardial’noj komorbidnosti [Protein oxidative stress in combined respiratory-cardiac comorbidity]. Kurskij nauchno-prakticheskij vestnik «Chelovek i ego zdorov’e» [Kursk scienti c and practical bulletin «Man and his health»]. 2015; (4): 8–12. (In Russ.)].

19.Горшунова Н.К., Рахманова О.В. Оксидативный стресс и его разновидности в патогенезе артериальной гипертонии // Современные проблемы науки и образования. – 2018. – No 3. – С.67. [Gorshunova NK, Rahmanova OV. Oksidativnyj stress i ego raznovidnosti v patogeneze arterial’noj gipertonii [Oxidative stress and its variations in the pathogenesis of arterial hypertension]. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education]. 2018; (3): 67. (In Russ.)].

20. Tenkorang MA, Snyder B, Cunningham RL. Sex-related di erences in oxidative stress and neurodegeneration. Steroids. 2018; 133: 21–27. DOI: 10.1016/j.steroids.2017.12.010.

21. Магомедов М.М., Магомедов А.А. Роль окислительного стресса и матриксных металло-протеиназ в патогенезе трофических язв // Современные проблемы науки и образования. – 2019. – No1. – С. [Magomedov MM, Magomedov AA. Rol’ okislitel’nogo stressa i matriksnyh metalloproteinaz v patogeneze tro cheskih yazv [The role of oxidative stress and matrix metalloproteinases in the pathogenesis of trophic ulcers]. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education]. 2019; 1: 39. (In Russ.)].

22. Medzhitov R. Origin and physiological roles of in ammation. Nature. 2008; 454 (7203): 428– 435. DOI: 10.1038/nature07201.

Sanchez-Rodriguez MA, Zacarias-Flores M, Arronte-Rosales A, et al. Association between hot ashes severity and oxidative stress among Mexican postmenopausal women: a cross-sectional study. PLoS One. 2019; 14 (9): e0214264. DOI: 10.1371/journal.pone.0214264.

Романенко И.А., Полятыкина Т.С., Маврычева Н.В., и др. Динамика метаболических показателей, маркеров окислительного стресса и повреждения сосудистой стенки при лечении больных ожирением с предиабетом // Клиническая медицина. – 2016. – Т.94, No3. – С.221–224. DOI: 10.18821/0023-2149-2016-94-3-221-224. [Romanenko IA, Polyatykina TS, Mavrycheva NV, Budnikova NV, Grinshtejn VB. Dinamika metabolicheskih pokazatelej, markerov okislitel’nogo stressa i povrezhdeniya sosudistoj stenki pri lechenii bol’nyh ozhireniem s prediabetom [Dynamics of metabolic characteristics, markers of oxidative stress and vascular wall damage during treatment of obese pre-diabetic patients]. Klinicheskaya medicina [Clinical Medicine]. 2016; 94 (3): 221–224. DOI: 10.18821/0023-2149-2016-94-3-221-224. (In Russ.)].

25. Jun-Won Y. Glutathione peroxidase-1 inhibits transcription of regenerating islet-derived protein-2 in pancreatic islets. Free Radic Biol Med. 2019; 134: 385–393. DOI: 10.1016/j. freeradbiomed.2019.01.024.

26. Нестеров В.С., Урванцева И.А. Хроническая сердечная недостаточность: современные проблемы и пути их решения // Лечащий врач. –2018. – No7. – С.11–14. [Nesterov VS, Urvanceva IA. Hronicheskaya serdechnaya nedostatochnost’: sovremennye problemy i puti ih resheniya [Chronic heart failure: modern problems and their solutions]. Lechashchij vrach [Lechaschi vrach]. 2018; (7): 11–14. (In Russ.)].

27. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011; 301: H2181–H2190. DOI:10.1152/ ajpheart.00554.2011.

28. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial in ammation. J Am Coll Cardiol. 2013; 62: 263–271. DOI: 10.1016/j.jacc.2013.02.092.

29. Aimo A, Castiglione V, Borrelli C, et al. Oxidative stress and in ammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. Eur J Prev Cardiol. 2020; 27 (5): 494– 510. DOI: 10.1177/2047487319870344.

30. Zhou B, Tian R. Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest. 2018; 128 (9): 3716–3726. DOI: 10.1172/ JCI120849.

31. Beckendorf L, Linke WA. Emerging importance of oxidative stress in regulating striated muscle elasticity. J Muscle Res Cell Motil. 2015; 36: 25– 36. DOI: 10.1007/s10974-014-9392-y.

32. Adameova A, Anureet S, Adameova ND. A. Role of Oxidative Stress in the Genesis of Ventricular Arrhythmias. Int J Mol Sci. 2020; 21 (12): 4200. DOI: 10.3390/ijms21124200.

33. Morotti S, Grandi E. Quantitative systems models illuminate arrhythmia mechanisms in heart failure: Role of the Na + - Ca 2+ - Ca 2+ / calmodulin-dependent protein kinase II-reactive oxygen species feedback. Wiley Interdiscip Rev Syst Biol Med. 2019; 11 (2): e1434. DOI: 10.1002/wsbm.1434.

34. Yang W, Wang BH, Wang I, et al. Inhibition of Apoptosis Signal-Regulating Kinase 1 Attenuates Myocyte Hypertrophy and Fibroblast Collagen Synthesis. Heart Lung Circ. 2019; 28 (3): 495– 504. DOI: 10.1016/j.hlc.2017.12.001.

35. Masi S, Virdis A. Angiotensin II and vascular damage in hypertension: Role of oxidative stress and sympathetic activation. Vascul Pharmacol. 2019; 115: 13–17. DOI: 10.1016/j. vph.2019.01.004.

36. Liu RM. Reciprocal regulation of TGF-b and reactive oxygen species: A perverse cycle for brosis. Desai Redox Biol. 2015; 6: 565–577. DOI: 10.1016/j.redox.2015.09.009.

37. Sinphitukkul K, Manotham K, Eiam-Ong S. Aldosterone nongenomically induces angiotensin II receptor dimerization in rat kidney: role of mineralocorticoid receptor and NADPH oxidase. Arch Med Sci. 2019; 15 (6): 1589–1598. DOI: 10.5114/aoms.2019.87135.

38. Frangogiannis NG. The in ammatory response in myocardial injury, repair, and remodeling. Nat Reviews Cardiol. 2014; 11: 255. DOI: 10.1038/ nrcardio.2014.28.

39. Mann DL. Innate immunity and the failing heart: The cytokine hypothesis revisited. Circ Res. 2015; 116: 1254–1268. DOI: 10.1161/ CIRCRESAHA.116.302317.

40. Liu L, Wang Y, Cao ZY, et al. Up-regulated TLR4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction. J Cell Mol Med. 2015; 19: 2728–2740. DOI: 10.1111/jcmm.12659

41. Rhian MT, Francisco JR, Rheure A, et al. Oxidative Stress: A Unifying Paradigm in Hypertension. Canadian Journal of Cardiology. 2020; 36: 659–670. DOI: 10.1016/j. cjca.2020.02.081.

42. Ахминеева А.Х., Полунина О.С., Севостьянова И.В., и др. Белковый оксидативный стресс при сочетанной респираторно-кардиальной коморбидности // Курский научно-практический вестник «Человек и его здоровье». – 2015. – No4. – С.8–12. [Ahmineeva AH, Polunina OS, Sevost’yanova IV, Voronina LP, Polunina EA. Belkovyj oksidativnyj stress pri sochetannoj respiratorno-kardial’noj komorbidnosti [Protein oxidative stress in combined respiratory-cardiac comorbidity]. Kurskij nauchno-prakticheskij vestnik «Chelovek i ego zdorov’e» [Kursk scienti c and practical bulletin «Man and his health»]. 2015; 4: 8–12. (In Russ.)].

43. Kleinewietfeld M, Manzel A, Titze J, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic Th-17 cells. Nature. 2013; 496 (7446): 496–518. DOI: 10.1038/ nature11868.

44. Горшунова Н.К., Мауер С.С. Взаимодействие вазотонических биоэффекторов в патогенезе эндотелиальной дисфункции при артериальной гипертензии на фоне старения // Успехи геронтологии. – 2012. – Т.25, No3. – С.461–467. DOI: 10.1134/S2079057013020070. [Gorshunova NK, Mauer SS. Vzaimodejstvie vazotonicheskih bioe ektorov v patogeneze endotelial’noj disfunkcii pri arterial’noj gipertenzii na fone stareniya [Interaction of vasotonic bioe ectors in endothelial dysfunction pathogenesis due to arterial hypertension on aging]. Uspekhi gerontologii [Advances in gerontology]. 2012; 25 (3): 461–467. (In Russ.)]. DOI: 10.1134/S2079057013020070.

45. Senoner T, Dichtl W. Oxidative stress in cardiovascular diseases: still a therapeutic target? Nutrients. 2019; 11 (9): 2090. DOI: 10.3390/nu11092090.

46. Liakopoulos V, Roumeliotis S, Gorny X, et al. Oxidative stress in hemodialysis patients: a review of the literature. Oxid. Med. Cell. Longev. 2017; 2017: 3081856. DOI: 10.1155/2017/3081856.

47. Cabello-Verrugio C, Simon F, Trollet C, et al. Oxidative stress in disease and aging: mechanisms and therapies. Oxid Med Cell Longev. 2017; 2017: 4310469. DOI: 10.1155/2017/4310469.

48. Бенимецкая К.С., Атюков П.А., Астраков С.В. Новые возможности гиполипидемической терапии // Сибирское медицинское обозрение. – 2017. – No4. – С.65–81. [Benimeckaya KS, Atyukov PA, Astrakov SV. Novye vozmozhnosti gipolipidemicheskoj terapii [New possibilities of hypolipidemic therapy]. Sibirskoe medicinskoe obozrenie [Siberian Medical Review]. 2017; 4: 65–81. (In Russ.)]. DOI: 10.20333/2500136-2017-4-65-81.

49. Gusev EYu, Zotova NV. Cellular stress and general pathological processes. Curr. Pharmac. Design. 2019; 25: 251–297. DOI: 10.2174/13816 12825666190319114641.

50. Durham AL, Speer MY, Scatena M. Role of smooth muscle cells in vascular calci cation: implications in atherosclerosis and arterial sti ness. Cardiovasc Res. 2018; 114: 590–600. DOI: 10.1093/cvr/cvy010.

51. Kyaw T, Peter K, Li Y, et al. Cytotoxic lymphocytes and atherosclerosis: signi cance, mechanisms and therapeutic challenges. Br J Pharmacol. 2017; 174 (22): 3956–3972. DOI: 10.1111/bph.13845.

52. Bergheanu SC, Bodde MC, Jukema JW, et al. Pathophysiology and treatment of atherosclerosis: Current view and future perspective on lipoprotein modi cation treatment. Neth Heart J. 2017; 25 (4): 231–242. DOI: 10.1007/s12471-017-0959-2.

53.Rodriguez-Iturbe B, Pons H, Johnson RJ, et al. Role of the immune system in hypertension. PhysiolRev. 2017; 97: 1127–1164. DOI: 10.1152/ physrev.00031.2016.

54.Tabas I, Bornfeldt KE. Macrophage phenotype and function in di erent stages of atherosclerosis. Circ Res. 2016; 118 (4): 653–667. DOI: 10.1161/ CIRCRESAHA.115.306256.

55.Alshaarawy O, Elbaz HA, Andrew ME. The association of urinary polycyclic aromatic hydrocarbon biomarkers and cardiovascular disease in the US population. EnvironInt. 2016; 89: 174–178. DOI: 10.1016/j.envint.2016.02.006.

56.Habib A, Finn AV. The role of iron metabolism as a mediator of macrophage in ammation and lipid handling in atherosclerosis. Front. Pharmacol. 2014; 5: 195. DOI: 10.3389/fphar.2014.00195.

57.Siqueira J, Abdul ZI, Russell DA, et al. Clinical and preclinical use of LOX-1-speci c antibodies in diagnostics and therapeutics. J. Cardiovasc. Transl. Res. 2015; 8 (8): 458–465. DOI: 10.1007/ s12265-015-9655-z.

58. Гусев Е.Ю., Зотова Н.В. Физиологическая и патогенетическая роль рецепторов-мусорщиков у человека // Медицинская иммунология. – 2020. – Т.22, No1. С.7–48. [Gusev EYu, Zotova NV. Fiziologicheskaya i patogeneticheskaya rol’ receptorov-musorshchikov u cheloveka [Physiological and pathogenic role of scavenger receptors in humans]. Medicinskaya immunologiya [Medical Immunology]. 2020; 22 (1): 7–48. (In Russ.)]. DOI: 10.15789/15630625-PAP-1893.

59. Zani IA, Stephen SL, Mughal NA. Ryanodine receptor structure and function in health and disease. Cells. 2015; 4 (2): 178–201. DOI: 10.1007/978-981-10-7757-911.

60.Meng-Chen L. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. L Meng-Chen. 2016; 36 (5): 924– 963. DOI: 10.1002/med.21396.


UDC: 616.381-089.85-084-089.168.1-06:616-089.5-031.84 DOI: 10.20969/VSKM.2022.15(1).118-124


KONTOREV KONSTANTIN V., ORCID ID: 0000-0002-0641-5720; Researcher ID: AAK-1749-2021; postgraduate student, Department of General Surgery named after professor Yu.M.Lubensky, Krasnoyarsk State Medical University named after professor V.F. Voino-Yasenetsky, 660022, Russian Federation, Krasnoyarsk, Partizana Zheleznyaka St., 1, e-mail: kkontorev@mail.ru

ZDZITOVETSKY DMITRII E., ORCID ID: 0000-0002-2498-3844; AuthorID: 242540; ResearcherID: Q-5439-2016; D. Med. Sci., Associate Professor, Head of the Department of General Surgery named after professor Yu.M.Lubensky, Krasnoyarsk State Medical University named after professor V.F. Voino-Yasenetsky, 660022, Russian Federation, Krasnoyarsk, Partizana Zheleznyaka St., 1, 660022, Krasnoyarsk, Partizana Zheleznyaka St., 1, e-mail: zdz64@mail.ru

BORISOV ROMAN N., ORCID ID: 0000-0001-9670-9476; AuthorID: 543149; C. Med. Sci., Associate Professor, Department of General Surgery named after professor Yu.M.Lubensky, Krasnoyarsk State Medical University named after professor V.F. Voino-Yasenetsky, 660022, Russian Federation, Krasnoyarsk, Partizana Zheleznyaka St., 1, 660022, Krasnoyarsk, Partizana Zheleznyaka St., 1, e-mail: boron-5@yandex.ru

Abstract. Introduction. Wound pain and postoperative complications are a leading problem for patients operated on abdominal organs. In most cases, these two issues are interrelated; that is why their management requires a comprehensive modern approach. Aim. The aim of the study is to evaluate the literature data to identify a causal relationship between wound pain and some complications after abdominal surgeries and to determine the advantages of local anaesthesia of a laparotomic wound, taking into account its additional favourable features. Material and methods. Based on the analysis of Russian and foreign articles, the review presents the structure of the main wound, intra- and extra-abdominal complications after laparotomy, and their producing factors. Moreover, the role of pain during the postoperative period with its multiorgan e ect is clearly demonstrated. We considered characteristics of local anaesthetics with their non- standard e ects, as well as a comparison of publications regarding the advantages of local anaesthesia in the wound with the systemic administration of parenteral (narcotic and non-narcotic) analgesics, where side e ects were also analyzed.Results and discussion. Wound, intra- and extra-abdominal complications after laparotomy are very common today. Pain in the wound area is important in developing each of the complications: it provokes hypodynamia in the postoperative period, develops intestinal paresis, reduces the chest excursion and, as a result, worsens the life quality. All this provokes an increase in intra-abdominal pressure, impaired blood circulation of abdominal organs, wound ischemia in the suture area, lung congestion, which worsens hemodynamics and leads to the systemic consequences. Local anaesthetics are devoid of the well-known side e ects of narcotic analgesics and non-steroidal anti-in ammatory drugs. However, they have additional positive local e ects. Conclusion. Scienti c data analysis has shown that continuous infusion of local anaesthetics into the preperitoneal space of a median laparotomic wound is a promising method for relieving wound pain and preventing postoperative intra- and extra-abdominal complications.

Key words: midline laparotomy, postoperative complications, local anesthetics, wound pain.

For reference: Kontorev KV, Zdzitovetsky DE, Borisov RN. The role of local anesthesia of a laparotomic wound in the prevention of postoperative complications. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1):118–124.DOI: 10.20969/VSKM.2022.15(1).118-124.


1. Малков И.С., Филиппов В.А., Коробков В.Н., и др. Диагностика и хирургическая тактика у больных с послеоперационными интрааб-доминальными осложнениями // Современная медицина – 2019. – No2 (14). – С. 134. [Malkov IS, Filippov VA, Korobkov VN, et al. Diagnostika i hirurgicheskaya taktika u bol'nyh s posleoperacionnymi intraabdominal'nymi oslozhneniyami [Diagnosis and surgical tactics in patients with postoperative intraabdominal complications]. Sovremennaya medicina [Modern medicine]. 2019; 2 (14): 134. (In Russ.)].

2. Bensignor T, Lefevre JH, Creavin B, et al. Postoperative Peritonitis After Digestive Tract Surgery: Surgical Management and Risk Factors for Morbidity and Mortality, a Cohort of 191 Patients. World J Surg. 2018; 42 (11): 3589-3598.

3. Мохов Е.М., ред. Материалы научно-практической конференции врачей России с международным участием // Тверь: ООО «Издательство «Триада», 2015. – Вып. 8. – С.116–117. [Mohov EM, ed. Materialy nauchno-prakticheskoj konferencii vrachej Rossii s mezhdunarodnym uchastiem [Materials of the scienti c and practical conference of Russian doctors with international participation]. Tver': OOO «Izdatel'stvo «Triada» [Tver: LLC "Publishing House "Triada"]. 2015; 8: 116–117. (In Russ.)].

4. Tiernan J, et al. Use of midi ed Delphi approach to develop research priorities for the Association of Coloproctology of Great Britain and Ireland. Colorectal desease. 2014; 16 (12): 965-970.

5. Зацаринный А.В., Бударев В.Н., Муравьев С.Ю., Авдеев С.С., и др. Результаты функционально ориентированных операций в герниологии // Наука молодых (Eruditio Juvenium). – 2013. – No3. – С.34-43. [Zacarinnyj AV, Budarev VN, Murav'ev SYu, Avdeev SS, et al. Rezul'taty funkcional'no orientirovannyh operacij v gerniologii [Results of functionally oriented operations in herniology]. Nauka molodyh (Eruditio Juvenium) [The Science of the Young (Eruditio Juvenium)]. 2013; 3: 34–43. (In Russ.)].

6. Bauer J, Keeley B, Krieger B, et al. Adhesive Small Bowel Obstruction: Early Operative versus Observational Management. Am Surg. 2015; 81 (6): 614-620.

7. Jung SW, Hwang S, Namgoong JM, Yoon SY. Incidence and management of postoperative abdominal bleeding after liver transplantation. Transplant Proc. 2012; 44 (3): 765–768.

8. MoghadamyeghanehZ,HwangGS,HannaMH,et al. Risk factors for prolonged ileus following colon surgery. Surg Endosc. 2016; 30 (2): 603-609.

9. De Groof EJ, Carbonnel F, Buskens CJ, Bemelman WA, et al. Abdominal abscess in Crohn's disease: multidisciplinary management. Dig Dis. 2014; 32 (1): 103–109.

10.Mihaljevic AL, Schirren R, Ozer M, Ottl S, et al. Multicenter double-blinded randomized controlled trial of standard abdominal wound edge protection with surgical dressings versus coverage with a sterile circular polyethylene drape for prevention of surgical site infections: a CHIR-Net trial (BaFO; NCT01181206). Ann Surg. 2014; 260 (5): 730–739.

11. Затехвахина И.И., Кириенко А.И., Кубышкина В.А., ред. Абдоминальная хирургия; Национальное руководство // М.: ГЭОТАР-Медиа, 2016. – 914 с. [Zatekhvahina II, Kirienko AI, Kubyshkina VA. Abdominal'naya hirurgiya: Nacional'noe rukovodstvo. [Abdominal surgery: National leadership.]. Moskva: GEOTAR-Media [Moscow: GEOTAR-Media]. 2016; 914 p. (In Russ.)].

12. SandyHodgetts K, Carville K, Leslie GD. Determining risk factors for surgical eventration and wound dehiscence: A literature review. Int Wound J. 2015; 12 (3): 265–275.

13. Федосеев А.В., Муравьев С.Ю., Бударев В.Н., Инютин А.С., и др. Морфофункциональная характеристика белой линии живота с позиции герниолога // Наука молодых (Eruditio Juvenium). – 2015. – No4. – С.73-82. [Fedoseev AV, Murav'ev SYu, Budarev VN, Inyutin AS, et al. Morfofunkcional'naya harakteristika beloj linii zhivota s pozicii gerniologa [Morphofunctional characteristics of the white line of the abdomen from the position of a herniologist]. Nauka molodyh (Eruditio Juvenium) [The science of the Young (Eruditio Juvenium)]. 2015; 4: 73–82. (In Russ.)].

14.Nguyen MT, Berger RL, Hicks SC, Davila JA, Li LT, Kao LS, Liang MK. Comparison of outcomes of synthetic mesh vs suture repair of elective primary ventral herniorrhaphy: a systematic review and meta-analysis. JAMA Surg. 2014; 149 (5): 415-421. DOI: 10.1001/jamasurg.2013.5014.

15.Егиев В.Н., Шурыгин С.Н., Чижов Д.В. Сравнение результатов пластики брюшной стенки «тяжелыми» и «легкими» полипропиленовыми эндопротезами при лечении послеоперационных вентральных грыж // Московский хирургический журнал. – 2012. – No 2. – С.20–23. [Egiev VN, Shurygin SN, Chizhov DV. Sravnenie rezul'tatov plastiki bryushnoj stenki «tyazhelymi» i «legkimi» polipropilenovymi endoprotezami pri lechenii posleoperacionnyh ventral'nyh gryzh [Comparison of the results of abdominal wall plastic surgery with "heavy " and" light " polypropylene endoprostheses in the treatment of postoperative ventral hernias]. Moskovskij hirurgicheskij zhurnal [Moscow Surgical Journal]. 2012; 2: 20–23. (In Russ.)].

16. Кузнецов Н.А., Счастливцев И.В., Цаплин С.Н. Роль операционного доступа в развитии послеоперационных вентральных грыж // Хирургия. – 2011. – No 7. – С.62–66. [Kuznecov NA, Schastlivcev IV, Caplin SN. Rol' operacionnogo dostupa v razvitii posleoperacionnyh ventral'nyh gryzh [The role of surgical access in the development of postoperative ventral hernias]. Hirurgiya [Surgery]. 2011; 7: 62–66. (In Russ.)].

17.Куликов Л.К., Буслаев О.А., Шалашов С.В., и др. Хирургическое лечение обширных и гигантских послеоперационных вентральных грыж // Новости хирургии. – 2013. – No 2. – С.37–44. [Kulikov LK, Buslaev OA, Shalashov SV, et al. Hirurgicheskoe lechenie obshirnyh i gigantskih posleoperacionnyh ventral'nyh gryzh [Surgical treatment of extensive and giant postoperative ventral hernias]. Novosti hirurgii [Surgery news]. 2013; 2: 37–44. (In Russ.)].

18.Diener MK, Knebel P, Kieser M, Schuler P, et al. E ectiveness of triclosan-coated PDS Plus versus uncoated PDS II sutures for prevention of surgical site infection after abdominal wall closure: the randomised controlled PROUD trial. Lancet. 2014; 384 (9938): 142–152.

19.Jammer I, Wickboldt N, Sander M, et al. Standards for de nitions and use of outcome measures for clinical e ectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) de nitions: a statement from the ESA-ESICM joint task force on perioperative outcome measures. Eur J Anaesthesiol. 2015; 32 (2): 88–105. DOI: 10.1097/EJA.0000000000000118.

20.Miskovic A, Lumb AB. Postoperative pulmonary complications. Br J Anaesth. 2017; 118 (3): 317– 334. DOI: 10.1093/bja/aex002.

21.Lumb AB. Pre-operative respiratory optimization: an expert review. Anaesthesia. 2019; 74 (1): 43– 48. DOI: 10.1111/anae.14508.

22.Canet J, Gallart L, Gomar C, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology. 2010; 113 (6): 1338–1350. DOI: 10.1097/ALN.0b013e3181fc6e0a.

23.Gan TJ, Habib AS, Miller TE, White W, et al. Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. Curr Med Res Opin. 2014; 30 (1): 149–160.

24.Murray AA, Retief FW. Acute postoperative pain in 1 231 patients at a developing country referral hospital: incidence and risk factors. S Afr J Anaesth Analg. 2016; 22 (1): 19–24.

25.Murthy S, Antwi-Kusi A, Jabir AR, Ofori-Amanfo G. Patient and practitioner perspectives on postoperative pain control in Kumasi, Ghana. S Afr J Anaesth Analg. 2013; 19 (2): 102–107.

26.Beck DE, Margolin DA, Babin SF, Russo CT. Bene ts of a multimodal regimen for postsurgical pain management in colorectal surgery. Ochsner J. 2015; 15 (4): 408–412.

27. Овечкин А.М., Карпов И.А., Люосев С.В. Послеоперационное обезболивание в абдоминальной хирургии: новый взгляд на старую тему // Анестезиология и реаніматологія. – 2003. – No 5. – С.71–76. [Ovechkin AM, Karpov IA, Lyuosev SV. Posleoperacionnoe obezbolivanie v abdominal'noj hirurgii: novyj vzglyad na staruyu temu [Postoperative analgesia in abdominal surgery: a new look at an old topic]. Anesteziologiya i reanіmatologіya [Anesthesiology and reanimatology]. 2003; 5: 71–76. (In Russ.)].

28.DuBay DA, Choi W, Urbanchek MG, et al. Incisional herniation induces decreased abdominal wall compliance via oblique muscle atrophy and brosis. Ann Surg. 2007; 245 (1): 140–146.

29. VanDenKerkhof EG, Hopman WM, Reitsma ML, Goldstein DH, et al. Chronic pain, healthcare utilization, and quality of life following gastrointestinal surgery. Can J Anaesth. 2012; 59 (7): 670–680.

30.Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006; 367 (9522): 1618–1625.

31.Joshi GP, Schug SA, Kehlet H. Procedurespeci c pain management and outcome strategies. Best Pract Res Clin Anaesth. 2014; 28 (2): 191–201.

32. Liang SS, Ying AJ, A an ET, Kakala BF, Strippoli GF, Bullingham A, Currow H, Dunn DW, Yeh ZY. Continuous local anaesthetic wound infusion for postoperative pain after midline laparotomy for colorectal resection in adults. Cochrane Database Syst Rev. 2019; 10 (10): CD012310. DOI: 10.1002/14651858.CD012310.pub2.

33. Hayhurst CJ, Durieux ME. Di erential opioid tolerance and opioid-induced hyperalgesia: a clinical reality. Anesthesiology. 2016; 124 (2): 483–488.

34. Haroutounian S. Postoperative opioids, endocrine changes, and immunosuppression. Pain Rep. 2018; 3 (2): e640.

35.Gupta A, Favaios S, Perniola A, Magnuson A, Berggren L, et al. A meta-analysis of the e cacy of wound catheters for post-operative pain management. Acta Anaesth Scand. 2011; 55 (7): 785–796.

36. Bell R, Pandanaboyana S, Prasad KR. Epidural versus local anaesthetic in ltration via wound catheters in open liver resection: a metaanalysis. ANZ J Surg. 2015; 85 (1–2): 16–21.

37.Harvey K, Adair J, Ischo M, Robinson R, Surg AmJ. Can intravenous lidocaine decrease postsurgical ileus and shorten hospital stay in elective bowel surgery: A pilot study and literature review. 2009; 198: 231–236.

38.Yoon-Mi L, Byeng CS, Kyung-Jin Y. Impact of volatile anesthetics on oxidative stress and in ammation. Biomed Res Int. 2015; 2015: 242709. DOI: 10.1155/2015/242709.

39.Li B, Li Y, Tian S. Anti-in ammatory e ects of perioperative dexmedetomidine administered as an adjunct to general anesthesia: a metaanalysis. Sci Rep. 2015; 5 (1): 12342. DOI: 10.1038/srep12342.

40. Овечкин А.М. Клиническая фармакология местных анестетиков: классические представления и новые перспективы применения в интенсивной терапии // Регионарная
анестезия и лечение острой боли. – 2013. – No 9. - С.6-15. [Ovechkin AM. Klinicheskaya farmakologiya mestnyh anestetikov: klassicheskie predstavleniya i novye perspektivy primeneniya v intensivnoj terapii [Clinical pharmacology of local anesthetics: classical concepts and new prospects for use in intensive care]. Regionarnaya anesteziya i lechenie ostroj boli [Regional anesthesia and treatment of acute pain]. 2013; 9: 6–15. (In Russ.)].

41.Tustin A, Kim SJ, Chomsky A, et al. Antibacterial properties of 2% lidocaine and reduced rate of endophthalmitis after intravitreal injection. Retina. 2014; 34: 935–942.

42. Lu CW, Lin TY, Shieh JS, et al. Antimicrobial e ect of continuous lidocaine infusion in a Staphylococcus aureus-induced wound infection in a mouse model. Ann Plast Surg. 2014; 73: 598–601.

43. Srisatjaluk RL, Klongnoi B, Wongsirichat N. Antimicrobial e ect of topical local anesthetic spray on oral micro ora. J Dent Anesth Pain Med. 2016; 16: 17–24.

44.Weng M, Chen W, Hou W, Li L, et al. The e ect of neuraxial anesthesia on cancer recurrence and survival after cancer surgery: an updated meta-analysis. Oncotarget. 2016; 7 (12): 15262- 15273. DOI: 10.18632/oncotarget.7683.

45.Joshi GP, Schug SA, Kehlet H. Procedure-speci c pain management and outcome strategies. Best Pract Res Clin Anaesthesiol. 2014; 28: 191-201.

46.Weibel S, Jokinen J, Pace NL, Schnabel A, et al. E cacy and safety of intravenous lidocaine for postoperative analgesia and recovery after surgery: a systematic review with trial sequential analysis. Br J Anaesth. 2016; 116: 770–783.

47. Chang Y–C, Liu C–L, Chen M–J, Hsu Y–W, et al. Local anesthetics induce apoptosis in human breast tumor cells. Anesth Analg. 2014; 118: 116–124.

48.Chang Y–C, Hsu Y–C, Liu C–L, Huang S–Y, et al. Local Anesthetics induce apoptosis in human thyroid cancer cells through the mitogen-activated protein kinase pathway. PloS One. 2014; 9: e89563. DOI: 10.1371/journal. pone.0089563.

49.Xing W, Chen D–T, Pan J–H, Chen Y–H, et al. Lidocaine induces apoptosis and suppresses tumor growth in human hepatocellular carcinoma cells in vitro and in a xenograft model in vivo. Anesthesiol J Am Soc Anesthesiol. 2017; 126 (5): 868-881.

50.Colucci DG, Puig NR, Hernandez PR. In uence of anesthetic drugs on immune response: from in ammation to immunosuppression. OA Anesthetics. 2013; 1: 21–38.

51.Jung SW, Hwang S, Namgoong JM, Yoon SY, et al. Incidence and management of postoperative abdominal bleeding after liver transplantation. Transplant Proc. 2012; 44 (3): 765–768.


UDC:616-001-089.5-031.83-083.98 DOI: 10.20969/VSKM.2022.15(1).125-130


SHARIPOVA VISOLATKHON H., ORCID ID: 0000-0003-2517-1183; D. Med. Sci, Head of the Department of Anesthesiology and Intensive Care, Republican Research Center of Emergency Medicine, Tashkent, Uzbekistan, 100107, Farhad str.2; E-mail: visolat_78@mail.ru.

ESHBOYEV ABDULKHAKIM T., ORCID ID: 0000-0003-4260-4155; Director of the Surkhandarya branch of the Republican Research Center of Emergency Medicine, Termez, Uzbekistan 190100, Zavqi str, 19; Phone: +998937986758; E-mail: termez9111@rambler.ru

ESHMURODOV DILSHODBEK B., ORCID ID: 0000-0002-3858-3163; Anesthesiologist and Intensive Care Physician, Surkhandarya branch of the Republican Research Center of Emergency Medicine, Termez, Uzbekistan 190100, Zavqi str, 19; Phone: +998901129200; E-mail: anestezolog@mail.ru.

Abstract. Introduction. Trauma patients are a special group in which pain control is often a challenge for the anesthetist and resuscitator. In recent years, the role of regional anesthesia in the anesthesia of patients with injuries has been growing and the methods of regional blockades have been improved. Aim. Analysis of scienti c medical literature on the pain relief of patients with traumatic injuries. Material and methods. The review and analysis of modern scienti c data about the problem of pain relief in patients with trauma in the search databases PubMed and Google Scholar is carried out. Results and discussion. Multimodal anesthesia consisting of ultrasound guided regional anesthesia methods contributes to better pain relief. Good quality pain relief for traumatic injuries reduces the body's stress response to trauma, reduces the opioid consumption and consequently their side e ects, signi cantly reduces the risk of development of chronic pain and improves the quality of life. Therefore, today, regional anesthesia methods are integrated into the protocols of Enhanced Recovery after Surgery (ERAS). This review highlights the literature data on the possibilities of using current regional anesthesia methods for injuries, in particular, combined and multiple traumas. The advantages and disadvantages of various regional blocks in trauma patients are described. Along with the methods of regional anesthesia of the extremities, relatively new methods of fascial blocks which are successfully used for anesthesia of the chest and abdomen are discussed. Conclusion. Personalized multimodal pain therapy aimed at the area of injury using ultrasound navigation is a promising direction in the treatment of pain in trauma patients.

Key words: pain, pain relief, multimodal analgesia, regional analgesia, trauma pain management.

For reference: Sharipova VH, Eshboyev AT, Eshmurodov DB. Regional analgesia methods for trauma patients. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1): 125–130. DOI: 10.20969/VSKM.2022.15(1).125-130.


1. Mavrogenis AF, Igoumenou VG, Kostroglou A. The ABC and pain in trauma. Eur J of Surg Traumatol. 2018; 28: 545-550. DOI: 10.1007/ s00590-018-2123-0.

2. ElsC,JacksonTD,KunykD,etal.Adverseevents associated with medium and longterm use of opioids for chronic noncancer pain: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017; 30: 10. DOI: 10.1002/14651858.

3. Chang AK, Bijur PE, Esses D, et al. E ect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department: a randomized clinical trial. JAMA. 2017; 17: 1661-1667. DOI: 10.1001/ jama.2017.16190.

4. Andrew LD, Anthony MS, Tracy JJ, Dennis WA. Multimodal analgesia and decreased opioids use in adult trauma patients. The American surgeon. 2020; 86 (8): 950-954. DOI: 10.1177/0003134820942177.

5. Theodosios S, Iosi na K, Оlga S, Marina T. Acute pain management in trauma: anatomy, ultrasound-guided peripheral nerve blocks and special conciderations. Minerva anestesiologika. 2019; 85 (7): 763-773. DOI: 10.23736/S0375-9393.19.13145-8.

6. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016; 17 (2): 131–157. DOI: 10.1016/j.jpain.2015.12.008.

7. Galvagno SM, Smith CE, Varon AJ, Hasenboehler EA, Sultan S, Shaefer G. Pain management for blunt thoracic trauma: a joint practice management guideline from the Eastern Association for the Surgery of Trauma and Trauma Anesthesiology Society. J Trauma Acute Care Surg. 2016; 81: 936–951. DOI: 10.1097/ TA.0000000000001209.

8. Carol JP, Geeta A, Robert JA, Guidelines for perioperative care for emergency laparotomy enhanced recovery after surgery (ERAS) society recommendations. World J Surgery. 2021; 45: 1272-1290. DOI: 10/1007/s00268-021-055994-9.

9. Jessica LG, Alysson RP. Pain management in trauma in the age of the opioid crisis. Anaesthesiology Clinics. 2019; 37 (1): 79-91. DOI: 10.1016/j.anclin.2018.09.010.

10.Todd KH. A review of current and emerging approaches to pain management in the emergency department. Pain Therapy. 2017; 6 (2): 193-202. DOI: 10.1007/s40122-017-0090-5.

11.Ruth NR, Michael JS, Acute pain in trauma patient. Current Trauma Repost. 2020; 6: 147-153. DOI: 10.1007/s40719-020-00198-3.

12.Slade IR, Samet RE, Regional anesthesia and analgesia for acute trauma patients. Anesthesiol Clin. 2018; 36 (3): 431-454. DOI: 10.1016/ j.anclin.2018.04.004.

13. Steenberg J, Möller AM. Systematic review of the e ects of fascia iliaca compartment block on hip fracture patients before operation. Br J anaesth. 2018; 120 (6): 1368-1380. DOI: 10.1016/ j.bja.2017.12.042

14.Guay J, Parker MJ. Periferal nerve blocks for hip fracturers: A Cochrane Review. Anesthesia & Analgesia. 2018; 136 (5):1695-1704.

15.Mark RJ, Alan DK. Upper extremity regional anesthesia techniques: A comprehensive review for clinical anesthesiologists. Best Practice & Research clinical anaesthesiology. 2020; 34 (1): 13-29. DOI: 10.1016/j.bpa.2019.07.005

16. Ilfeld BM. Continious peripheral nerve blocks: an update of the published evidence and comparison with novel, alternatives analgesic modalities. Anesth Analg. 2017; 124 (1): 308-335. DOI: 10.1213/ANE.0000000000001581.

17.Manay P, Satocar R, Karthik V, Prajapati RP. Studying morbidity and predicting mortality in patients with blunt chest trauma using a novel clinical score. J Emergency trauma shock. 2017; 103 (3): 128-133. DOI: 10.4103/JETS. JETS_131_16.

18.Gade A, Rivara F, Wang J. The e ect of epidural placement in patients after blunt thoracic trauma. Trauma Acute Care Surg. 2014; 76 (1): 39. DOI: 10.1097/TA.0b013e3182ab1b08.

19.Carrier FM, Turgeon AF, Nicole PC. E ect of epidural analgesia in patients with traumatic rib fracture: A systematic review and meta-analysis of randomized controlled trials. Canadian J Anaesth. 2009; 56 (3): 230-242. DOI: 10.1007/ s12630-009-9052-7

20.Duch P, Moller MH. Epidural analgesia in patients with traumatic rib fractures: a systematic review of randomized controlled trials. Acta Anaesthesiol Scan. 2015; 59 (6): 698-709. DOI: 10.1111/aas.12475.

21.McKendy KM, Lee LF, Boulva K. Еpidural analgesia for traumatic rib fractures is associated with worse outcomes: a matched analysis. J Surg Res. 2017; 214: 117-123. DOI: 10.1016/j. jss.2017.02.057.

22.Karamchandani KJ, Klick JC, Kunal MD. Pain management in trauma patients a ected by the opioid epidemic: a narrative review. Trauma acute Care Surg. 2019; 87 (2): 430-439. DOI: 10.1097/TA.0000000000002292

23.Ban CH, Fonseca A, Munshey F, Mcfadyen G. The erector spinae plane (ESP) block: a pulled review of 242 cases. J Clin Anesth. 2019; 53: 29-34. DOI: 10.1016/j.jclinane.2018.09.036.

24. Шарипова В.Х., Фокин И.В. Фасциальная блокада мышцы, выпрямляющей спину, при множественных переломах ребер (клиническое наблюдение) // Общая реаниматология. – 2020. - No 16 (5). - С.22-29. [Sharipova VKh, Fokin IV. Fascialnaya blocada mishci vipremlyayushey spinu pri mnojestvennich perelomax reber (klinicheskoe nabludenie) [Fascial blockade of the muscle that straightens the back, with multiple fractures of the ribs (clinical observation)]. Obshaya reanimatologiya [General Reanimatology]. 2020; 16 (5): 22-29. (In Russ.)]. DOI: 10.15360/1813-9779-2020-5-22-29.

25.Xu JL, Con J, Parikh SB. Ultrasound-guided erector spinae plane block using long-range multi ori ce catheter with multiple rib fracture. Am Surg. 2019; 85 (1): 6-8. PMID: 30760358

26.Adhikary SD, Liu WM. The e ect of erector spinae plane block on respiratory and analgetic outcomes in multiple rib fractures: a retrospective cohort study. Anaesthesia. 2019; 74 (5): 585-593. DOI: 10.1111/anae.14579.

27.Josh Luftig PA, Arun N. Successful emergency pain control for posterior rib fractures with ultrasound-guided erector spinae plane block. The American J of Emerg Med. 2018; 36 (4): 1391-1396. DOI: 10.1016/j.ajem.2017.12.060.

28.Kenzy A, Hassan H. The use of the erector spinae plane block to decrease pain and opioid consumption in the emergency department. Clin Review in Emerg Med. 2020; 58 (4): 603-609. DOI: 10.1016/j.jemermed.2020.02.022.

29.Michelle K, James EM. Chest trauma: Current recomendations for rib fracture, pneumothoracs, and other injuries. Current Anesthes report. 2020; 10: 61-68. DOI: 10.1007/s40140-020-00374-w

30. Peltrini R, Cantoni V, Green R. E cacy of transverses abdominis plane (TAP) block in colorectal surgery: a systematic review and meta-analysis. Techniques in Coloproctology. 2020; 24: 787-802. DOI: 10.1007/s10151-020-02206-9.

31.Anna K, Jacek Z, Joanna K, Waldemar G. The analgesic e ciency of transversus abdominis plane block (TAP) after caesarean delivery. Ginekologia Polska. 2018; 89 (8): 420-423. DOI: 10.5603/GP.a.2018.0072.

32.Mohammed Sh, David IL. Application of TAP Block in laparoscopic Urological Surgery: Current status and Future direction. Curr Urol Rep. 2019; 20 (5): 20. DOI: 10 1007/s11934-019-0883-7.

33.Hamid HKS, Ahmed AY, Saber AA, Emile SH, Ibrahim M, Ruiz-Tovar J. Transversus abdominis plane block using a short-acting local anesthetic reduces pain and opioid consumption after laparoscopic bariatric surgery: a meta-analysis. Surg Obes Relat Dis. 2020; 16 (9): 1349-1357. DOI: 10.1016/j.soard.2020.04.023.

34.Pirrera B, Alagna V, Lucchi A. Transversus abdominis plane (TAP) block versus thoracic epidural analgesia (TEA) in laparoscopic colon surgery in ERAS program. Surg Endosc. 2018; 32: 376-383. DOI:10.1007/s00464-017-5686-7.



UDC 614.2:364.614.8(049.3) DOI: 10.20969/VSKM.2022.15(1).131-138


OSLOPOV VLADIMIR N., ORCID ID: 0000-0003-2901-0694; SCOPUS Author ID: 6602523658: Dr. Med. Sci., professor of the Department of Introduction to Internal Diseases named after Professor S.S. Zimnitsky, Kazan State Medical University, 420012, st., Butlerova 49, Kazan, Russia, tel. 8 (905)316-25-35,
e-mail: voslopov1845@gmail.com

MISHANINA YULIANA S., pediatric faculty student, Kazan State Medical University, 420012, st., Butlerova 49, Kazan, Russia, tel. 8-906-321-21-23, e-mail: mishanina.1998@list.ru.

OSLOPOVA JULIA V., ORCID ID : 0000-0002-9752-8703, C. Med. Sci., associate professor of the Department of the Fundamentals of Clinical Medicine, Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008, st., Kremlevskaya 18, Kazan, Russia, tel. 8 (917) 287-94-56,
e-mail: oslopovajul@mail.ru

Abstract. Introduction. The study of social justice and equality in health care is presented in the context of scienti c, expert and media conceptualizations of this phenomenon. Opinions and social perceptions of justice are characterized in terms of the liberal, socialist model of equitable health care and the modern concept of equality of opportunity in access to system resources. Aim. Conduct a critical analysis of the social project “Fairness and Equality in Health Care”, described in the monograph “Fairness and Equality in Health Care. Opinions of patients, experts and media discourse” by Zh.V. Saveleva, L.M. Mukharyamova, I.B. Kuznetsova. Material and methods. The article provides a review and critical analysis of the social project “Fairness and Equality in Health Care”, described in the monograph “Fairness and Equality in Health Care. Opinions of patients, experts and media discourse” by Zh.V. Saveleva, L.M. Mukharyamova, I.B. Kuznetsova.Results and discussion. The purpose of the project under review was to show how, through the analysis of the incidence in two Russian republics - the industrialized Republic of Tatarstan, and the predominantly agrarian Republic of Mari El - the cause of justice and equality in healthcare is presented and how contradictions can be resolved. Di erent positions, expectations regarding health care reforms and models of social justice are compared. The method of triangulation was used [lat. triangulum - triangle] quantitative and qualitative research methods. Semi-structured surveys of the population, experts, focus groups were conducted, and a mass survey was conducted. From the results obtained by the authors, 2 conclusions stand out: 1) an integrated approach to the analysis of equity in healthcare is needed; 2) actions are needed to equalize the accessibility of medical care to the population. Conclusion. Monograph “Fairness and equality in healthcare. Opinions of patients, experts and media discourse” by Zh.V. Saveleva, L.M. Mukharyamova, I.B. Kuznetsova, touches on one of the most burning issues that arise in modern Russian healthcare, issues that concern almost every inhabitant of Russia - "justice and equality". It is impossible to solve them in isolation from the global social policy in the state. The authors of the monograph literally keep their nger on the pulse of this important problem - as they say, they do it here and now. I hope that the authors will not con ne themselves to one monograph on this vitally important topic (raising the question) and that the next monograph will be devoted to solving this most important problem.

Keywords: justice, equality, healthcare, population studies, review, critical analysis.

For reference: Oslopov VN, Mishanina YuS, Oslopova YuV. The Justice and Equality in Healthcare: a Review and Critical Analysis of the 2016-2017 sociological project - monographs by Zh.V.Savelyeva, L.M.Mukharyamova and I.B.Kuznetsova. Bulletin of Contemporary Clinical Medicine. 2022; 15 (1): 131–138. DOI: 10.20969/VSKM.2022.15(1).131-138.


1. Министерство здравоохранения Россий-1. Министерство здравоохранения Россий-ской Федерации. Здравоохранение в Рос-сии. 2015: Статистический сборник // Москва,2015. – 174 c. [Ministerstvo zdravookhraneniyaRossiyskoy Federatsii [Ministry of Health of theRussian Federation]. Healthcare in Russia 2015;Statistical Book (2015) [Zdravookhraneniye vRossii. 2015: Statisticheskiy sbornik]. Moskva[Moscow]. 2015; 174 p. (In Russ)]. https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2015-god

2. Кислицына О. Влияние социально-экономиче-ских факторов, на состояние здоровья: рольабсолютных или относительных лишений //Журнал исследований социальной политики.– 2015. - № 13 (2). – С.289-302. [Kislitsyna O.Vliyaniye sotsial’no-ekonomicheskikh faktorov,na sostoyaniye zdorov’ya: rol’ absolyutnykhili otnositel’nykh lisheniy [Influence of socioeconomicfactors on health status: the roleof absolute or relative deprivation]. Zhurnalsotsial’noy politiki [Journal of Social PolicyResearch]. 2015: 13 (2): 289-302 (In Russ)].

3. Мухарямова Л.М., Кузнецова-Моренко И.Б., Пе-трова Р.Г., Салахатдинова Л.Н. Региональноездравоохранение в условиях реализации наци-онального проекта «Здоровье» и разграничения бюджетных полномочий // Журнал исследова-ний социальной политики. 2008. - № 6 (4)ю –С.438 – 504. [Mukharyamova LM, Kuznetsova-Morenko IB, Petrova RG, Salakhatdinova LN.Regional’noye zdravookhraneniye v usloviyakhrealizatsii natsional’nogo proyekta «Zdorov’ye»i razgranicheniya byudzhetnykh polnomochiy[Regional health care in the context of theimplementation of the national project «Health»and the delineation of budgetary powers]. Zhurnalissledovaniy sotsial’noy politiki [Journal of SocialPolicy Research]. 2008; 6 (4): 438–504. (In Russ)].

4. Левченко А. Интервью: «В правительстве ус-лышали замечания Счетной палаты к рефор-ме системы здравоохранения» // Независи-мая газета. – 2015. – Режим доступа: http:ng.ru/news/500318.html [Levchenko A. Interv’yu:«V pravitel’stve uslyshali zamechaniya Schetnoypalaty k reforme sistemy zdravookhraneniya»[Interview: «The government has heard thecomments of the Accounts Chamber on thereform of the health care system»]. Nezavisimayagazeta [Independent newspaper]. 2015; http:ng.ru/news/500318.html (In Russ)].

5. Потапчик Е.Г., Селезнева Е.В., Шишкин С.В.Доступность медицинской помощи для на-селения (по материалам мониторинга эко-номических процессов в здравоохранении)// Москва: ИД Высшей школы экономики,2011. – 36 c. [Potapchik E.G., Selezneva E.V.,Shishkin S.V. Dostupnost’ meditsinskoy pomoshchidlya naseleniya (po materialam monitoringaekonomicheskikh protsessov v zdravookhranenii)[Availability of medical care for the population(based on monitoring of economic processesin health care)]. Moskva: ID Vysshey shkolyekonomiki [Moscow: Publishing House of theHigher School of Economics]. 2011; 36 p. (In Russ)].

6. Савельева Ж.В. Кому принадлежит здоровье?Социологические дискуссии и массмедийныеинтерпретации // Журнал социологии и социальной антропологии. – 2013. – № 16 (2). – C.131-141. [Savelyeva ZhV. Komu prinadlezhitzdorov’ye? Sotsiologicheskiye diskussii i massmediynyye interpretatsii [Who owns health? Sociological discussions and mass media interpretations]. Zhurnal sotsiologii i sotsial’noy antropologii [Journal of Sociology and Social Anthropology]. 2013; 16 (2): 131-141. (In Russ)].

7. Sen A. The idea of justice. Belknap Press: An Imprint of Harvard University Press; Reprint edition. 2011; 496 p.

8. Esping-Andersen G, ed. Welfare states in transition: National adaptations in global economies. SAGE Publications Ltd. 1996; https://www.doi.org/10.4135/9781446216941

9. Qxevesque JF, Harris MF, Russell G. Patientcentred access to health care: conceptualising access at the interface of health systems and populations. International Journal for equity in health. 2013; 12 (1): 18.

10. Wikler D. Personal and social responsibility for health. Ethics & International affairs. 2002; 16 (2): 47-55.

11. Albertsen A. Drinking in the last chance saloon: luck egalitarianism, alcohol consumption, and the organ transplant waiting list. Medicine, Health Care and Philosophy. 2016; 19 (2): 325-338.

12. Skinner D. Health justice. Critical Public Health. 2013; 23 (2): 240.

13. Батенёва Т. Полис с плюсом // Российская Бизнес-газета – 2015. - № 3 (982). Режим доступа: httрs://rg.ru/2015/01/27/роlis.html [Batenova T. Polis s plyusom [Polis with a plus]. Rossiyskaya Biznes-gazeta [Russian Business Newspaper]. 2015; 3 (982): ttрs://rg.ru/2015/01/27/роlis.html (In Russ)].

14. Невинная И. Путь к здоровью через кассу? // Российская газета - Столичный выпуск. - 2015. - № 258 (6829). Режим доступа: https:// rg.ru/2015/11/16/med.html [Nevinnaya I. Put’ k zdorov’yu cherez kassu? [The way to health through the cashier?]. Rossiyskaya gazeta – Stolichnyy vypusk [Russian newspaper – Capital issue]. 2015; 6829 (258). https:// rg.ru/2015/11/16/med.html (In Russ)].



UDC: 575.224.22:[616-009.7: 615.211] DOI: 10.20969/VSKM.2022.15(1).139-144


ABDASHIMOV ZAFAR BAKHTIYAROVICH, ORCID ID: 0000-0002-7807-9463, C. Med. Sci., doctoral student of the Department of subjects of therapeutic direction No. 2, Tashkent State Dental Institute, Uzbekistan, 100047, Tashkent, Yashnabad district, Taraqqiyot street, 103, tel. +99-871-2302073, e-mail: zafar_abdashimov@mail.com

Abstract. Introduction. One of the key roles in the excretion of a number of drugs, in particular nonsteroidal anti- in ammatory drugs, has a transport protein glycoprotein P, encoded by the MDR1 gene. In this connection, the in uence of genetic polymorphism of glycoprotein P on the pharmacokinetics of these drugs contributes to the prediction of clinical consequences. Aim. The aim of the current study was to study the associations of polymorphic markers C1236T and C3435T of the MDR1 gene encoding glycoprotein P with the development of undesirable drug reactions in patients with pain syndrome. Material and methods. The study included 69 patients with pain syndrome and were divided into 2 groups depending on the presence of adverse drug reactions: NLR+ - 20 patients and NLR - - 49 patients with pain syndrome. The association of the polymorphic marker C3435T of the MDR1 gene was also studied among 22 patients with adverse drug reactions (ADR+) and 47 patients with pain syndrome without the presence of adverse drug reactions (ADR-). Molecular genetic studies were carried out on the basis of the Laboratory of medical genetics of NIIG and the PC of the Ministry of Health of the Republic of Uzbekistan. Results and discussion. During the genotyping, it was found that the occurrence of alleles and genotypes of the polymorphic marker C3435T of the MDR1 gene had signi cantly signi cant di erences among the patients of the examined groups, depending on adverse drug reactions. Conclusion. The association of the polymorphic marker C3435T of the MDR1 gene with the development of undesirable drug reactions in pain syndrome, the TT genotype and the T allele may be genetic risk factors (OR=4.0 and 8.25; 95% CI 1.78-9.09 and 2.56-26.57, respectively) predisposing to the development of undesirable drug reactions in patients with pain syndrome. Therefore, further study is necessary in order to carry out genotyping of the polymorphic marker C3435T of the MDR1 gene to increase the e ectiveness and safety of therapy of nonsteroidal anti-in ammatory drugs.

Key words: adverse drug reactions, MDR1 gene, polymorphic marker C3435T, nonsteroidal anti-in ammatory drugs, NSAIDs.

For reference: Abdashimov ZB. The role of polymorphism of the mdr1 gene for the appointment of nonsteroidal anti-in ammatory drugs in pain syndrome. The Bulletin of Contemporary Clinical Medicine. 2022; 15 (1):139–144.DOI: 10.20969/VSKM.2022.15(1).139-144


1. Кукес В.Г., Грачев С.В., Сычев Д.А., Раменская Г.В. Метаболизм лекарственных средств: научные основы персонализированной медицины // М.: ГЭОТАР-Медиа, 2008. – 304 с. [Kukes VG, Grachev SV, Sychev DA, Ramenskaya GV. Metabolizm lekarstvennykh sredstv: nauchnyye osnovy personalizirovannoy meditsiny [Metabolism of drugs: scienti c foundations of personalized medicine]. Moskva: GEOTAR-Media [Moscow: GEOTAR-Media]. 2008; 304 p. (In Russ.)].

2. Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician. 2013; 87 (11): 766–772.

3. Ташенова А.И. Транспортная система гликопротеина-Р и фармакокинетика лекарственных средств // Биомедицина. – 2010. – No 4. – С.24–32. [Tashenova AI. Transportnaya sistema glikoproteina-R i farmakokinetika lekarstvennykh sredstv [Transport system of glycoprotein-P and pharmacokinetics of drugs]. Biomedicine [Biomeditsina]. 2010; 4: 24–32. (In Russ.)].

4. Якушева Е.Н., Черных И.В., Щулькин А.В., Попова Н.М. Гликопротеин - P: структура, физиологическая роль и молекулярные механизмы модуляции функциональной активности // Успехи физиологических наук. – 2014. - No 45 (4). – С.90–98. [Yakusheva YeN, Chernykh IV, Shchul’kin AV, Popova NM. Glikoprotein-P: struktura, ziologicheskaya rol’ i molekulyarnyye mekhanizmy modulyatsii funktsional’noy aktivnosti [Glycoprotein – P: structure, physiological role and molecular mechanisms of modulation of functional activity]. Uspekhi ziologicheskikh nauk [Uspekhi ziologicheskikh nauk]. 2014; 45 (4): 90–98. (In Russ.)].

5. Li YH, Wang YH, Li Y, Yang L. MDR1 gene polymorphisms and clinical relevance. Yi Chuan Xue Bao. 2006; 33 (2): 93104.

6. Yiannakopoulou E. Pharmacogenomics of ace-tylsalicylic acid and other nonsteroidal antiin ammatory agents: clinical implications. Eur J Clin Pharmacol. 2013; 69: 1369-1373.

7. Биккинина Г.М., Сафуанов А.Р. Нежелательные лекарственные реакции нестероидных противовоспалительных препаратов // Молодой ученый. – 2015. – No 7 (87). – С.269-272. [Bikkinina GM, Safuanov AR. Nezhelatel’nyye lekarstvennyye reaktsii nesteroidnykh protivovospalitel’nykh preparatov [Adverse drug reactions of non-steroidal anti-in ammatory drugs]. Molodoy uchenyy [Young scientist]. 2015; 7 (87): 269-272. (In Russ.)].

8. Cro ord LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013; 15 (Suppl 3): 2. DOI: 10.1186/ar4174.

9. Алексеев В.В. Современные представления и основные принципы терапии боли // Русский медицинский журнал. - 2011. - No 1. - С.6–11. [Alekseyev VV. Sovremennyye predstavleniya i osnovnyye printsipy terapii boli [Modern ideas and basic principles of pain therapy]. Russkiy meditsinskiy zhurnal [Russian Medical Journal]. 2011; 1: 6–11. (In Russ.)].

10.Журавлева М.В., Кукес В.Г., Прокофьев А.Б., Сереброва С.Ю., Городецкая Г.И., Бердникова Н.Г. Рациональное применение НПВП– баланс эффективности и безопасности (обзор литературы) // Международный журнал прикладных и фундаментальных исследований. – 2016. – No 6-4. – С.687-696. [Zhuravleva MV, Kukes VG, Prokof’yev AB, Serebrova SYu, Gorodetskaya GI, Berdnikova NG. Ratsional’noye primeneniye NPVP– balans e ektivnosti i bezopasnosti (obzor literatury) [Rational use of NSAIDs – balance of e ectiveness and safety (literature review)]. Mezhdunarodnyy zhurnal prikladnykh i fundamental’nykh issledovaniy [International Journal of Applied and Fundamental Research]. 2016; 6-4: 687-696. (In Russ.)].

11. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal e ects of non-steroidal anti-in ammatory drugs: metaanalyses of individual participant data from randomised trials. Lancet. 2013; 382 (9894): 769–779. DOI: 10.1016/S0140–6736(13)60900–9.